<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Exp Immunol</journal-id><journal-id journal-id-type="iso-abbrev">Clin Exp Immunol</journal-id><journal-id journal-id-type="pmc-domain-id">335</journal-id><journal-id journal-id-type="pmc-domain">clinexpimmunol</journal-id><journal-id journal-id-type="publisher-id">CEI</journal-id><journal-title-group><journal-title>Clinical and Experimental Immunology</journal-title></journal-title-group><issn pub-type="ppub">0009-9104</issn><issn pub-type="epub">1365-2249</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC7597597</article-id><article-id pub-id-type="pmcid-ver">PMC7597597.1</article-id><article-id pub-id-type="pmcaid">7597597</article-id><article-id pub-id-type="pmcaiid">7597597</article-id><article-id pub-id-type="pmid">32935331</article-id><article-id pub-id-type="doi">10.1111/cei.13517</article-id><article-id pub-id-type="publisher-id">CEI13517</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Review Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Article Collection: COVID&#8208;19</subject><subj-group subj-group-type="heading"><subject>Review Articles</subject></subj-group></subj-group></article-categories><title-group><article-title>Vaccines for COVID&#8208;19</article-title><alt-title alt-title-type="right-running-head">Vaccines for COVID&#8208;19</alt-title><alt-title alt-title-type="left-running-head">J. S. Tregoning et al.</alt-title></title-group><contrib-group><contrib id="cei13517-cr-0001" contrib-type="author" corresp="yes"><name name-style="western"><surname>Tregoning</surname><given-names initials="JS">J. S.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8093-8741</contrib-id><xref ref-type="aff" rid="cei13517-aff-0001">
<sup>1</sup>
</xref><address><email>john.tregoning@imperial.ac.uk</email></address></contrib><contrib id="cei13517-cr-0002" contrib-type="author"><name name-style="western"><surname>Brown</surname><given-names initials="ES">E. S.</given-names></name><xref ref-type="aff" rid="cei13517-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="cei13517-cr-0003" contrib-type="author"><name name-style="western"><surname>Cheeseman</surname><given-names initials="HM">H. M.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9044-1341</contrib-id><xref ref-type="aff" rid="cei13517-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="cei13517-cr-0004" contrib-type="author"><name name-style="western"><surname>Flight</surname><given-names initials="KE">K. E.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3841-6864</contrib-id><xref ref-type="aff" rid="cei13517-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="cei13517-cr-0005" contrib-type="author"><name name-style="western"><surname>Higham</surname><given-names initials="SL">S. L.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4139-7780</contrib-id><xref ref-type="aff" rid="cei13517-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="cei13517-cr-0006" contrib-type="author"><name name-style="western"><surname>Lemm</surname><given-names initials="NM">N.&#8208;M.</given-names></name><xref ref-type="aff" rid="cei13517-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="cei13517-cr-0007" contrib-type="author"><name name-style="western"><surname>Pierce</surname><given-names initials="BF">B. F.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0834-5201</contrib-id><xref ref-type="aff" rid="cei13517-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="cei13517-cr-0008" contrib-type="author"><name name-style="western"><surname>Stirling</surname><given-names initials="DC">D. C.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8098-7161</contrib-id><xref ref-type="aff" rid="cei13517-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="cei13517-cr-0009" contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="Z">Z.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1110-808X</contrib-id><xref ref-type="aff" rid="cei13517-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="cei13517-cr-0010" contrib-type="author"><name name-style="western"><surname>Pollock</surname><given-names initials="KM">K. M.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9513-5183</contrib-id><xref ref-type="aff" rid="cei13517-aff-0001">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="cei13517-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Department of Infectious Disease</named-content>
<institution>St Mary&#8217;s Campus</institution>
<institution>Imperial College London</institution>
<city>London</city>
<country country="GB">UK</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label>
Correspondence: J. S. Tregoning, Department of Infectious Disease, St Mary&#8217;s Campus, London W2 1PG, UK.<break/>
E&#8208;mail: <email>john.tregoning@imperial.ac.uk</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>18</day><month>10</month><year>2020</year></pub-date><pub-date pub-type="ppub"><month>11</month><year>2020</year></pub-date><volume>202</volume><issue>2</issue><issue-id pub-id-type="pmc-issue-id">367897</issue-id><issue-id pub-id-type="doi">10.1111/cei.v202.2</issue-id><fpage>162</fpage><lpage>192</lpage><history><date date-type="received"><day>10</day><month>7</month><year>2020</year></date><date date-type="rev-recd"><day>04</day><month>9</month><year>2020</year></date><date date-type="accepted"><day>04</day><month>9</month><year>2020</year></date></history><pub-history><event event-type="pmc-release"><date><day>18</day><month>10</month><year>2020</year></date></event><event event-type="pmc-live"><date><day>05</day><month>11</month><year>2020</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-02-11 00:25:09.943"><day>11</day><month>02</month><year>2024</year></date></event><event event-type="pmc-version" specific-use="live"><article-id pub-id-type="pmcaiid">7597597</article-id><article-id pub-id-type="doi">10.1111/cei.13517</article-id><article-version>1</article-version><pub-date><day>18</day><month>10</month><year>2020</year></pub-date></event><event event-type="pmc-version" specific-use="live"><article-id pub-id-type="pmcaiid">8689870</article-id><article-id pub-id-type="doi">10.1111/cei.13517</article-id><article-version>2</article-version><pub-date><day>18</day><month>10</month><year>2020</year></pub-date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2020 The Authors. <italic toggle="yes">Clinical and Experimental Immunology</italic> published by John Wiley &amp; Sons Ltd on behalf of British Society for Immunology</copyright-statement><license license-type="creativeCommonsBy"><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="CEI-202-162.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:CEI-202-162.pdf"/><abstract abstract-type="graphical" id="cei13517-abs-0001"><p>The spread of the virus SARS&#8208;CoV&#8208;2, the cause of COVID&#8208;19 has triggered a tidal wave of vaccine development. In the first 9 months since the virus emerged over 200 vaccines have begun pre&#8208;clinical development, 36 of which have entered clinical trials. This review will cover the platforms under assessment, the immune responses underpinning the vaccines, the results so far and the considerations for the next steps.<boxed-text position="anchor" content-type="graphic" id="cei13517-blkfxd-0001" orientation="portrait"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="nlm-graphic-1" orientation="portrait" xlink:href="CEI-202-162-g003.jpg"/></boxed-text>
</p></abstract><abstract id="cei13517-abs-0002"><title>Summary</title><p>Since the emergence of COVID&#8208;19, caused by the SARS&#8208;CoV&#8208;2 virus at the end of 2019, there has been an explosion of vaccine development. By 24 September 2020, a staggering number of vaccines (more than 200) had started preclinical development, of which 43 had entered clinical trials, including some approaches that have not previously been licensed for human vaccines. Vaccines have been widely considered as part of the exit strategy to enable the return to previous patterns of working, schooling and socializing. Importantly, to effectively control the COVID&#8208;19 pandemic, production needs to be scaled&#8208;up from a small number of preclinical doses to enough filled vials to immunize the world&#8217;s population, which requires close engagement with manufacturers and regulators. It will require a global effort to control the virus, necessitating equitable access for all countries to effective vaccines. This review explores the immune responses required to protect against SARS&#8208;CoV&#8208;2 and the potential for vaccine&#8208;induced immunopathology. We describe the profile of the different platforms and the advantages and disadvantages of each approach. The review also addresses the critical steps between promising preclinical leads and manufacturing at scale. The issues faced during this pandemic and the platforms being developed to address it will be invaluable for future outbreak control. Nine months after the outbreak began we are at a point where preclinical and early clinical data are being generated for the vaccines; an overview of this important area will help our understanding of the next phases.</p></abstract><funding-group><award-group id="funding-0001"><funding-source>Engineering and Physical Sciences Research Council (EPSRC)</funding-source><award-id>EP/R013764/1</award-id></award-group></funding-group><counts><fig-count count="3"/><table-count count="5"/><page-count count="31"/><word-count count="58590"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>November 2020</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:5.9.9 mode:remove_FC converted:05.03.2021</meta-value></custom-meta></custom-meta-group></article-meta></front><body id="cei13517-body-0001"><sec id="cei13517-sec-0001"><title>Introduction</title><p>In November 2019, a cluster of pneumonia cases was detected in Wuhan, China [<xref rid="cei13517-bib-0001" ref-type="ref">1</xref>]. These were the first cases of COVID&#8208;19 caused by the novel beta&#8208;coronavirus SARS&#8208;CoV&#8208;2. The genetic information was made publicly available on 10 January 2020, 54 days after the first declared case. Sixty&#8208;three days after the SARS&#8208;CoV&#8208;2 sequence was published, on 13 March 2020, the first doses of the first human vaccine were being tested. By 24 September 2020, the SARS&#8208;CoV&#8208;2 vaccine landscape included 43 candidates being tested in clinical trials and more than 200 candidates. As the results from the Phase I trials and earliest Phase II/III trials emerge, this review will cover the platforms under development, the type of immune response required and the path to a clinical product.</p></sec><sec id="cei13517-sec-0002"><title>SARS&#8208;CoV&#8208;2 virology</title><p>Coronaviruses are unusually large enveloped RNA viruses, with a large positive&#8208;sense, single&#8208;stranded RNA genome. The integrity of this lengthy genome is maintained by a proof&#8208;reading replicase. The SARS&#8208;CoV&#8208;2 genome encodes 11 open reading frames (ORF), many of which have unknown functions (Fig. <xref rid="cei13517-fig-0001" ref-type="fig">1</xref>). ORF1a and ORF1b both encode polyproteins, which are cleaved into multiple non&#8208;structural proteins. ORF4 encodes the envelope protein, a viroporin [<xref rid="cei13517-bib-0002" ref-type="ref">2</xref>], and ORF5 encodes the membrane protein; together, they coordinate viral assembly and release. ORF9 encodes the nucleocapsid (N) protein. ORF2 encodes the spike (S) surface glycoprotein, the viral entry protein and key antigenic determinant, which binds the angiotensin converting enzyme 2 (ACE2) receptor on the host cells. ACE2 is commonly found on type II pneumocyte cells in the airways. SARS&#8208;CoV&#8208;2 has a 10&#8211;20 times higher affinity for ACE2 than the related coronavirus SARS&#8208;CoV&#8208;1 [<xref rid="cei13517-bib-0003" ref-type="ref">3</xref>], which was responsible for the 2002&#8211;04 SARS outbreak. SARS&#8208;CoV&#8208;2 is able to bind ACE2 from a wide range of mammalian species [<xref rid="cei13517-bib-0004" ref-type="ref">4</xref>]. Having bound ACE2, spike protein is cleaved by a host cell surface bound proteinase, either Furin or TMPRSS2, enabling entry of the viral capsid. There may be a relationship between the mechanism of viral entry via ACE2 and the pathogenesis of disease.</p><fig fig-type="Fig." xml:lang="en" id="cei13517-fig-0001" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>SARS&#8208;CoV&#8208;2 virus. The SARS&#8208;CoV&#8208;2 encodes 11 ORF, ORF1a and ORF1b are polyproteins that are cleaved into multiple individual proteins. The spike (S) protein is the major antigenic determinant, coat is made of spike (S), membrane (M) and envelope (E) proteins. The RNA in encapsulated with the nucleocapsid (N) protein). Created with Biorender.com</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="nlm-graphic-3" position="float" orientation="portrait" xlink:href="CEI-202-162-g001.jpg"/></fig><sec id="cei13517-sec-0003"><title>Pathology in natural disease</title><p>Human coronaviruses can cause both mild (OC43, HKU1, 229E and NL63) and severe (SARS&#8208;CoV&#8208;1, SARS&#8208;CoV&#8208;2 and MERS) disease. For most patients (approximately 80%), SARS&#8208;CoV&#8208;2 causes an asymptomatic infection or mild symptoms [<xref rid="cei13517-bib-0005" ref-type="ref">5</xref>]. The following signs are associated with a virus positive polymerase chain reaction (PCR) test: fatigue, fever, chills, loss of appetite and persistent cough [<xref rid="cei13517-bib-0006" ref-type="ref">6</xref>]. A striking feature of infection with SARS&#8208;CoV&#8208;2 is anosmia, a loss of smell and taste, reported in approximately 64% of cases in one study [<xref rid="cei13517-bib-0007" ref-type="ref">7</xref>]. Whether viral spread to the lower respiratory tract is a precursor for severe disease is unclear; pneumonia with characteristic pulmonary ground glass opacity changes on chest CT scans is common, even in asymptomatic individuals [<xref rid="cei13517-bib-0008" ref-type="ref">8</xref>]. Blood clotting, respiratory compromise, renal damage and cardiovascular collapse are all features of severe disease. The greatest risk factor for severe COVID&#8208;19 disease is age: the remarkable relationship with age is consistently observed, despite geographic variability in reported case fatality rates [<xref rid="cei13517-bib-0009" ref-type="ref">9</xref>].</p></sec></sec><sec id="cei13517-sec-0004"><title>Immune response to SARS&#8208;CoV&#8208;2</title><sec id="cei13517-sec-0005"><title>Protective immunity</title><p>While SARS&#8208;CoV&#8208;2 is a new virus and, therefore, the exact correlates of protection are not completely defined, there are precedents from other respiratory infections in general and coronaviruses in particular [<xref rid="cei13517-bib-0010" ref-type="ref">10</xref>]. There has been discussion that natural immunity to SARS&#8208;CoV&#8208;2 declines quickly; whether this is the case is still unclear. It is our speculation that because vaccines aim to evoke an immune response they could be more immunogenic than the virus itself, which might have mechanisms to dampen immune response: whether this speculation is correct or not is yet to be determined.</p><sec id="cei13517-sec-0006"><title>T cells</title><p>The T cell response is important in the control of other respiratory infections, and therefore likely to be important in COVID&#8208;19 [<xref rid="cei13517-bib-0011" ref-type="ref">11</xref>]. Models of SARS&#8208;CoV&#8208;1 indicate that T cells can be protective. CD4<sup>+</sup> T cell depletion in mouse models delayed viral clearance and enhanced disease [<xref rid="cei13517-bib-0012" ref-type="ref">12</xref>]; similarly, T cell transfer resulted in rapid viral clearance and disease amelioration [<xref rid="cei13517-bib-0013" ref-type="ref">13</xref>, <xref rid="cei13517-bib-0014" ref-type="ref">14</xref>]. SARS&#8208;CoV&#8208;1&#8208;specific CD8<sup>+</sup> T resident memory were protective in a mouse model in the absence of antibody [<xref rid="cei13517-bib-0015" ref-type="ref">15</xref>]. T cell memory can be long&#8208;lived; SARS&#8208;CoV&#8208;1 T cells were detected 4&#160;years after infection [<xref rid="cei13517-bib-0015" ref-type="ref">15</xref>, <xref rid="cei13517-bib-0016" ref-type="ref">16</xref>]. For SARS&#8208;CoV&#8208;2, T cell responses have been observed to a range of antigens, including S, M, N and other ORFs [<xref rid="cei13517-bib-0017" ref-type="ref">17</xref>]. SARS&#8208;CoV&#8208;2&#8208;specific T cells have been detected in individuals who had asymptomatic or mild COVID&#8208;19 [<xref rid="cei13517-bib-0018" ref-type="ref">18</xref>] and SARS&#8208;CoV&#8208;2&#8208;specific T cells have been observed in contacts of infected individuals [<xref rid="cei13517-bib-0019" ref-type="ref">19</xref>]. Patients suffering from COVID&#8208;19 had fewer T cells than healthy controls [<xref rid="cei13517-bib-0020" ref-type="ref">20</xref>].</p><p>T cells, especially CD4<sup>+</sup> T cells, can influence the immune response through the production of cytokines, and elevated cytokines have been associated with exacerbated disease [<xref rid="cei13517-bib-0020" ref-type="ref">20</xref>]. The skewing of the CD4<sup>+</sup> T cell response is likely to be important. T helper type 1 (Th1) responses are central to the successful control of SARS&#8208;CoV&#8208;1 and MERS&#8208;CoV [<xref rid="cei13517-bib-0021" ref-type="ref">21</xref>]. Th17 responses have been speculated to be deleterious [<xref rid="cei13517-bib-0022" ref-type="ref">22</xref>], and increased Th2 cytokines were seen in severe disease [<xref rid="cei13517-bib-0023" ref-type="ref">23</xref>]. Regulatory T cells are important in the resolution of infection, and were observed to be elevated in COVID&#8208;19 patients [<xref rid="cei13517-bib-0020" ref-type="ref">20</xref>]. Circulating follicular T helper cells, important in defining recall antibody response to infection, have been observed in a small number of individuals with COVID&#8208;19 [<xref rid="cei13517-bib-0024" ref-type="ref">24</xref>]. It is not clear whether the &#8216;cytokine storm&#8217; is a cause or effect of disease; understanding this relationship is critical in monitoring vaccine safety.</p></sec><sec id="cei13517-sec-0007"><title>Antibody response</title><p>The humoral response is pivotal in later stages of infection and helps to inhibit subsequent reinfection. Virus&#8208;specific antibodies were detectable in 80&#8211;100% of SARS&#8208;CoV&#8208;1 and MERS&#8208;CoV patients 2&#160;weeks after onset of symptoms [<xref rid="cei13517-bib-0025" ref-type="ref">25</xref>, <xref rid="cei13517-bib-0026" ref-type="ref">26</xref>, <xref rid="cei13517-bib-0027" ref-type="ref">27</xref>, <xref rid="cei13517-bib-0028" ref-type="ref">28</xref>, <xref rid="cei13517-bib-0029" ref-type="ref">29</xref>, <xref rid="cei13517-bib-0030" ref-type="ref">30</xref>, <xref rid="cei13517-bib-0031" ref-type="ref">31</xref>], with delayed antibody responses associated with more severe disease. A number of studies have been performed to try to more clearly understand the antibody response to SARS&#8208;CoV&#8208;2; a systematic review of studies on antibody to coronaviruses [<xref rid="cei13517-bib-0032" ref-type="ref">32</xref>] observed that antibody was rarely seen in the first 7&#160;days of infection, but rose in the second and third weeks post&#8208;infection. It is unclear whether antibodies correlate with COVID&#8208;19 severity.</p><p>Antibodies are likely to be an important part of vaccine&#8208;induced protection. In SARS&#8208;CoV&#8208;1, the antibody response is short&#8208;lived [immunoglobulin (Ig)M and IgA responses last less than 6&#160;months and IgG lasts approximately 1&#160;year]; this is possibly the same for SARS&#8208;CoV&#8208;2 [<xref rid="cei13517-bib-0033" ref-type="ref">33</xref>]. Human challenge studies using non&#8208;COVID&#8208;19 coronavirus strains suggest that higher antibody levels correlate with protection [<xref rid="cei13517-bib-0032" ref-type="ref">32</xref>]. These challenge studies have also suggested that reinfection is possible [<xref rid="cei13517-bib-0034" ref-type="ref">34</xref>], but the dose in challenge studies may be higher than experienced during natural infection. Two recent studies have observed natural reinfections with SARS&#8208;CoV&#8208;2, one asymptomatic [<xref rid="cei13517-bib-0035" ref-type="ref">35</xref>] and one symptomatic [<xref rid="cei13517-bib-0036" ref-type="ref">36</xref>], although this is in the context of more than 25 million recorded cases globally, suggesting that it is a rare event. Because of the overlap between SARS&#8208;CoV&#8208;1 and SARS&#8208;CoV&#8208;2 spike proteins, antibodies could be cross&#8208;neutralizing [<xref rid="cei13517-bib-0037" ref-type="ref">37</xref>]. However, the most potent specific, neutralizing monoclonal antibodies against the receptor binding domain (RBD) of SARS&#8208;CoV&#8208;1 did not bind to the spike protein of SARS&#8208;CoV&#8208;2 [<xref rid="cei13517-bib-0038" ref-type="ref">38</xref>]. One promising observation is that isolated neutralizing antibodies have minimally mutated VDJ genes, which make inducing them possible with fewer rounds of vaccination [<xref rid="cei13517-bib-0039" ref-type="ref">39</xref>].</p><p>Most attention has focused upon neutralizing IgG antibodies in the serum, but other antibody&#8208;mediated mechanisms may be important in disease pathogenesis. Fragment crystallizable (Fc) and Fc receptor (FcR) interactions can regulate the inflammatory response [<xref rid="cei13517-bib-0040" ref-type="ref">40</xref>] and the SARS&#8208;CoV&#8208;2 virus&#8211;antibody complex could potentially trigger such FcR&#8208;mediated inflammatory responses, causing acute lung injury [<xref rid="cei13517-bib-0041" ref-type="ref">41</xref>]. The IgA response may be important in determining disease severity of COVID&#8208;19 patients, but remains relatively unexplored so far [<xref rid="cei13517-bib-0042" ref-type="ref">42</xref>].</p></sec></sec></sec><sec id="cei13517-sec-0008"><title>Vaccine&#8208;induced immunopathology</title><p>One concern with vaccine development for SARS&#8208;CoV&#8208;2 is that the immune response can cause disease, often in the act of clearing the infection. Understanding vaccine&#8208;induced immunopathology is critically important for all emerging infectious diseases. Vaccines for emerging infections will, by necessity, require a shorter turn&#8208;around from discovery to deployment, and therefore predicting safety early in the process is critical. Vaccine&#8208;induced immunopathology can either present as an acute response to the vaccine itself or as disease enhancement after viral infection.</p><sec id="cei13517-sec-0009"><title>Acute immune reaction to vaccination</title><p>Vaccines can occasionally induce an acute autoimmune disease. This was observed during the 1976 H1N1 swine flu outbreak, where vaccination in the United States led to an increased risk of Guillain&#8211;Barr&#233; syndrome (GBS) [<xref rid="cei13517-bib-0043" ref-type="ref">43</xref>]. The mechanism has not been fully determined, but one suggestion is off&#8208;target antibodies against ganglioside GM1. Off&#8208;target autoimmune effects were also observed during the 2009 H1N1 swine flu pandemic, with narcolepsy observed in a subset of children immunized with a vaccine adjuvanted with AS03 [Pandemrix; GlaxoSmithKline (GSK)]. There was a very tight association with <italic toggle="yes">HLA&#8208;DQB1*06:02</italic> [<xref rid="cei13517-bib-0044" ref-type="ref">44</xref>]. The proposed mechanism is inhibition of the hypocretin signalling pathway. Curiously, another swine flu vaccine made by GSK (Arepanrix; GSK) using the same adjuvant was not associated with narcolepsy [<xref rid="cei13517-bib-0045" ref-type="ref">45</xref>], suggesting that the side effect was not caused by the adjuvant. The level of viral proteins, specifically nucleoprotein, may have been the problem [<xref rid="cei13517-bib-0046" ref-type="ref">46</xref>]; anti&#8208;nucleoprotein antibodies have been seen to cross&#8208;react with hypocretin [<xref rid="cei13517-bib-0047" ref-type="ref">47</xref>]. These acute events are relatively rare; the rate of GBS was 8&#160;per million individuals vaccinated and narcolepsy at approximately 30&#160;per million individuals vaccinated (all in individuals aged less than 20&#160;years) [<xref rid="cei13517-bib-0048" ref-type="ref">48</xref>]. The delayed effects of vaccines are difficult to predict; post&#8208;licensure monitoring will be critical, especially as the vaccines will potentially have been tested in fewer people during the prelicensure Phases than other licensed products.</p></sec><sec id="cei13517-sec-0010"><title>Vaccine&#8208;induced disease enhancement</title><p>Disease enhancement following infection of vaccinated individuals has been seen in other viral diseases; for example, measles, respiratory syncytial virus (RSV) and dengue virus. Of children who received formalin&#8208;inactivated measles vaccine and were then subsequently exposed to the wild&#8208;type measles virus, 15&#8211;60% developed a severe form of the disease [<xref rid="cei13517-bib-0049" ref-type="ref">49</xref>], causing the vaccine to be withdrawn in 1967. A similar situation was observed with formalin&#8208;inactivated RSV vaccination (FI&#8208;RSV) in a clinical trial in 1966. The FI&#8208;RSV vaccine induced mainly non&#8208;protective antibodies, and children who were seronegative to the virus prevaccination had enhanced disease and hospitalization compared to the control groups [<xref rid="cei13517-bib-0050" ref-type="ref">50</xref>]. Vaccine&#8208;enhanced disease has also been observed with the live attenuated tetravalent dengue vaccine (Dengvaxia; Sanofi Pasteur Inc., Swiftwater, PA, USA), specifically in seronegative children [<xref rid="cei13517-bib-0051" ref-type="ref">51</xref>].</p><p>Disease enhancement following vaccination can occur by two main mechanisms: priming for a detrimental T cell response and priming for antibodies that can increase the risk of infection or severe disease.</p></sec><sec id="cei13517-sec-0011"><title>T cell immunopathology</title><p>The cellular response to vaccination, particularly T cells and eosinophils, and the inflammatory mediators these cells release has been suggested to promote vaccine&#8208;enhanced disease [<xref rid="cei13517-bib-0052" ref-type="ref">52</xref>, <xref rid="cei13517-bib-0053" ref-type="ref">53</xref>, <xref rid="cei13517-bib-0054" ref-type="ref">54</xref>]. Whether SARS&#8208;CoV&#8208;2 vaccine platforms will have negative outcomes on infection is currently speculative, and draws upon experience with other respiratory viruses.</p><p>One important factor determining the T cell response is antigen selection. Specific epitopes can affect T cell polarization and activation, therefore antigen selection for vaccine applications requires careful consideration [<xref rid="cei13517-bib-0055" ref-type="ref">55</xref>]. Both the S and N proteins of SARS&#8208;CoV&#8208;1 have epitopes that are recognized by CD4<sup>+</sup> and CD8<sup>+</sup> T cells. Some vaccines which used the N protein induced an eosinophilic response associated with vaccine&#8208;enhanced disease [<xref rid="cei13517-bib-0013" ref-type="ref">13</xref>], and post&#8208;vaccination challenge of animals immunized with SARS&#8208;CoV&#8208;1 N protein induced severe pneumonia [<xref rid="cei13517-bib-0056" ref-type="ref">56</xref>]. Mismatch of epitopes between vaccine and challenge strain can also lead to T cell enhanced disease due to original antigenic sin, as seen in dengue [<xref rid="cei13517-bib-0057" ref-type="ref">57</xref>].</p><p>The vaccine platform may be critical in determining disease outcome on infection. Immunopathology in animal models has most commonly been linked to inactivated, alum&#8208;adjuvanted vaccines. For example, double inactivation [ultraviolet (UV) and formalin] of SARS&#8208;CoV&#8208;1 enhanced the eosinophilic response from the vaccine, eliciting a proinflammatory pulmonary response and failing to provide complete protection [<xref rid="cei13517-bib-0056" ref-type="ref">56</xref>]. Enhanced disease was also observed following immunization with a gamma&#8208;irradiated MERS&#8208;CoV vaccine [<xref rid="cei13517-bib-0056" ref-type="ref">56</xref>]. The mode of inactivation can influence both the quality of antibodies and the polarization of the T cell response to the vaccine. Formalin inactivation in particular has been associated with deleterious Th2 skewing by the addition of carbonyl groups [<xref rid="cei13517-bib-0058" ref-type="ref">58</xref>], and Th2 skewing has been seen for a formalin&#8208;inactivated vaccine for SARS&#8208;CoV&#8208;1 [<xref rid="cei13517-bib-0059" ref-type="ref">59</xref>]. Other methods of inactivation have been explored; for example, beta&#8208;propiolactone, UV or gamma radiation, which could prove to be a promising avenue forward for eliciting the correct T cell response [<xref rid="cei13517-bib-0060" ref-type="ref">60</xref>]. Immunopathology is not restricted to inactivated vaccines. It can occur following immunization with a range of vaccine platforms; for example, it has been seen in animal models of RSV vaccination with both viral vectors and DNA vaccines [<xref rid="cei13517-bib-0061" ref-type="ref">61</xref>]. Similarly, a range of vaccines against SARS&#8208;CoV&#8208;1 induced Th2&#8208;directed pulmonary immunopathology in mouse models [<xref rid="cei13517-bib-0056" ref-type="ref">56</xref>]. Age at vaccination may also be an important consideration in immunopathology: the FI&#8208;RSV vaccine was given to infants. Infants have a different immune response to adults, and this may predispose towards a qualitatively different immune memory [<xref rid="cei13517-bib-0062" ref-type="ref">62</xref>].</p></sec><sec id="cei13517-sec-0012"><title>Antibody&#8208;dependent enhancement</title><p>The humoral arm of the adaptive immune response can also contribute to disease, called &#8216;antibody&#8208;dependent enhancement&#8217; (ADE). ADE has been observed with flaviviruses, coronaviruses and some viruses of the <italic toggle="yes">Paramyxoviridae</italic> family [<xref rid="cei13517-bib-0063" ref-type="ref">63</xref>]. ADE can occur in two ways, either by causing immune complexes or by enhancing infection. Antibodies are bispecific molecules; as such, they can form antigen&#8211;antibody complexes. These complexes can cause direct damage when complex deposition in the vasculature leads to complement deposition and vessel damage, as seen after the feline coronavirus infection [<xref rid="cei13517-bib-0064" ref-type="ref">64</xref>]. Immune complexes can trigger macrophage activation leading to the release of proinflammatory cytokines. Immune complexes have been proposed to have a role in the enhanced disease seen after FI&#8208;RSV immunization [<xref rid="cei13517-bib-0065" ref-type="ref">65</xref>], and may have a role in SARS&#8208;CoV&#8208;2 [<xref rid="cei13517-bib-0041" ref-type="ref">41</xref>].</p><p>Antibodies can also increase viral disease by enhancing infection; some viruses utilize antibodies to enter target cells. In the case of dengue virus, pre&#8208;existing antibodies for one serotype of the virus can cause enhancement of infection upon subsequent exposure to a new serotype [<xref rid="cei13517-bib-0063" ref-type="ref">63</xref>]. A number of mechanisms have been proposed: antibody bound to virus could facilitate entry into macrophages through their FcRs [<xref rid="cei13517-bib-0066" ref-type="ref">66</xref>] and antibody might stabilize viral surface antigen into a mature form [<xref rid="cei13517-bib-0067" ref-type="ref">67</xref>]. The avidity of the antibody has been suggested as an important factor, with low antibody avidity a risk factor [<xref rid="cei13517-bib-0068" ref-type="ref">68</xref>]. ADE has been reported in SARS&#8208;CoV&#8208;1 after viral challenge in mice [<xref rid="cei13517-bib-0069" ref-type="ref">69</xref>], ferrets [<xref rid="cei13517-bib-0070" ref-type="ref">70</xref>] and macaques [<xref rid="cei13517-bib-0071" ref-type="ref">71</xref>] using a range of different vaccine strategies. In MERS&#8208;CoV, a neutralizing monoclonal antibody targeting the spike protein promoted viral entry via the Fc receptor [<xref rid="cei13517-bib-0072" ref-type="ref">72</xref>]. It is not yet known whether antibodies to SARS&#8208;CoV&#8208;2 will enhance disease, but it is something that is being closely monitored [<xref rid="cei13517-bib-0073" ref-type="ref">73</xref>].</p></sec><sec id="cei13517-sec-0013"><title>Models to assess vaccine safety and efficacy</title><sec id="cei13517-sec-0014"><title>Animal models</title><p>As coronaviruses have previously been associated with immunopathogenesis, vaccine&#8208;enhanced disease is a potential concern for efficient vaccine design for SARS&#8208;CoV&#8208;2. The use of models can improve understanding [<xref rid="cei13517-bib-0074" ref-type="ref">74</xref>], potentially predicting correlates of protection or disease. The ideal animal model is permissive to infection with the virus and reproduces the pathology and clinical course observed in humans. Since the SARS&#8208;CoV&#8208;1 outbreak in 2002&#8211;04 a range of species, including hamsters, cats, ferrets and non&#8208;human primates, have all been used to study pathogenesis of coronaviruses [<xref rid="cei13517-bib-0075" ref-type="ref">75</xref>, <xref rid="cei13517-bib-0076" ref-type="ref">76</xref>]. Despite productive infection in a wide range of laboratory species, few displayed overt clinical disease.</p><p>Several inbred mouse strains have been investigated to model SARS&#8208;CoV&#8208;1, including BALB/c, C57BL/6, RAG1<sup>&#8722;/&#8722;</sup> and 129SvEv mice. Although young adult mice infected with varying doses of SARS&#8208;CoV&#8208;1 showed evidence of infection, the inbred strains do not accurately reflect the alveolar damage seen in humans [<xref rid="cei13517-bib-0074" ref-type="ref">74</xref>]. However, aged mice show signs of clinical disease despite, in many cases, the absence of the lung lesions seen in humans [<xref rid="cei13517-bib-0077" ref-type="ref">77</xref>], and therefore have been used more extensively than younger mice. Transgenic mice expressing human ACE2 (hACE2) have also been generated; disease severity in transgenic mice largely correlated with the level of hACE2 expression, and when challenged with SARS&#8208;CoV&#8208;1 they developed severe infection and 100% mortality was reached by day 7 [<xref rid="cei13517-bib-0078" ref-type="ref">78</xref>]. MERS&#8208;CoV appears to be even more challenging to model, with most species resistant to infection, except for some primate species [<xref rid="cei13517-bib-0079" ref-type="ref">79</xref>] and camelids [<xref rid="cei13517-bib-0080" ref-type="ref">80</xref>, <xref rid="cei13517-bib-0081" ref-type="ref">81</xref>].</p><p>The same models are being used for SARS&#8208;CoV&#8208;2. Infection of human ACE2 transgenic mice with SARS&#8208;CoV&#8208;2 led to weight loss and viral RNA was detectable in the lungs, as well as lung pathology [<xref rid="cei13517-bib-0082" ref-type="ref">82</xref>]. Symptomatic infection and transmission of SARS&#8208;CoV&#8208;2 between animals has been observed in hamsters [<xref rid="cei13517-bib-0083" ref-type="ref">83</xref>], and asymptomatic infection and transmission of SARS&#8208;CoV&#8208;2 has been observed in ferrets [<xref rid="cei13517-bib-0083" ref-type="ref">83</xref>]. SARS&#8208;CoV&#8208;2 is also infectious in experimental settings using cats, but not dogs, pigs, chickens or ducks [<xref rid="cei13517-bib-0084" ref-type="ref">84</xref>]. As with SARS&#8208;CoV&#8208;1, non&#8208;human primates, e.g. rhesus or cynomologous macaques, have been helpful for evaluating immune protection [<xref rid="cei13517-bib-0085" ref-type="ref">85</xref>].</p></sec><sec id="cei13517-sec-0015"><title>Human challenge</title><p>As animal models do not fully recapitulate human disease, alternative strategies may be required. Controlled human infection models (CHIM) are studies in which participants (either vaccinated or not) are intentionally challenged with an infectious organism [<xref rid="cei13517-bib-0086" ref-type="ref">86</xref>]. CHIM trials of SARS&#8208;CoV&#8208;2 vaccine candidates could be particularly beneficial in vaccine and drug efficacy studies, especially if the community infection rate has declined due to epidemiological interventions [<xref rid="cei13517-bib-0087" ref-type="ref">87</xref>]. The deliberate exposure of healthy individuals to SARS&#8208;CoV&#8208;2 requires a tight ethical and regulatory framework [<xref rid="cei13517-bib-0088" ref-type="ref">88</xref>]. The major concerns are that we do not have complete understanding of the long&#8208;term sequelae of SARS&#8208;CoV&#8208;2 infection and there is a lack of rescue therapy to enable the resolution of severe infection, although recent findings suggest that dexamethasone may reduce mortality in severe disease [<xref rid="cei13517-bib-0089" ref-type="ref">89</xref>] and Remdesivir (Gilead Sciences, Foster City, CA, USA) may improve clinical status [<xref rid="cei13517-bib-0090" ref-type="ref">90</xref>]. The lack of rescue therapy is not unique to a SARS&#8208;CoV&#8208;2 CHIM. Rhinovirus and RSV CHIM do not have a specific anti&#8208;viral treatment but are self&#8208;resolving, which may also be true for SARS&#8208;CoV&#8208;2 in healthy young adults. There are also challenges associated with the manufacture of a challenge virus stock, which requires a high&#8208;containment [biosafety level III (BSLIII)] laboratory. At the time of writing, no study had been established, although the World Health Organization (WHO) has published guidance [<xref rid="cei13517-bib-0091" ref-type="ref">91</xref>] and several academic and contract research organizations are investigating the approach [<xref rid="cei13517-bib-0092" ref-type="ref">92</xref>]. An alternative use of deliberate human infection has been proposed: to infect young, low&#8208;risk individuals to build herd&#8208;immunity, and therefore safeguard the unvaccinated, immunocompromised and immunologically naive [<xref rid="cei13517-bib-0093" ref-type="ref">93</xref>, <xref rid="cei13517-bib-0094" ref-type="ref">94</xref>]. However, this strategy is unattractive because the risk factors for severe disease are not fully understood: ethically there are also questions about infecting groups of individuals for the greater benefit, especially if there is a financial incentive.</p></sec></sec></sec><sec id="cei13517-sec-0016"><title>Vaccines against SARS&#8208;CoV&#8208;2</title><p>A huge range of vaccine approaches against SARS&#8208;CoV&#8208;2 have been proposed (Table <xref rid="cei13517-tbl-0001" ref-type="table">1</xref>). These include traditional approaches&#160;&#8211; inactivated, live attenuated and protein/adjuvant approaches and more novel, as yet, unlicensed approaches&#160;&#8211;&#160;viral vectors and nucleic acids. This has been a rapidly evolving field and some of the vaccines are more advanced than others. We are focusing upon those that are in clinical trials at the time of writing (Table <xref rid="cei13517-tbl-0002" ref-type="table">2</xref>). Several factors need to be considered before any vaccine progresses to widespread usage. First and foremost is vaccine safety and efficacy. Closely linked is the scope for global scale&#8208;up manufacture to produce enough doses to achieve herd immunity.</p><table-wrap id="cei13517-tbl-0001" xml:lang="en" content-type="Table" orientation="portrait" position="float"><label>Table 1</label><caption><p>Vaccines under consideration by platform and manufacturer/ developer, all stages from pre&#8208;clinical; correct at 1<sup>st</sup> September 2020. See <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://vac-lshtm.shinyapps.io/ncov_vaccine_landscape/">https://vac&#8208;lshtm.shinyapps.io/ncov_vaccine_landscape/</ext-link> for updates. Bold are in clinical trials</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">
<bold>Platform (vaccines in development)</bold>
</th><th align="center" valign="top" rowspan="1" colspan="1">
<bold>Developer/ Manufacturer</bold>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">RNA (30)</td><td align="left" rowspan="1" colspan="1">Arcturus, BIOCAD, <bold>BioNTech/Pfizer</bold>, Cansino, CNB&#8208;CSIC, Chimeron Bio, China CDC, Chula VRC, <bold>CureVac</bold>, Elixirgen, Emergex Vaccines, eTheRNA, FBRI, Fudan University/ RNACure Biopharma, GeneOne, Gennova, Greenlight, IDIBAPS, <bold>Imperial College London/ VacEquity Global Health</bold>, Max Planck Institute, <bold>Moderna/ NIAID</bold>, <bold>People&#8217;s Liberation Army</bold>, RNAimmune, Rochester clinical research, Selcuk University, Translate Bio/ Sanofi, University of Tokyo, University of Washington, Ziphius</td></tr><tr><td align="left" rowspan="1" colspan="1">DNA (19)</td><td align="left" rowspan="1" colspan="1">Aegis, BioNet, Chula VRC, Ege University, Entos Pharmaceuticals, <bold>Genexine</bold>, Immunomic/ PharmaJet, <bold>Inovio</bold>, Karolinska Institute, Mediphage Bioceuticals, National Research Centre (Egypt), <bold>Osaka University/ AnGeS</bold>, Scancell, Statens Serum Institute, Takis, Touchlight Genetics, DIOSynVax/ Cambridge University, UW&#8208;Madison, <bold>Zydus&#8208;Cadila</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Non&#8208;replicating viral vector (29)</td><td align="left" rowspan="1" colspan="1">Altimmune, Ankara University, Bharat Biotech, <bold>CanSino</bold>, CNB&#8208;CSIC, DZIF, Erciyes University, <bold>Gamaleya Research Institute</bold>, GeoVax, Greffex, ID Pharma, IDIBAPS, ImmunityBio, <bold>Janssen</bold>, AveXis, McMaster University, BIOTEC, National Research Centre (Egypt), <bold>ReiThera</bold>, Stabilitech, Tsinghua University, University of Georgia, University of Manitoba, <bold>University of Oxford/ AstraZeneca</bold>, Valo Therapeutics, Vaxart, Vaxinz.</td></tr><tr><td align="left" rowspan="1" colspan="1">Replicating Viral vector (21)</td><td align="left" rowspan="1" colspan="1">Aurobindo, <bold>Beijing Wantai Biological Pharmacy/ Xiamen University</bold>, BIOCAD, DZIF, FBRI, FIOCRUZ, IAVI/Merck, <bold>Institut Pasteur/Themis/Merck/University of Pittsburgh</bold>, Intravacc, Weizmann Institute, KU Leuven, Lancaster University, Sumagen, Tonix Pharma, University of Hong Kong, University of Western Ontario, UW&#8208;Madison, Zydus Cadila.</td></tr><tr><td align="left" rowspan="1" colspan="1">Inactivated (14)</td><td align="left" rowspan="1" colspan="1">
<bold>Sinopharm/ Beijing institute of biological products/ Wuhan institute of biological products</bold>, Beijing Minhai, <bold>Bharat Biotech</bold>, Erciyes University, <bold>Institute of Medical Biology/ Chinese Academy of Medical Sciences</bold>, KM Biologics, National Research Centre (Egypt), Osaka University, <bold>Research Institute for Biological Safety Problems</bold>, Selcuk University, <bold>Sinovac</bold>, Valneva.</td></tr><tr><td align="left" rowspan="1" colspan="1">Live Attenuated (4)</td><td align="left" rowspan="1" colspan="1">Codagenix/Serum Insitute India, Indian Immunologicals Ltd, Abicadem, Meissa</td></tr><tr><td align="left" rowspan="1" colspan="1">Protein (71)</td><td align="left" rowspan="1" colspan="1">AdaptVac, <bold>Adimmmune</bold>, AJ Vaccines, Akers Biosciences, <bold>Anhui Zhifei</bold>, AnyGo, Applied Biotechnology Institute, Axon Neuroscience, Baiya Phytopharm, Baylor Colloge, Biological E, BiOMVis, Bogazici, Chulalongkorn, <bold>Clover Biopharm/ GSK</bold>, <bold>Covaxx</bold>, EpiVax, ExpreS2ion, FBRI, Flow Pharma, G+Flas life science, Generex, Heat Biologics, Helix Biogen, iBio, ImmunoPrecise, IMV Inc, InnoMedica, Innovax, <bold>Instituto Finlay</bold>, Intravacc, Izmir Biomedicine, <bold>Kentucky Bioprocessing</bold>, LakePharma Inc, Liaoning Chengda, Lomonosov Moscow State University, Max Planck Institute, <bold>Medigen</bold>, MIGAL, MOGAM, Mynvax, Shionogi, National Research Centre (Egypt), Neovii, Oncogen, BIKEN, PDS Biotech, Quadram Institute, Research Institute for Biological Safety Problems, <bold>Sanofi/ GSK</bold>, Sichuan University, SK Biosciences, Soligenix, St Petersburg Scientific research institute of vaccines and sera, University of Alberta, UCSD, University of Pittsburgh, <bold>University of Queensland/ CSL/ Sequirus</bold>, CONICET, University of Virginia, Vabiotech, Vaxil Bio, <bold>Vaxine Pty</bold>, Versatope, VIDO&#8208;InterVac, Walter Reed Army Institute of Research, Yisheng</td></tr><tr><td align="left" rowspan="1" colspan="1">VLP/ Nanoparticle (13)</td><td align="left" rowspan="1" colspan="1">ARTES, Bezmialem Vakif, Doherty Institute, Imophoron, IrsiCaixa, Mahidol University, <bold>Medicago/ GSK</bold>, Middle East Technical University, <bold>Novavax</bold>, Navvarabiomed, OSIVAX, Saiba, University of Sao Paolo, VBI Vaccines</td></tr><tr><td align="left" rowspan="1" colspan="1">Cell based (4)</td><td align="left" rowspan="1" colspan="1">
<bold>Shenzhen Geno&#8208;Immune Medical Institute</bold>, Henan Provincial centre for Disease Control and Prevention, <bold>Avita Biomed</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Bacterial Vector (3)</td><td align="left" rowspan="1" colspan="1">
<bold>Symvivo</bold>, UCLA, Versatope</td></tr></tbody></table><permissions><copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder></permissions></table-wrap><table-wrap id="cei13517-tbl-0002" xml:lang="en" content-type="Table" orientation="portrait" position="float"><label>Table 2</label><caption><p>
<bold>Vaccines in clinical trials</bold>: Correct at 1<sup>st</sup> September 2020. See <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://vac-lshtm.shinyapps.io/ncov_vaccine_landscape/">https://vac&#8208;lshtm.shinyapps.io/ncov_vaccine_landscape/</ext-link> for updates. Published data included where found: this may be an incomplete record</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Company/Organisation developing</th><th align="left" valign="top" rowspan="1" colspan="1">Platform</th><th align="left" valign="top" rowspan="1" colspan="1">Manufacturer/Sponsor Location</th><th align="left" valign="top" rowspan="1" colspan="1">What antigen</th><th align="left" valign="top" rowspan="1" colspan="1">Previous experience for other pathogens</th><th align="left" valign="top" rowspan="1" colspan="1">Funding source (where public)</th><th align="left" valign="top" rowspan="1" colspan="1">Vaccine available prediction</th><th align="left" valign="top" rowspan="1" colspan="1">Clinical Trial stage</th><th align="left" valign="top" rowspan="1" colspan="1">Reported Results</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Arcturus</td><td align="left" rowspan="1" colspan="1">self&#8208;amplifying RNA (saRNA)/LNP</td><td align="left" rowspan="1" colspan="1">Singapore</td><td align="left" rowspan="1" colspan="1">Pre&#8208;fusion Spike</td><td align="left" rowspan="1" colspan="1">Influenza, Gene Therapy</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<p>Phase I</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04480957">NCT04480957</ext-link></p>
</td><td align="left" rowspan="1" colspan="1">On company website: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://arcturusrx.com/">https://arcturusrx.com/</ext-link>
</td></tr><tr><td align="left" rowspan="1" colspan="1">BioNTech/Pfizer/Forsun</td><td align="left" rowspan="1" colspan="1">
<p>Modified nucleoside mRNA</p>
<p>LNP formulation</p>
</td><td align="left" rowspan="1" colspan="1">Germany</td><td align="left" rowspan="1" colspan="1">
<p>Spike</p>
<p>Receptor binding domain (RBD)</p>
</td><td align="left" rowspan="1" colspan="1">Phase I cancer vaccine</td><td align="left" rowspan="1" colspan="1">
<p>Pfizer contract</p>
<p>Forsun for China</p>
</td><td align="left" rowspan="1" colspan="1">Early 2021</td><td align="left" rowspan="1" colspan="1">
<p>Phase I (China)</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04523571">NCT04523571</ext-link></p>
<p>Phase I (China)</p>
<p>ChiCTR2000034825</p>
<p>Phase I/II (Germany, USA)</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04380701">NCT04380701</ext-link></p>
<p>Phase II/III (USA, Argentina, Brazil)</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04368728">NCT04368728</ext-link></p>
</td><td align="left" rowspan="1" colspan="1">
<p>Pre&#8208;clinical (mice) [<xref rid="cei13517-bib-0197" ref-type="ref">197</xref>]</p>
<p>Phase I trials [<xref rid="cei13517-bib-0198" ref-type="ref">198</xref>, <xref rid="cei13517-bib-0199" ref-type="ref">199</xref>, <xref rid="cei13517-bib-0200" ref-type="ref">200</xref>]</p>
</td></tr><tr><td align="left" rowspan="1" colspan="1">CureVac</td><td align="left" rowspan="1" colspan="1">mRNA</td><td align="left" rowspan="1" colspan="1">Germany</td><td align="left" rowspan="1" colspan="1">Spike</td><td align="left" rowspan="1" colspan="1">Rabies, Lassa, Yellow Fever, RSV, Influenza</td><td align="left" rowspan="1" colspan="1">BMGF, CEPI, EU</td><td align="left" rowspan="1" colspan="1">Expects clinical tests by June</td><td align="left" rowspan="1" colspan="1">
<p>Phase I</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04449276">NCT04449276</ext-link></p>
</td><td align="left" rowspan="1" colspan="1">On company website: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.curevac.com/en/://www.curevac.com/en/">https://www.curevac.com/en/</ext-link>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Imperial College London/VacEquity Global Health</td><td align="left" rowspan="1" colspan="1">saRNA/LNP</td><td align="left" rowspan="1" colspan="1">UK</td><td align="left" rowspan="1" colspan="1">Stabilised Spike</td><td align="left" rowspan="1" colspan="1">EBOV; LASV, MARV, Inf (H7N9), RABV</td><td align="left" rowspan="1" colspan="1">UK government (MRC and NIHR)</td><td align="left" rowspan="1" colspan="1">June 2021</td><td align="left" rowspan="1" colspan="1">
<p>Phase I/II</p>
<p>ISRCTN 17072692</p>
</td><td align="left" rowspan="1" colspan="1">Pre&#8208;clinical (mice) [<xref rid="cei13517-bib-0103" ref-type="ref">103</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Moderna</td><td align="left" rowspan="1" colspan="1">mRNA</td><td align="left" rowspan="1" colspan="1">USA</td><td align="left" rowspan="1" colspan="1">Stabilised Spike</td><td align="left" rowspan="1" colspan="1">MERS&#8208;CoV, CMV, Zika, RSV, PIV3, RSV, Influenza</td><td align="left" rowspan="1" colspan="1">CEPI</td><td align="left" rowspan="1" colspan="1">
<p>June 2021</p>
<p>Emergency for HCW 2020</p>
</td><td align="left" rowspan="1" colspan="1">
<p>Phase I <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04283461">NCT04283461</ext-link></p>
<p>Phase II</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04405076">NCT04405076</ext-link></p>
<p>Phase III</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04470427">NCT04470427</ext-link></p>
</td><td align="left" rowspan="1" colspan="1">
<p>Pre&#8208;clinical (mice) [<xref rid="cei13517-bib-0195" ref-type="ref">195</xref>]</p>
<p>Phase I trial [<xref rid="cei13517-bib-0196" ref-type="ref">196</xref>]</p>
</td></tr><tr><td align="left" rowspan="1" colspan="1">People&#8217;s Liberation Army/Walvax</td><td align="left" rowspan="1" colspan="1">mRNA</td><td align="left" rowspan="1" colspan="1">China</td><td align="left" rowspan="1" colspan="1">Spike RBD</td><td align="left" rowspan="1" colspan="1">Meningococcus, HiB, <italic toggle="yes">Streptococcus pneumoniae</italic>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Phase 1 ChiCTR2000034112</td><td align="left" rowspan="1" colspan="1">None published</td></tr><tr><td align="left" rowspan="1" colspan="1">Genexine</td><td align="left" rowspan="1" colspan="1">DNA</td><td align="left" rowspan="1" colspan="1">Korea</td><td align="left" rowspan="1" colspan="1">Spike</td><td align="left" rowspan="1" colspan="1">HPV</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<p>Phase I</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04445389">NCT04445389</ext-link></p>
</td><td align="left" rowspan="1" colspan="1">None published</td></tr><tr><td align="left" rowspan="1" colspan="1">INOVIO</td><td align="left" rowspan="1" colspan="1">DNA</td><td align="left" rowspan="1" colspan="1">USA</td><td align="left" rowspan="1" colspan="1">Spike</td><td align="left" rowspan="1" colspan="1">MERS&#8208;CoV, HPV, HIV, Ebola, Lassa</td><td align="left" rowspan="1" colspan="1">BMGF, CEPI, DoD</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<p>Phase I (USA)</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04336410">NCT04336410</ext-link></p>
<p>Phase I/II (Korea)</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04447781">NCT04447781</ext-link></p>
</td><td align="left" rowspan="1" colspan="1">
<p>Pre&#8208;clinical (mice) [<xref rid="cei13517-bib-0185" ref-type="ref">185</xref>]</p>
<p>Pre&#8208;clinical (NHP) [<xref rid="cei13517-bib-0186" ref-type="ref">186</xref>]</p>
<p>Phase I trial on company website <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.inovio.com/">https://www.inovio.com/</ext-link>
</p>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Osaka University/AnGes</td><td align="left" rowspan="1" colspan="1">DNA</td><td align="left" rowspan="1" colspan="1">Japan</td><td align="left" rowspan="1" colspan="1">Spike</td><td align="left" rowspan="1" colspan="1">Gene therapy</td><td align="left" rowspan="1" colspan="1">Unknown</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<p>Phase I</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04463472">NCT04463472</ext-link></p>
</td><td align="left" rowspan="1" colspan="1">None published</td></tr><tr><td align="left" rowspan="1" colspan="1">Zydus Cadila</td><td align="left" rowspan="1" colspan="1">DNA</td><td align="left" rowspan="1" colspan="1">India</td><td align="left" rowspan="1" colspan="1">Spike</td><td align="left" rowspan="1" colspan="1">Rabies, Flu, MMR, Tetanus</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Early 2021</td><td align="left" rowspan="1" colspan="1">
<p>Phase I</p>
<p>CTRI/2020/07/026352</p>
</td><td align="left" rowspan="1" colspan="1">On company website: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://zyduscadila.com/research://zyduscadila.com/research">https://zyduscadila.com/research</ext-link>
</td></tr><tr><td align="left" rowspan="1" colspan="1">CanSino Beijing Institute of Biotechnology</td><td align="left" rowspan="1" colspan="1">Adenovirus Type 5 Vector</td><td align="left" rowspan="1" colspan="1">China</td><td align="left" rowspan="1" colspan="1">Spike</td><td align="left" rowspan="1" colspan="1">Ebola</td><td align="left" rowspan="1" colspan="1">Unknown</td><td align="left" rowspan="1" colspan="1">2021</td><td align="left" rowspan="1" colspan="1">
<p>Phase I</p>
<p>ChiCTR2000030906</p>
<p>Phase II (China)</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04341389">NCT04341389</ext-link></p>
<p>Phase I/II (Canada)</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04398147">NCT04398147</ext-link></p>
</td><td align="left" rowspan="1" colspan="1">
<p>Phase I [<xref rid="cei13517-bib-0165" ref-type="ref">166</xref>]</p>
<p>Phase II [<xref rid="cei13517-bib-0167" ref-type="ref">167</xref>]</p>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Gamaleya Research Institute</td><td align="left" rowspan="1" colspan="1">
<p>Adenovirus prime boost</p>
<p>(Ad26 and then Ad5)</p>
</td><td align="left" rowspan="1" colspan="1">Russia</td><td align="left" rowspan="1" colspan="1">Spike</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<p>2021 Jan</p>
<p>&#8216;Sputnik V&#8217;</p>
</td><td align="left" rowspan="1" colspan="1">
<p>Phase I</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04436471">NCT04436471</ext-link></p>
<p>Phase I (lyophilised)</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04437875">NCT04437875</ext-link></p>
<p>Phase III</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04530396">NCT04530396</ext-link></p>
</td><td align="left" rowspan="1" colspan="1">Phase I [<xref rid="cei13517-bib-0171" ref-type="ref">171</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Janssen</td><td align="left" rowspan="1" colspan="1">Ad26 adenovirus vector</td><td align="left" rowspan="1" colspan="1">USA, Belgium</td><td align="left" rowspan="1" colspan="1">Spike</td><td align="left" rowspan="1" colspan="1">Ebola (Ad26.ZEBOV)</td><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<p>Phase I/II (USA/Belgium)</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04436276">NCT04436276</ext-link></p>
<p>Phase I (Japan)</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04509947">NCT04509947</ext-link></p>
<p>Phase III (Multi&#8208;site)</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04505722">NCT04505722</ext-link> (not yet started)</p>
</td><td align="left" rowspan="1" colspan="1">Pre&#8208;clinical (NHP) [<xref rid="cei13517-bib-0170" ref-type="ref">170</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">University of Oxford/AstraZeneca</td><td align="left" rowspan="1" colspan="1">Adenovirus: ChAdOx1 nCov&#8208;19/AZD1222</td><td align="left" rowspan="1" colspan="1">UK</td><td align="left" rowspan="1" colspan="1">Spike</td><td align="left" rowspan="1" colspan="1">MERS, influenza, TB, Chikungunya, Zika, MenB, plague</td><td align="left" rowspan="1" colspan="1">UK Government, CEPI, US Government</td><td align="left" rowspan="1" colspan="1">Early 2021</td><td align="left" rowspan="1" colspan="1">
<p>Phase I/II (UK)</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04324606">NCT04324606</ext-link></p>
<p>Phase I/II (South Africa +/&#8208; HIV)</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04444674">NCT04444674</ext-link></p>
<p>Phase II/III (UK)</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04400838">NCT04400838</ext-link></p>
<p>Phase II/III (Brazil)</p>
<p>ISRCTN89951424</p>
<p>Phase III (USA)</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04516746">NCT04516746</ext-link></p>
</td><td align="left" rowspan="1" colspan="1">
<p>Pre&#8208;clinical (mice/pigs) [<xref rid="cei13517-bib-0162" ref-type="ref">162</xref>]</p>
<p>Pre&#8208;clinical (NHP) [<xref rid="cei13517-bib-0163" ref-type="ref">163</xref>]</p>
<p>Phase I/II [<xref rid="cei13517-bib-0164" ref-type="ref">164</xref>]</p>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Reithera</td><td align="left" rowspan="1" colspan="1">Simian Adenovirus</td><td align="left" rowspan="1" colspan="1">Italy</td><td align="left" rowspan="1" colspan="1">Spike</td><td align="left" rowspan="1" colspan="1">Gene delivery/Vectored vaccines</td><td align="left" rowspan="1" colspan="1">Italian Government</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<p>Phase I</p>
<p>2020&#8208;002835&#8208;31</p>
</td><td align="left" rowspan="1" colspan="1">None published</td></tr><tr><td align="left" rowspan="1" colspan="1">Institut Pasteur/Themis/Merck/University of Pittsburgh</td><td align="left" rowspan="1" colspan="1">Live attenuated recombinant measles vector</td><td align="left" rowspan="1" colspan="1">Austria/USA</td><td align="left" rowspan="1" colspan="1">Modified Spike</td><td align="left" rowspan="1" colspan="1">Chikungunya virus</td><td align="left" rowspan="1" colspan="1">CEPI</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<p>Phase I</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04497298">NCT04497298</ext-link></p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04498247">NCT04498247</ext-link></p>
</td><td align="left" rowspan="1" colspan="1">None published</td></tr><tr><td align="left" rowspan="1" colspan="1">Beijing Wantai Biological Pharmacy/Xiamen University</td><td align="left" rowspan="1" colspan="1">Influenza virus vector</td><td align="left" rowspan="1" colspan="1">China</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Hepatitis E vaccine</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<p>Phase I</p>
<p>ChiCTR2000037782</p>
</td><td align="left" rowspan="1" colspan="1">None Published</td></tr><tr><td align="left" rowspan="1" colspan="1">Beijing institute of biological products/Wuhan institute of biological products/Sinopharm</td><td align="left" rowspan="1" colspan="1">Beta&#8208;propiolactone inactivated virus</td><td align="left" rowspan="1" colspan="1">China</td><td align="left" rowspan="1" colspan="1">Whole virus</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Dec 2020</td><td align="left" rowspan="1" colspan="1">
<p>Phase I/II (China)</p>
<p>ChiCTR2000031809</p>
<p>Phase III (UAE)</p>
<p>ChiCTR2000034780</p>
<p>Phase III (UAE, Bahrain)</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04510207">NCT04510207</ext-link></p>
</td><td align="left" rowspan="1" colspan="1">Phase I/II [<xref rid="cei13517-bib-0150" ref-type="ref">150</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Bharat Biotech</td><td align="left" rowspan="1" colspan="1">Inactivated virus</td><td align="left" rowspan="1" colspan="1">India</td><td align="left" rowspan="1" colspan="1">Whole Virus</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Indian Council of Medical Research</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<p>Phase I/II (India)</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04471519">NCT04471519</ext-link></p>
</td><td align="left" rowspan="1" colspan="1">None Published</td></tr><tr><td align="left" rowspan="1" colspan="1">Institute of Medical Biology, Chinese Academy of Medical Sciences</td><td align="left" rowspan="1" colspan="1">Inactivated virus</td><td align="left" rowspan="1" colspan="1">China</td><td align="left" rowspan="1" colspan="1">Whole Virus</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<p>Phase I/II</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04412538">NCT04412538</ext-link></p>
<p>Phase I/II (Over 60s)</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04470609">NCT04470609</ext-link></p>
</td><td align="left" rowspan="1" colspan="1">None Published</td></tr><tr><td align="left" rowspan="1" colspan="1">Research Institute for Biological Safety Problems/National Scientific Center for Phthisiopulmonology of the Republic of Kazakhstan</td><td align="left" rowspan="1" colspan="1">Inactivated virus</td><td align="left" rowspan="1" colspan="1">Kazakhstan</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<p>Phase I</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04530357">NCT04530357</ext-link></p>
</td><td align="left" rowspan="1" colspan="1">None Published</td></tr><tr><td align="left" rowspan="1" colspan="1">Sinovac</td><td align="left" rowspan="1" colspan="1">
<p>Beta&#8208;propiolactone Inactivated</p>
<p>Alum Adjuvant</p>
</td><td align="left" rowspan="1" colspan="1">China</td><td align="left" rowspan="1" colspan="1">Whole inactivated virus adjuvanted Alum or CpG</td><td align="left" rowspan="1" colspan="1">Hand&#8208;Foot and Mouth, Hepatitis A, Influenza</td><td align="left" rowspan="1" colspan="1">Ministry of science and technology, China</td><td align="left" rowspan="1" colspan="1">Late November 2020</td><td align="left" rowspan="1" colspan="1">
<p>Phase I/II (China)</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04383574">NCT04383574</ext-link></p>
<p>Phase I/II (China)</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04352608">NCT04352608</ext-link></p>
<p>Phase III (Brazil)</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04456595">NCT04456595</ext-link></p>
<p>Phase III (Indonesia)</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04508075">NCT04508075</ext-link></p>
</td><td align="left" rowspan="1" colspan="1">Phase I [<xref rid="cei13517-bib-0149" ref-type="ref">149</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Adimmune</td><td align="left" rowspan="1" colspan="1">Protein (Baculovirus derived) +Alum adjuvant</td><td align="left" rowspan="1" colspan="1">Taiwan</td><td align="left" rowspan="1" colspan="1">Spike Receptor binding domain (RBD)</td><td align="left" rowspan="1" colspan="1">EV71, Influenza, Japanese Encephalitis Virus</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<p>Phase I</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04522089">NCT04522089</ext-link></p>
</td><td align="left" rowspan="1" colspan="1">None published</td></tr><tr><td align="left" rowspan="1" colspan="1">Anhui Zhifei</td><td align="left" rowspan="1" colspan="1">Protein</td><td align="left" rowspan="1" colspan="1">China</td><td align="left" rowspan="1" colspan="1">RBD Dimer</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<p>Phase I</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04445194">NCT04445194</ext-link></p>
<p>Phase II</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04466085">NCT04466085</ext-link></p>
</td><td align="left" rowspan="1" colspan="1">None published</td></tr><tr><td align="left" rowspan="1" colspan="1">Clover Australia and GSK</td><td align="left" rowspan="1" colspan="1">
<p>Protein subunit S&#8208;Trimer</p>
<p>AS03 adjuvant</p>
</td><td align="left" rowspan="1" colspan="1">Australia</td><td align="left" rowspan="1" colspan="1">
<p>Trimeric SARS&#8208;CoV&#8208;2 S protein subunit</p>
<p>AS03 Adjuvant</p>
</td><td align="left" rowspan="1" colspan="1">Influenza</td><td align="left" rowspan="1" colspan="1">CEPI funding for phase I, adjuvant provided by GSK</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<p>Phase I</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04405908">NCT04405908</ext-link></p>
</td><td align="left" rowspan="1" colspan="1">None published</td></tr><tr><td align="left" rowspan="1" colspan="1">Covaxx/University of Nebraska Medical Center</td><td align="left" rowspan="1" colspan="1">Multi&#8208;epitope peptide</td><td align="left" rowspan="1" colspan="1">Taiwan/USA</td><td align="left" rowspan="1" colspan="1">RBD peptide plus CTL pool from M, S2 and N</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<p>Phase I</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04545749">NCT04545749</ext-link></p>
</td><td align="left" rowspan="1" colspan="1">None published`</td></tr><tr><td align="left" rowspan="1" colspan="1">Vector Institute</td><td align="left" rowspan="1" colspan="1">Peptide + Adjuvant (Alum)</td><td align="left" rowspan="1" colspan="1">Russia</td><td align="left" rowspan="1" colspan="1">Multiple epitopes</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<p>Phase I</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04527575">NCT04527575</ext-link></p>
</td><td align="left" rowspan="1" colspan="1">None published</td></tr><tr><td align="left" rowspan="1" colspan="1">Instituto Finlay de Vacunas</td><td align="left" rowspan="1" colspan="1">Protein + Adjuvant</td><td align="left" rowspan="1" colspan="1">Cuba</td><td align="left" rowspan="1" colspan="1">Spike RBD</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<p>Phase I</p>
<p>IFV/COR/04</p>
</td><td align="left" rowspan="1" colspan="1">None published</td></tr><tr><td align="left" rowspan="1" colspan="1">Kentucky Bioprocessing</td><td align="left" rowspan="1" colspan="1">Protein + (Plant derived)</td><td align="left" rowspan="1" colspan="1">USA</td><td align="left" rowspan="1" colspan="1">Spike</td><td align="left" rowspan="1" colspan="1">Influenza</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<p>Phase I</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04473690">NCT04473690</ext-link></p>
</td><td align="left" rowspan="1" colspan="1">None published</td></tr><tr><td align="left" rowspan="1" colspan="1">Medigen</td><td align="left" rowspan="1" colspan="1">Protein + CPG + Alum</td><td align="left" rowspan="1" colspan="1">USA</td><td align="left" rowspan="1" colspan="1">Spike</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<p>Phase I</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04487210">NCT04487210</ext-link></p>
</td><td align="left" rowspan="1" colspan="1">None published</td></tr><tr><td align="left" rowspan="1" colspan="1">Sanofi/GSK</td><td align="left" rowspan="1" colspan="1">Protein + Adjuvant (AS03? + other)</td><td align="left" rowspan="1" colspan="1">France/USA</td><td align="left" rowspan="1" colspan="1">Spike</td><td align="left" rowspan="1" colspan="1">Multiple</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Early 2021</td><td align="left" rowspan="1" colspan="1">
<p>Phase I/II</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04537208">NCT04537208</ext-link></p>
</td><td align="left" rowspan="1" colspan="1">None published</td></tr><tr><td align="left" rowspan="1" colspan="1">University of Queensland/CSL</td><td align="left" rowspan="1" colspan="1">Protein + adjuvant (MF59)</td><td align="left" rowspan="1" colspan="1">Australia</td><td align="left" rowspan="1" colspan="1">Clamped Spike protein</td><td align="left" rowspan="1" colspan="1">Influenza, RSV</td><td align="left" rowspan="1" colspan="1">
<p>Australian Government</p>
<p>CEPI</p>
</td><td align="left" rowspan="1" colspan="1">Early 2021</td><td align="left" rowspan="1" colspan="1">
<p>Phase I</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04495933">NCT04495933</ext-link></p>
</td><td align="left" rowspan="1" colspan="1">None published</td></tr><tr><td align="left" rowspan="1" colspan="1">Vaxine PTY</td><td align="left" rowspan="1" colspan="1">Protein + Adjuvant (Advax)</td><td align="left" rowspan="1" colspan="1">Australia</td><td align="left" rowspan="1" colspan="1">Spike</td><td align="left" rowspan="1" colspan="1">Influenza, JEV, West Nile</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<p>Phase I</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04453852">NCT04453852</ext-link></p>
</td><td align="left" rowspan="1" colspan="1">None published</td></tr><tr><td align="left" rowspan="1" colspan="1">West China Hospital/Sichuan University</td><td align="left" rowspan="1" colspan="1">Protein (insect cell derived)</td><td align="left" rowspan="1" colspan="1">China</td><td align="left" rowspan="1" colspan="1">RBD</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<p>Phase I</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04530656">NCT04530656</ext-link></p>
</td><td align="left" rowspan="1" colspan="1">None published</td></tr><tr><td align="left" rowspan="1" colspan="1">Novavax</td><td align="left" rowspan="1" colspan="1">
<p>Recombinant nanoparticle vaccine (NVX&#8208;CoV2373)</p>
<p>Matrix M adjuvant</p>
</td><td align="left" rowspan="1" colspan="1">USA</td><td align="left" rowspan="1" colspan="1">Spike</td><td align="left" rowspan="1" colspan="1">Previous vaccine phase I work for SARS, MERS and Ebola</td><td align="left" rowspan="1" colspan="1">CEPI</td><td align="left" rowspan="1" colspan="1">June 2021</td><td align="left" rowspan="1" colspan="1">
<p>Phase I</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04368988">NCT04368988</ext-link></p>
</td><td align="left" rowspan="1" colspan="1">
<p>Pre&#8208;clinical (Mice/NHP) [<xref rid="cei13517-bib-0129" ref-type="ref">129</xref>]</p>
<p>Phase I [<xref rid="cei13517-bib-0128" ref-type="ref">128</xref>]</p>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Medicago</td><td align="left" rowspan="1" colspan="1">Protein VLP (Plant derived) + CpG + AS03</td><td align="left" rowspan="1" colspan="1">Canadia</td><td align="left" rowspan="1" colspan="1">Spike</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<p>Phase I</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04450004">NCT04450004</ext-link></p>
</td><td align="left" rowspan="1" colspan="1">None published</td></tr><tr><td align="left" rowspan="1" colspan="1">Avita</td><td align="left" rowspan="1" colspan="1">Dendritic cell vaccine +GMCSF</td><td align="left" rowspan="1" colspan="1">USA</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<p>Phase I</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04386252">NCT04386252</ext-link></p>
</td><td align="left" rowspan="1" colspan="1">None published</td></tr><tr><td align="left" rowspan="1" colspan="1">Shenzhen Geno&#8208;Immune Medical Institute</td><td align="left" rowspan="1" colspan="1">Lentiviral transfected artificial APC (and DC)</td><td align="left" rowspan="1" colspan="1">China</td><td align="left" rowspan="1" colspan="1">S, M, E, N and P proteins</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">2023/24</td><td align="left" rowspan="1" colspan="1">
<p>Phase I</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04276896">NCT04276896</ext-link></p>
<p>Phase I</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04299724">NCT04299724</ext-link></p>
</td><td align="left" rowspan="1" colspan="1">None published</td></tr><tr><td align="left" rowspan="1" colspan="1">Symvivo</td><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">Bifidobacterium longum</italic> vector, delivered orally</td><td align="left" rowspan="1" colspan="1">Canada</td><td align="left" rowspan="1" colspan="1">Spike</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<p>Phase I</p>
<p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04334980">NCT04334980</ext-link></p>
</td><td align="left" rowspan="1" colspan="1">None published</td></tr></tbody></table><permissions><copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder></permissions></table-wrap><sec id="cei13517-sec-0017"><title>Possible antigens</title><sec id="cei13517-sec-0018"><title>The spike (S) protein</title><p>Before looking at the platforms being developed, the antigen needs to be considered. Based on experience with SARS&#8208;CoV&#8208;1, most vaccines target the SARS&#8208;CoV&#8208;2 spike protein. Within the spike, the receptor binding domain (RBD) responsible for binding to and entering host cells is the primary target of neutralizing antibodies [<xref rid="cei13517-bib-0095" ref-type="ref">95</xref>], and some vaccines only include this region. However, a recent study that isolated monoclonal antibodies found that most of them targeted areas outside the RBD [<xref rid="cei13517-bib-0039" ref-type="ref">39</xref>]. An important consideration is the correct folding of the protein, both during production and when the vaccine is in storage prior to deployment. The coronavirus spike is a type 1 fusion protein and is metastable, undergoing an irreversible conformational change to enable membrane fusion [<xref rid="cei13517-bib-0003" ref-type="ref">3</xref>, <xref rid="cei13517-bib-0096" ref-type="ref">96</xref>, <xref rid="cei13517-bib-0097" ref-type="ref">97</xref>]. This may affect the ability of the antigen to induce neutralizing antibodies. A similar effect has been seen with the RSV fusion (F) glycoprotein. Antibodies specific to prefusion F (pre&#8208;F) have better neutralizing capacity than post&#8208;fusion F&#8208;specific antibodies [<xref rid="cei13517-bib-0098" ref-type="ref">98</xref>, <xref rid="cei13517-bib-0099" ref-type="ref">99</xref>, <xref rid="cei13517-bib-0100" ref-type="ref">100</xref>, <xref rid="cei13517-bib-0101" ref-type="ref">101</xref>]: stabilization of the pre&#8208;F form can lead to better responses. Based on this, prefusion SARS&#8208;CoV&#8208;2 spike protein could elicit a more potent immune response and stabilized SARS&#8208;CoV&#8208;2 spike proteins have been generated with stabilizing proline mutations in the S2 domain [<xref rid="cei13517-bib-0003" ref-type="ref">3</xref>, <xref rid="cei13517-bib-0102" ref-type="ref">102</xref>, <xref rid="cei13517-bib-0103" ref-type="ref">103</xref>].</p></sec><sec id="cei13517-sec-0019"><title>The nucleocapsid (N) protein</title><p>Coronavirus nucleocapsid (N) is also immunogenic: antibodies against the SARS&#8208;CoV&#8208;1 N protein are abundant and longer&#8208;lived than those against the S protein in recovered patients [<xref rid="cei13517-bib-0104" ref-type="ref">104</xref>]. Interestingly, in model systems of SARS&#8208;CoV&#8208;1, immunization with the N protein is associated with vaccine&#8208;enhanced disease [<xref rid="cei13517-bib-0105" ref-type="ref">105</xref>, <xref rid="cei13517-bib-0106" ref-type="ref">106</xref>]. It is not known whether the N protein is a potential protective immunogen for SARS&#8208;CoV&#8208;2, although vaccine approaches that use whole virus&#160;&#8211;&#160;either inactivated virus or live attenuated approaches&#160;&#8211;&#160;will potentially include N protein. The N protein can be a useful diagnostic for infection during Phase III trials of S protein&#8208;based vaccines.</p></sec><sec id="cei13517-sec-0020"><title>T cell epitopes</title><p>While the emphasis has been on the generation of neutralizing antibodies, targeting T cell epitopes may provide additional protection [<xref rid="cei13517-bib-0011" ref-type="ref">11</xref>]. In other respiratory viruses, for example RSV, T cell only strategies can enhance disease [<xref rid="cei13517-bib-0061" ref-type="ref">61</xref>] and T cells can be deleterious in dengue [<xref rid="cei13517-bib-0057" ref-type="ref">57</xref>], although less evidence of this has been seen with influenza vaccines [<xref rid="cei13517-bib-0107" ref-type="ref">107</xref>]. It is not yet clear whether SARS&#8208;CoV&#8208;2 behaves more like RSV or influenza. Drawing on information about SARS&#8208;CoV&#8208;1 and MERS&#8208;CoV and using bioinformatics, potential immunogenic epitopes in the SARS&#8208;CoV&#8208;2 proteome have been predicted. A total of 781 human leucocyte antigen (HLA) class I and 418 HLA class II epitopes common between SARS&#8208;CoV&#8208;1 and SARS&#8208;CoV&#8208;2 were found [<xref rid="cei13517-bib-0108" ref-type="ref">108</xref>]. T cell responses against the structural proteins of SARS&#8208;CoV&#8208;1 were found to be more immunogenic than non&#8208;structural proteins [<xref rid="cei13517-bib-0013" ref-type="ref">13</xref>].</p></sec></sec></sec><sec id="cei13517-sec-0021"><title>Platforms</title><p>A wide range of different platforms have been developed, which can be loosely grouped as proteins, inactivated virus, vectored vaccines, live attenuated and nucleic acid (Fig. <xref rid="cei13517-fig-0002" ref-type="fig">2</xref>). This is clearly a fast&#8208;moving space and the following is based on data accessed in September 2020; an updated website is available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://vac-lshtm.shinyapps.io/ncov_vaccine_landscape/">https://vac&#8208;lshtm.shinyapps.io/ncov_vaccine_landscape/</ext-link> and the WHO has a vaccine tracker [<xref rid="cei13517-bib-0109" ref-type="ref">109</xref>]. As many of the vaccines under development are produced by commercial organizations, peer&#8208;reviewed publications concerning their development and efficacy are limited, as such some information has been taken from press releases which may be less robust in their scrutiny. Published results from clinical trials are summarized in Table <xref rid="cei13517-tbl-0003" ref-type="table">3</xref>.</p><fig fig-type="Fig." xml:lang="en" id="cei13517-fig-0002" orientation="portrait" position="float"><label>Fig. 2</label><caption><p>Vaccine platforms; Over 200 different vaccines are in development. They loosely group into protein, inactivated, VLP, viral vector, mRNA, self&#8208;amplifying RNA, DNA and live attenuated vaccines. Created with Biorender.com</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="nlm-graphic-5" position="float" orientation="portrait" xlink:href="CEI-202-162-g002.jpg"/></fig><table-wrap id="cei13517-tbl-0003" xml:lang="en" content-type="Table" orientation="portrait" position="float"><label>Table 3</label><caption><p>Data from Published Phase I studies. Data from peer&#8208;reviewed journals or pre&#8208;prints. Data published on company websites not included</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Vaccine manufacturer</th><th align="left" valign="top" rowspan="1" colspan="1">Safety</th><th align="left" valign="top" rowspan="1" colspan="1">Immunogenicity</th><th align="left" valign="top" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">University of Oxford/AstraZeneca</td><td align="left" rowspan="1" colspan="1">
<p>Mild/Moderate injection site pain</p>
<p>Mild&#8208;Severe systemic adverse reactions including chills, fatigue, malaise and headache, peaking day one, reduced by paracetamol.</p>
</td><td align="left" rowspan="1" colspan="1">
<p>Seroconversion with neutralising antibodies, (91% after one dose, 100% after two doses).</p>
<p>IFN&#947; ELISPOT responses detected,.</p>
</td><td align="left" rowspan="1" colspan="1">[<xref rid="cei13517-bib-0165" ref-type="ref">165</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Wuhan Institute of Biological Products/Sinopharm</td><td align="left" rowspan="1" colspan="1">
<p>Local reactions in 25% of highest dose (Phase I)</p>
<p>Adverse reactions in 6&#8208;19% (Phase II)</p>
</td><td align="left" rowspan="1" colspan="1">
<p>Phase I: 95&#8208;100% seroconversion (ELISA and neutralisation).</p>
<p>Phase II: 85&#8208;100% seroconversion</p>
</td><td align="left" rowspan="1" colspan="1">[<xref rid="cei13517-bib-0149" ref-type="ref">149</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">BioNTech/Pfizer</td><td align="left" rowspan="1" colspan="1">
<p>Dose 1: Local reactions in 100% of 30&#181;g (mild&#8208;moderate) and 100&#181;g groups (mild&#8208;severe)</p>
<p>Systemic reactions in up to 80% of 100&#181;g (mild&#8208;severe).</p>
<p>Dose 2: systemic reactions in 100% of 30&#181;g group (mild&#8208;severe)</p>
<p>Similar results seen in second study with same construct (BNT162b1)</p>
<p>Comparative study with alternate construct (BNT162b2) showed lower reactogenicity</p>
</td><td align="left" rowspan="1" colspan="1">
<p>Seroconversion with neutralising antibodies and ELISA binding</p>
<p>Higher response in higher dose group</p>
<p>Neutralising antibody increased on booster in 10&#181;g and 30&#181;g groups.</p>
<p>Similar results seen in second study with same construct</p>
<p>Comparative study with alternative construct had equivalent immunogenicity</p>
</td><td align="left" rowspan="1" colspan="1">[<xref rid="cei13517-bib-0198" ref-type="ref">198</xref>, <xref rid="cei13517-bib-0199" ref-type="ref">199</xref>, <xref rid="cei13517-bib-0200" ref-type="ref">200</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">CanSino Biological Inc./Beijing Institute of Biotechnology</td><td align="left" rowspan="1" colspan="1">
<p>Phase I: Local reactions in 54% (mild or moderate)</p>
<p>Systemic adverse events in 46 % (mild&#8208;severe)</p>
<p>No effect of dose size on effects.</p>
<p>Phase II: Adverse reactions in 72%, more severe events in larger dose group (9%). Including injection site pain (56%) and fever (32% in high dose)</p>
<p>Adverse effects lower in individuals with pre&#8208;existing anti&#8208;Ad5 antibodies</p>
</td><td align="left" rowspan="1" colspan="1">
<p>Phase I: Seroconversion (ELISA binding) 44&#8208;61% after 1 dose, 97&#8208;100% after 2 doses.</p>
<p>Seroconversion (Neutralising) 28&#8208;42% after 1 dose, 50&#8208;75% after 2 doses.</p>
<p>IFN&#947; ELISPOT responses detected.</p>
<p>Phase II: Seroconversion (Neutralising) 59&#8208;61% after 2 doses.</p>
<p>IFN&#947; ELISPOT responses detected after 2 doses.</p>
</td><td align="left" rowspan="1" colspan="1">[<xref rid="cei13517-bib-0166" ref-type="ref">166</xref>, <xref rid="cei13517-bib-0167" ref-type="ref">167</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Moderna/NIAID</td><td align="left" rowspan="1" colspan="1">
<p>Systemic adverse events &#8211; mild/moderate after first dose, increasing with &#181;g RNA administered.</p>
<p>More adverse effects on second dose. All of 250 &#181;g group reported systemic adverse effects after second dose, 21% were severe.</p>
</td><td align="left" rowspan="1" colspan="1">
<p>100% seroconversion by after second dose by ELISA and neutralisation.</p>
<p>Increase in response from 25 &#181;g to 100&#181;g dose, rough equivalence between 100&#181;g and 250&#181;g dose.</p>
<p>Antigen specific T cells detectable, greater in 100&#181;g group than 25&#181;g.</p>
</td><td align="left" rowspan="1" colspan="1">[<xref rid="cei13517-bib-0196" ref-type="ref">196</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Sinovac</td><td align="left" rowspan="1" colspan="1">Low rate of adverse effects &#8211; no different to placebo</td><td align="left" rowspan="1" colspan="1">
<p>90% seroconversion reported by ELISA and neutralisation</p>
<p>Slight reduction in titre in older groups.</p>
</td><td align="left" rowspan="1" colspan="1">[<xref rid="cei13517-bib-0148" ref-type="ref">148</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Gamaleya Research Institute</td><td align="left" rowspan="1" colspan="1">
<p>Mild&#8208;moderate systemic adverse effects (mild fever in 95% of volunteers) for liquid formulation, less for lyophilised.</p>
<p>Mild local adverse effects (injection site pain)</p>
</td><td align="left" rowspan="1" colspan="1">
<p>100% seroconversion reported by ELISA and neutralisation.</p>
<p>Anti&#8208;vector antibodies observed but did not correlate with sero&#8208;conversion or anti&#8208;RBD titre.</p>
<p>Antigen specific IFN&#947; T ELISPOT responses.</p>
</td><td align="left" rowspan="1" colspan="1">[<xref rid="cei13517-bib-0171" ref-type="ref">171</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Novavax</td><td align="left" rowspan="1" colspan="1">
<p>Mostly mild systemic adverse effects, some moderate&#8208;severe, increased severity on second dose; headache and fatigue most common.</p>
<p>Mild&#8208;moderate local adverse effects (Tenderness and site pain).</p>
<p>Increased adverse effects with adjuvant.</p>
</td><td align="left" rowspan="1" colspan="1">
<p>100% seroconversion by ELISA in groups with adjuvant, no difference in antibody response between high (25&#181;g) and low (5&#181;g) groups. Boosting effect observed by 2 shots. Neutralisation titres much greater in adjuvanted groups, but only 100% after boost.</p>
<p>Subset had T cell responses analysed.</p>
</td><td align="left" rowspan="1" colspan="1">[<xref rid="cei13517-bib-0128" ref-type="ref">128</xref>]</td></tr></tbody></table><permissions><copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder></permissions></table-wrap></sec><sec id="cei13517-sec-0022"><title>Protein vaccines</title><p>As with other pathogens, recombinantly produced viral surface proteins can safely be used as vaccines for COVID&#8208;19. Although protein vaccines have a good safety profile they can have low levels of immunogenicity, which means that many require adjuvants to improve their efficacy. While bacterial protein vaccines can be made through the purification of whole pathogen preparations, viral subunit vaccines necessitate recombinant genetic engineering. The genes encoding the chosen antigens are cloned or synthesized, expressed and purified using a variety of expression systems, including insect, bacterial, yeast and mammalian cells [<xref rid="cei13517-bib-0110" ref-type="ref">110</xref>]. Bacterial expression systems are often used because they have high levels of expression and are easy to scale&#8208;up, with fermenter repurposing relatively easy. However, for viral antigens, where post&#8208;translational modification can be important, the use of insect cells or mammalian cells may be preferential [<xref rid="cei13517-bib-0111" ref-type="ref">111</xref>, <xref rid="cei13517-bib-0112" ref-type="ref">112</xref>].</p><sec id="cei13517-sec-0023"><title>Protein vaccines for other coronaviruses</title><p>Several protein subunit vaccination approaches were under development for SARS&#8208;CoV&#8208;1 and MERS&#8208;CoV [<xref rid="cei13517-bib-0113" ref-type="ref">113</xref>, <xref rid="cei13517-bib-0114" ref-type="ref">114</xref>, <xref rid="cei13517-bib-0115" ref-type="ref">115</xref>]. A subunit vaccine made up of SARS&#8208;CoV&#8208;1 spike protein fragments, expressed in <italic toggle="yes">Escherichia coli</italic>, induced neutralizing antibodies in rabbits [<xref rid="cei13517-bib-0116" ref-type="ref">116</xref>]. Neutralizing antibodies were induced in mice after immunization with transgenic plants [<xref rid="cei13517-bib-0117" ref-type="ref">117</xref>] or mammalian expressed [<xref rid="cei13517-bib-0118" ref-type="ref">118</xref>] recombinant SARS&#8208;CoV&#8208;1 spike protein. Most MERS&#8208;CoV subunit vaccines use mammalian cell&#8208;expressed spike protein [<xref rid="cei13517-bib-0113" ref-type="ref">113</xref>, <xref rid="cei13517-bib-0114" ref-type="ref">114</xref>, <xref rid="cei13517-bib-0115" ref-type="ref">115</xref>, <xref rid="cei13517-bib-0119" ref-type="ref">119</xref>].</p></sec><sec id="cei13517-sec-0024"><title>Protein vaccines in development for SARS&#8208;CoV&#8208;2</title><p>Several SARS&#8208;CoV&#8208;2 protein vaccines are in development; eight candidates are in clinical trials, but no data are yet available from these trials. Two of the earliest to be announced are from Clover Biopharmaceuticals and the University of Queensland. Clover Biopharmaceuticals has used &#8216;Trimer&#8208;Tag&#8217; technology to make a mammalian cell&#8208;expressed, spike protein subunit trimer vaccine [<xref rid="cei13517-bib-0120" ref-type="ref">120</xref>]. This antigen can be recognized by antibodies in the sera of people who have recovered from SARS&#8208;CoV&#8208;2 [<xref rid="cei13517-bib-0121" ref-type="ref">121</xref>]. The vaccine will be given in conjunction with GSK&#8217;s adjuvant AS03 or cytosine&#8211;phosphate&#8211;guanosine (CpG)/alum during the Phase I trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04405908">NCT04405908</ext-link>). The University of Queensland, funded by the Coalition for Epidemic Preparedness Innovations (CEPI) has developed a recombinant subunit vaccine using spike protein that has been &#8216;locked&#8217; in prefusion conformation using the molecular clamp technique [<xref rid="cei13517-bib-0122" ref-type="ref">122</xref>]. This is currently being tested with MF59 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04495933">NCT04495933</ext-link>).</p><p>Sanofi are developing a protein subunit vaccine against SARS&#8208;CoV&#8208;2, expressed using a baculovirus platform, funded by the US Biomedical Advanced Research and Development Authority (BARDA). This has been reported to be delivered in conjunction with AS03 from GSK [<xref rid="cei13517-bib-0122" ref-type="ref">122</xref>, <xref rid="cei13517-bib-0123" ref-type="ref">123</xref>] or potentially one other adjuvant which has not been revealed. Phase I clinical trials were initiated on 3 September 2020 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04537208">NCT04537208</ext-link>), with an aim to make the vaccine available in early 2021 [<xref rid="cei13517-bib-0122" ref-type="ref">122</xref>].</p><p>Other protein candidates in clinical trials (Table <xref rid="cei13517-tbl-0002" ref-type="table">2</xref>) are from Adimmune (baculovirus&#8208;derived, alum adjuvanted), Anhui Zhifei (RBD only), Instituto Finlay de Vacunas (RBD), Kentucky Bioprocessing (tobacco&#8208;derived protein), Medigen (alum/CpG adjuvanted) and Vaxxine (Advax adjuvanted). Differences in cost of manufacturing, location of the manufacturer and impact of the adjuvant will determine which candidates progress beyond clinical trials.</p></sec></sec><sec id="cei13517-sec-0025"><title>Nanoparticles and virus&#8208;like particles</title><p>Virus&#8208;like particles (VLPs) are a subset of protein vaccines which are artificially produced nanoparticles that resemble viruses. Rather than an individual protein, VLPs are made up of some or all of the proteins that form the viral capsid [<xref rid="cei13517-bib-0124" ref-type="ref">124</xref>]. They have some similarities to live attenuated or inactivated vaccines, and can produce strong cellular and humoral immune responses with no risk of reversion, because they contain none of the genetic material of the virus. They are used for a wide range of viruses, including HPV, and a preclinical SARS&#8208;CoV&#8208;1 VLP has been tested [<xref rid="cei13517-bib-0125" ref-type="ref">125</xref>]. VLP Nanoparticles are self&#8208;assembling protein particles, not necessarily derived from the virus capsid proteins.</p><p>Novavax, funded by CEPI and US Operation Warp Speed, have developed a recombinant nanoparticle vaccine (NVX&#8208;CoV2373) that displays the SARS&#8208;CoV&#8208;2 spike protein [<xref rid="cei13517-bib-0122" ref-type="ref">122</xref>, <xref rid="cei13517-bib-0126" ref-type="ref">126</xref>]. This is produced using engineered baculovirus to infect Sf9 insect cells [<xref rid="cei13517-bib-0127" ref-type="ref">127</xref>]. For the clinical trial with NVX&#8208;CoV2373 Novavax are using their own saponin&#8208;based Matrix&#8208;M adjuvant (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04368988">NCT04368988</ext-link>), the data from which have recently been published [<xref rid="cei13517-bib-0128" ref-type="ref">128</xref>]. The vaccine was immunogenic, but required the addition of adjuvant to achieve 100% seroconversion; two doses were required for neutralising antibody in all individuals. Immunized animal models develop spike protein&#8208;specific antibodies that prevent the attachment of the spike protein to host cell ACE&#8208;2 receptors and also neutralize the wild&#8208;type virus [<xref rid="cei13517-bib-0129" ref-type="ref">129</xref>]. Another company (Medicago) are using a plant&#8208;based system, <italic toggle="yes">Nicotiana benthamiana</italic>, to produce a VLP [<xref rid="cei13517-bib-0130" ref-type="ref">130</xref>] which is currently in clinical trial in combination with CpG or AS03 adjuvant (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04450004">NCT04450004</ext-link>).</p><p>Other groups at the preclinical stage include Saiba AG, based in Switzerland, who are using a cucumber mosaic virus VLP that is bound to SARS&#8208;CoV&#8208;2 RBD, which induced neutralizing antibody in mice [<xref rid="cei13517-bib-0131" ref-type="ref">131</xref>].</p></sec><sec id="cei13517-sec-0026"><title>Peptide vaccines</title><p>Peptide vaccination is based upon the concept that, as induction of T cell responses can be achieved using a fraction of the entire protein [<xref rid="cei13517-bib-0132" ref-type="ref">132</xref>, <xref rid="cei13517-bib-0133" ref-type="ref">133</xref>], only the minimal immunogenic peptide sequence needs to be included. By selecting conserved epitopes, peptide vaccines can potentially induce broad&#8208;spectrum immunity against multiple strains of a given pathogen [<xref rid="cei13517-bib-0134" ref-type="ref">134</xref>, <xref rid="cei13517-bib-0135" ref-type="ref">135</xref>]. Peptides are easier to produce than whole protein antigens, as they can be produced synthetically and do not require folding into a tertiary structure. However, peptide vaccines are often weakly immunogenic. This is due to several factors, including the relatively small size of the peptide and differences in MHC processing; they therefore may require carrier proteins or adjuvants [<xref rid="cei13517-bib-0136" ref-type="ref">136</xref>, <xref rid="cei13517-bib-0137" ref-type="ref">137</xref>]. Several groups are exploring the use of multi&#8208;epitope peptide vaccines against SARS&#8208;CoV&#8208;2; following bioinformatic and immune&#8208;informatic&#8208;based predictions of immunogenic epitopes [<xref rid="cei13517-bib-0138" ref-type="ref">138</xref>, <xref rid="cei13517-bib-0139" ref-type="ref">139</xref>, <xref rid="cei13517-bib-0140" ref-type="ref">140</xref>, <xref rid="cei13517-bib-0141" ref-type="ref">141</xref>], the studies are focusing upon T rather than B cell epitopes. OSE Immunotherapeutics have used a multi&#8208;epitope peptide approach to induce T cell responses in mice [<xref rid="cei13517-bib-0142" ref-type="ref">142</xref>]. Covaxx and the University of Nebraska Medical center have recently registered a Phase I clinical trial for a multi&#8208;epitope peptide vaccine (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04545749">NCT04545749</ext-link>) as has the Vector Institute (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04527575">NCT04527575</ext-link>) currently in clinical trial.</p></sec><sec id="cei13517-sec-0027"><title>Artificial antigen&#8208;presenting cells</title><p>Artificial antigen&#8208;presenting cells (aAPC) are immunotherapeutic agents that can stimulate antigen&#8208;specific T cell responses [<xref rid="cei13517-bib-0143" ref-type="ref">143</xref>] They have been widely explored for cancer vaccines and have also been proposed for infectious disease vaccines. In the case of SARS&#8208;CoV&#8208;2, aAPCs are transfected with a lentivirus encoding the structural and protease proteins. The cells are then administered via subcutaneous injection [<xref rid="cei13517-bib-0144" ref-type="ref">144</xref>]. The Shenzhen Geno&#8208;Immune Medical Institute in China are undertaking an ongoing Phase I clinical trial with an aAPC approach (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04299724">NCT04299724</ext-link>) and a modified dendritic cell platform (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04276896">NCT04276896</ext-link>). Aivita Biomedical Inc. are following a similar platform (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04386252">NCT04386252</ext-link>). Due to the need to isolate and purify cells and maintain them at GMP quality, this approach seems impractical for mass vaccination campaigns.</p></sec><sec id="cei13517-sec-0028"><title>Inactivated vaccines</title><p>Isolating and then inactivating a virus, historically with formaldehyde, is one of the oldest methods of viral vaccination. Inactivation of viruses has been effective for a range of different viruses. However, there have been major safety concerns relating to SARS&#8208;CoV&#8208;1 and MERS&#8208;CoV&#8208;inactivated vaccines, reminiscent of FI&#8208;RSV, and these concerns are also valid for SARS&#8208;CoV&#8208;2. Lung pathology of vaccinated animals on virus challenge has been seen for both a gamma&#8208;irradiated MERS&#8208;CoV vaccine [<xref rid="cei13517-bib-0056" ref-type="ref">56</xref>] and a UV irradiation&#8208;inactivated SARS&#8208;CoV&#8208;1 vaccine [<xref rid="cei13517-bib-0145" ref-type="ref">145</xref>]. The choice of both the adjuvant and the inactivating agent is important in shaping the immune response. For example, a formaldehyde inactivated MERS&#8208;CoV vaccine adjuvanted with alum and CpG demonstrated enhanced protection without inducing eosinophil&#8208;mediated vaccine&#8208;related pathology [<xref rid="cei13517-bib-0146" ref-type="ref">146</xref>].</p><sec id="cei13517-sec-0029"><title>Inactivated viral vaccines in development for SARS&#8208;CoV&#8208;2</title><p>There are four inactivated vaccine candidates in clinical trials. Sinovac Biotech are using a platform previously developed for SARS&#8208;CoV&#8208;1 [<xref rid="cei13517-bib-0147" ref-type="ref">147</xref>]. The virus is grown in Vero cells and inactivated with beta&#8208;propiolactone. The inactivated vaccine was safe and immunogenic in rhesus macaques and offered complete protection against SARS&#8208;CoV&#8208;2 challenge, where no virus was detected in the pharynx or lungs [<xref rid="cei13517-bib-0148" ref-type="ref">148</xref>]. Two different versions of this inactivated vaccine have been developed, adjuvanted with either alum or CpG108. This vaccine has completed a Phase II human trial in 600 healthy adults aged 18&#8211;59&#160;years (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04352608">NCT04352608</ext-link>), with 90% seroconversion observed after the second dose of vaccine and some neutralizing antibody detected [<xref rid="cei13517-bib-0149" ref-type="ref">149</xref>]. It is interesting to note that the production method for the virus was changed between Phases I and II trials, and this may have increased immunogenicity. The vaccine has entered Phase III clinical trials in Brazil (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04456595">NCT04456595</ext-link>) and Indonesia (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04508075">NCT04508075</ext-link>).</p><p>Sinopharm, working with both the Beijing Institute of Biological Products and the Wuhan Institute of Biological Products, have also developed an inactivated vaccine. This vaccine has now been tested in a Phases I/II clinical trial (ChiCTR2000031809). No serious adverse effects were observed, and more than 95% of individuals seroconverted with detectable neutralizing antibody in the two different trials [<xref rid="cei13517-bib-0150" ref-type="ref">150</xref>]. The antibody was mainly observed after the second dose.</p><p>Two other organizations, Bharat Biotech (India) and the Institute of Medical Biology/Chinese Academy of Medical Sciences, are running clinical trials of inactivated vaccines, but these are ongoing with no published data as yet. Valneva, based in Scotland, have just expanded their BSL3 manufacturing capacity and have signed a deal with the UK government for 100&#160;million doses of a formaldehyde&#8208;inactivated vaccine adjuvanted with CpG, based on their Japanese encephalitis virus vaccine [<xref rid="cei13517-bib-0151" ref-type="ref">151</xref>].</p></sec></sec><sec id="cei13517-sec-0030"><title>Live vaccines</title><p>The use of a live virus to prevent infection is the oldest vaccine approach. The original vaccine, cowpox, used exactly this approach to prevent smallpox. We are grouping two approaches under live viral vaccine platforms: attenuation of the virus or the use of a viral vector to deliver transgenes.</p><sec id="cei13517-sec-0031"><title>Live attenuated vaccines</title><p>Live attenuated vaccines closely resemble natural infection. As a result, they are often immunogenic with a single administration without an adjuvant [<xref rid="cei13517-bib-0152" ref-type="ref">152</xref>]. One consideration is balancing attenuation and replication&#160;&#8211;&#160;over&#8208;attenuated vaccines may not replicate enough to be immunogenic, and this balance can vary between different individuals, especially the very young or immunocompromised. Historically, serial passage for attenuating mutations has been used; for example, live attenuated influenza vaccine (LAIV) is cold&#8208;adapted, restricting it to the upper airway. This method requires time and extensive testing: the yellow fever vaccine YF17D was passaged more than 200 times. Alternatively, attenuated viruses can be generated by reverse genetics [<xref rid="cei13517-bib-0153" ref-type="ref">153</xref>], introducing site&#8208;directed mutations into genes associated with virulence. The E protein has been targeted for both SARS&#8208;CoV&#8208;1 and MERS&#8208;CoV [<xref rid="cei13517-bib-0154" ref-type="ref">154</xref>, <xref rid="cei13517-bib-0155" ref-type="ref">155</xref>]. However, this method requires the identification of genes that would attenuate viral replication and the mutation(s) inserted to be phenotypically stable [<xref rid="cei13517-bib-0153" ref-type="ref">153</xref>]. A novel method of codon&#8208;pair de&#8208;optimization has been developed. The codon de&#8208;optimized virus is chemically synthesized to retain 100% amino acid sequence identical to the parent virus, but to contain an increased number of CpG and UpA RNA dinucleotides to up&#8208;regulate host responses. Codon&#8208;pair de&#8208;optimization has been used for attenuating RSV [<xref rid="cei13517-bib-0156" ref-type="ref">156</xref>]. Codagenix and the Serum Institute of India are developing a live attenuated SARS&#8208;CoV&#8208;2 vaccine, using codon de&#8208;optimization technology, building on previous experience with RSV and influenza [<xref rid="cei13517-bib-0157" ref-type="ref">157</xref>].</p></sec><sec id="cei13517-sec-0032"><title>Vectored vaccines</title><p>In vectored vaccines, the antigenic gene of interest is expressed from another micro&#8208;organism, either virus or bacteria. Adenovirus, VSV and modified vaccinia virus Ankara (MVA) are some of the common viral vectors used [<xref rid="cei13517-bib-0158" ref-type="ref">158</xref>]. The vectors can either be replication&#8208;deficient, delivering a gene cargo but not growing themselves, or replication&#8208;competent, reproducing in the immunization site. The different platforms may alter the reactogenicity and immunogenicity of the vaccine.</p><p>A recombinant MVA expressing the SARS&#8208;CoV&#8208;1 S protein delivered via intranasal or intramuscular routes induced protective immunity in mice [<xref rid="cei13517-bib-0159" ref-type="ref">159</xref>]. An adenovirus vaccine against MERS&#8208;CoV offered complete protection against challenge in mice [<xref rid="cei13517-bib-0152" ref-type="ref">152</xref>]. As pre&#8208;existing immunity against human adenovirus is widespread and can hamper its clinical application as a vector [<xref rid="cei13517-bib-0158" ref-type="ref">158</xref>], a chimpanzee adenovirus can be used. A recombinant chimpanzee adenovirus (ChAdOx1) encoding the S protein, known as MERS001, was immunogenic in mice and safe in Phase I clinical trials in humans [<xref rid="cei13517-bib-0160" ref-type="ref">160</xref>].</p></sec></sec><sec id="cei13517-sec-0033"><title>Non&#8208;replicating vectored vaccines in development for SARS&#8208;CoV&#8208;2</title><p>Five non&#8208;replicating viral vectored vaccines are currently in clinical trials all based around adenoviral vectors. Replication&#8208;deficient adenoviral vectors lack the E1A and E1B genes; these are the early genes which are essential for reproduction of the virus [<xref rid="cei13517-bib-0161" ref-type="ref">161</xref>], and deliver the antigen gene without replicating in the vaccinated individual.</p><p>Building on experience with MERS&#8208;CoV, the University of Oxford are developing a chimpanzee adenovirus vaccine vector expressing the wild&#8208;type S protein (ChAdOx1 nCov&#8208;19, also known as AZD1222). The AZD1222 vaccine was immunogenic in mice and pigs [<xref rid="cei13517-bib-0162" ref-type="ref">162</xref>]. In rhesus macaques it reduced viral load and pneumonia after challenge with SARS&#8208;CoV&#8208;2 [<xref rid="cei13517-bib-0163" ref-type="ref">163</xref>, <xref rid="cei13517-bib-0164" ref-type="ref">164</xref>]. The AZD1222 vaccine entered Phase I clinical trial on April 23 2020 in 543 volunteers aged 18&#8211;55&#160;years (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04324606">NCT04324606</ext-link>). In this study, there were local and systemic reactions to the vaccine, controlled by paracetamol, but no severe adverse effects. The vaccine was immunogenic, with 91% participants having neutralizing antibody after one dose and 100% after two doses. Interferon (IFN)&#8208;&#947;&#8208;producing T cells were also detectable [<xref rid="cei13517-bib-0165" ref-type="ref">165</xref>]. In partnership with AstraZeneca, this vaccine received a further $1.2&#160;billion from BARDA towards its global development, manufacturing and distribution. The vaccine has now progressed into Phases II/III trials in the United Kingdom (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04444674">NCT04444674</ext-link>), Brazil (ISRCTN89951424) and the United States (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04516746">NCT04516746</ext-link>).</p><p>Cansino Biologics (China) are developing a human Ad5&#8208;vectored vaccine. In Phase I trials (ChiCTR2000030906), the Ad5 vectored COVID&#8208;19 vaccine was tolerable and immunogenic at 28 days post&#8208;vaccination [<xref rid="cei13517-bib-0166" ref-type="ref">166</xref>]. Both humoral responses and specific T cell responses were observed in healthy individuals 28&#160;days after vaccination. Transient and self&#8208;limiting adverse events such as severe fever, fatigue and muscle pain were reported in the high vaccine dose group. Similar results were reported after the Phase II trial [<xref rid="cei13517-bib-0167" ref-type="ref">167</xref>]. The vaccine is now in a Phases I/II trial in Canada (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04398147">NCT04398147</ext-link>).</p><p>Janssen (part of J and J) are using an experimental, replication incompetent adenovirus vector (AdVac<sup>&#174;</sup>) in their PER.C6<sup>&#174;</sup> cell line technology [<xref rid="cei13517-bib-0168" ref-type="ref">168</xref>]. This platform has been used for Zika, RSV and HIV vaccine candidates. An Ebola vaccine (Ad26.ZEBOV) using the same platform has been proven safe and immunogenic, and has been used as part of efforts to contain Democratic Republic of the Congo (DRC) Ebola outbreaks [<xref rid="cei13517-bib-0169" ref-type="ref">169</xref>]. The vaccine has been seen to be protective against SARS&#8208;CoV&#8208;2 challenge in rhesus macaques [<xref rid="cei13517-bib-0170" ref-type="ref">170</xref>] and is in Phase I trials in the United States, Belgium (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04436276">NCT04436276</ext-link>) and Japan (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04509947">NCT04509947</ext-link>).</p><p>One other vectored vaccine that has received a great deal of press attention is from the Gamaleya Research Institute, which has been given the tradename Sputnik V. This vaccine uses two different adenovirus vectors, Ad26 and Ad5. To date, two clinical trials have been registered giving individually or as a prime&#8208;boost, either as a solution (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04436471">NCT04436471</ext-link>) or lyophilized formulation (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04437875">NCT04437875</ext-link>) in a total of 75 people. The trial recorded mild&#8211;moderate systemic effects and mild local effects, including injection site pain; 100% seroconversion rate by binding enzyme&#8208;linked immunosorbent assay (ELISA) was observed. Interestingly, there was also some anti&#8208;vector antibody detected after immunization [<xref rid="cei13517-bib-0171" ref-type="ref">171</xref>]. The registration of this vaccine is presumably subject to larger efficacy trials, with a Phase III trial registered in September 2020 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04530396">NCT04530396</ext-link>).</p></sec><sec id="cei13517-sec-0034"><title>Replicating vectored vaccines in development for SARS&#8208;CoV&#8208;2</title><p>An alternative to replication deficient vectors is to use a live attenuated vector. Merck has recently acquired Themis, who have developed an attenuated measles vector vaccine approach using an attenuated strain of measles derived from the original 1954 vaccine strain. Themis have previously used this approach to develop a Chikungunya vaccine, which was safe and immunogenic [<xref rid="cei13517-bib-0172" ref-type="ref">172</xref>]. In collaboration with Institut Pasteur and the University of Pittsburgh they are now running clinical trials with these vaccines (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04497298">NCT04497298</ext-link> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04498247">NCT04498247</ext-link>).</p><sec id="cei13517-sec-0035"><title>Mucosal delivery of vectored vaccines</title><p>Live and vectored vaccines may lend themselves to mucosal delivery which may achieve better local immunity and has been used for other vaccines; for example, intranasal live attenuated influenza vaccine (LAIV). However, the enthusiasm for mucosal vaccines based on preclinical data has not always translated into clinical success. Symvivo is using oral delivery of a probiotic bacteria, <italic toggle="yes">Bifidobacterium longum</italic>, to deliver the spike transgene (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04334980">NCT04334980</ext-link>). The Migal Galilee Research Institute have adopted an existing vaccine against infectious bronchitis virus (IBV), which has been used in a preclinical veterinary trial inducing humoral, cellular and mucosal immunity [<xref rid="cei13517-bib-0173" ref-type="ref">173</xref>] to be delivered orally, but this is not yet in clinical trials. Beijing Wantai Biological Pharmacy and Xiamen University have recently registered a phase I clinical trial using an influenza viral vector (ChiCTR2000037782).</p></sec></sec><sec id="cei13517-sec-0036"><title>Nucleic acid vaccines</title><p>Nucleic acid vaccines have been highlighted for their potential in pandemic situations due to their low cost and potential rapid development, although this potential has yet to be translated into a real&#8208;world vaccine [<xref rid="cei13517-bib-0174" ref-type="ref">174</xref>]. They utilize either plasmid DNA or RNA, encoding a target antigen. Following delivery of the vaccine, the nucleic acid is taken up by the cells and the encoded antigen is expressed. Conceptually, one facility can produce any required nucleic acid vaccine and production can be theoretically scaled&#8208;up to meet pandemic level demands. The COVID&#8208;19 pandemic will serve as an important test case for nucleic acid vaccines, with six RNA platforms and four DNA platforms currently in clinical trial.</p></sec><sec id="cei13517-sec-0037"><title>DNA vaccines</title><p>Most DNA vaccines are constructed from plasmids that contain prokaryotic sequences that support the plasmids&#8217; propagation in <italic toggle="yes">E. coli</italic>, and a mammalian expression cassette that controls the expression of the target transgene in the vaccinated organism. The expression cassette contains an upstream promoter to drive transgene expression, a Kozak sequence, the inserted transgene and a 3&#8242; polyadenylation (polyA) tail. Following delivery, the DNA vaccine is taken up by host cells local at the immunization site or by migrating APCs [<xref rid="cei13517-bib-0175" ref-type="ref">175</xref>]. To induce an adaptive immune response the DNA must enter the cell nucleus. In transiting to the nucleus the DNA passes through the cytosol which is inflammatory, being sensed by intracellular pattern recognition receptors, for example STING1 [<xref rid="cei13517-bib-0175" ref-type="ref">175</xref>] or TBK1 [<xref rid="cei13517-bib-0176" ref-type="ref">176</xref>], inducing an innate immune response. The triggering of innate immunity is essential for promoting adaptive immunity to DNA vaccines. If APCs are transfected directly with a DNA vaccine, they will load vaccine&#8208;encoded peptides onto both MHCI and MHCII molecules and activate T cells [<xref rid="cei13517-bib-0177" ref-type="ref">177</xref>]. Transfected stromal cells will generate antigen, which will be encountered by APCs and B cells following antigen release from cell exosomes or apoptotic bodies. Transit of injected naked DNA to the nucleus is highly inefficient, with a large majority of the DNA failing to cross the cell membrane or nuclear envelope [<xref rid="cei13517-bib-0178" ref-type="ref">178</xref>, <xref rid="cei13517-bib-0179" ref-type="ref">179</xref>]. To mitigate this loss, DNA vaccine programmes employ delivery platforms such as electroporation and bio&#8208;injection.</p><sec id="cei13517-sec-0038"><title>DNA vaccines&#160;&#8211;&#160;coronaviruses</title><p>Preclinical animal studies have demonstrated that DNA vaccines encoding the M, N, 3a or S proteins of the SARS&#8208;CoV&#8208;1 virus could elicit immune responses [<xref rid="cei13517-bib-0180" ref-type="ref">180</xref>, <xref rid="cei13517-bib-0181" ref-type="ref">181</xref>, <xref rid="cei13517-bib-0182" ref-type="ref">182</xref>]. A multivalent DNA vaccine encoding S and M protein epitopes could protect from SARS&#8208;CoV&#8208;1 cytopathic effects. The S protein is the target of the only SARS&#8208;CoV&#8208;1 DNA vaccine to progress to Phase I clinical trial, delivered by bio&#8208;injector, and it was safe and induced neutralizing antibody responses [<xref rid="cei13517-bib-0183" ref-type="ref">183</xref>]. The leading DNA vaccine against MERS&#8208;CoV (INO&#8208;4700) was developed by Inovio. Phase I clinical trials were completed in 2019, with the vaccine showing a good safety profile and inducing humoral immunity and polyfunctional CD8<sup>+</sup> T cell responses [<xref rid="cei13517-bib-0184" ref-type="ref">184</xref>].</p></sec><sec id="cei13517-sec-0039"><title>DNA vaccines in development for SARS&#8208;CoV&#8208;2</title><p>The Inovio MERS INO4700 (GLS&#8208;5300) vaccine that was due to be taken to Phase II clinical trials (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03721718">NCT03721718</ext-link>) has now been redeployed as INO&#8208;4800 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04336410">NCT04336410</ext-link>) to begin clinical trials for protection against SARS&#8208;CoV&#8208;2. In preclinical studies of the INO&#8208;4800 vaccine, neutralizing antibody and T cell responses were observed in mice and blocking antibody responses in vaccinated guinea pigs [<xref rid="cei13517-bib-0185" ref-type="ref">185</xref>] and macaques [<xref rid="cei13517-bib-0186" ref-type="ref">186</xref>]. The Phase I trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04336410">NCT04336410</ext-link>) is ongoing, but the data have not yet been published. Genexine, in South Korea (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04445389">NCT04445389</ext-link>), Zydus Cadila in India (CTRI/2020/07/026352) and Osaka University in Japan (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04463472">NCT04463472</ext-link>) have initiated Phase I trials of DNA vaccines.</p></sec></sec><sec id="cei13517-sec-0040"><title>RNA vaccines</title><p>RNA vaccines are based on the same premise as DNA vaccines of expressing a vaccine antigen transgene in the host cell, but they are one step further along the expression pathway, skipping the transcription step. Unlike DNA vaccines, expression of RNA vaccines begins once they enter the cell cytosol, which can increase the efficiency of expression.</p><p>As with DNA vaccines, the presence of &#8216;foreign&#8217; RNA is sensed in both the endosome and cytosol [<xref rid="cei13517-bib-0187" ref-type="ref">187</xref>], giving RNA vaccines a self&#8208;adjuvanting effect [<xref rid="cei13517-bib-0188" ref-type="ref">188</xref>]. However, the early triggering of type I IFN responses can down&#8208;regulate protein expression [<xref rid="cei13517-bib-0189" ref-type="ref">189</xref>]. Modified nucleosides can be incorporated into the mRNA product to create a &#8216;silenced&#8217; RNA vaccine that avoids detection by TLRs and does not trigger a type I IFN response [<xref rid="cei13517-bib-0190" ref-type="ref">190</xref>, <xref rid="cei13517-bib-0191" ref-type="ref">191</xref>], but there is a balance between antigen expression from the vaccine construct and triggering enough inflammation to activate the immune response. This balance may be altered by the formulation to deliver the vaccine and can be different between different animal species, making predictions from preclinical studies difficult.</p><p>There are two primary types of RNA vaccine mRNA and self&#8208;amplifying mRNA (saRNA). Non&#8208;replicating mRNA vaccines are constructs engineered to encode the gene of interest, and typically have a 5&#8242; cap, UTRs flanking the gene of interest and poly A tail. The 5&#8242; cap is essential for mRNA to associate with the eukaryotic translation complex. UTRs are selected to optimize RNA protein expression, avoiding the inclusion of sequences that would hamper translation [<xref rid="cei13517-bib-0192" ref-type="ref">192</xref>, <xref rid="cei13517-bib-0193" ref-type="ref">193</xref>]. mRNA vaccine constructs are made using bacteriophage&#8208;derived RNA polymerases and NTPs to transcribe linearized DNA <italic toggle="yes">in vitro</italic>.</p><p>Self&#8208;amplifying RNA vaccines are alphavirus&#8208;derived RNA replicons modified to encode the antigen of interest in place of RNA structural proteins. The viral replicon also contains an open reading frame (ORF) that encodes four alphavirus non&#8208;structural proteins (nsP1&#8208;4) and a subgenomic promoter. The non&#8208;structural proteins form an RNA&#8208;dependent RNA polymerase (RDRP). The RDRP complex transcribes more copies of the vaccine in the transfected cell. As a result, saRNA vaccines express protein at higher levels and persist for longer than non&#8208;replicating RNA [<xref rid="cei13517-bib-0194" ref-type="ref">194</xref>].</p><sec id="cei13517-sec-0041"><title>RNA vaccines in development for SARS&#8208;CoV&#8208;2</title><p>As it is a newer technology, RNA vaccines were not developed against SARS&#8208;CoV&#8208;1. Six RNA vaccines are in clinical trials for SAR&#8208;CoV&#8208;2.</p><p>Moderna fast&#8208;tracked their candidate vaccine mRNA&#8208;1273 and were first to begin clinical trials on 17 March 2020 with the National Institute of Health&#8217;s National Institute of Allergy and Infectious Diseases (NIAID) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04283461">NCT04283461</ext-link>). This Phase I study involved 45&#160;patient volunteers, divided into three group cohorts, as a dose escalation: low (25&#160;&#181;g), middle (100&#160;&#181;g) and high (250&#160;&#181;g) in a prime boost. A preclinical study using the same vaccines was protective in mice against viral challenge [<xref rid="cei13517-bib-0195" ref-type="ref">195</xref>]. The vaccine was immunogenic, with increasing antibody titres with increasing dose administered; of note, three individuals (of 15, 21%) in the 250&#8208;&#181;g group reported severe adverse events, with severity increasing after the second vaccination [<xref rid="cei13517-bib-0196" ref-type="ref">196</xref>]. The vaccine is now in Phase II (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04405076">NCT04405076</ext-link>) and Phase III (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04470427">NCT04470427</ext-link>) trials, focusing on the 100&#8208;&#181;g dose.</p><p>BioNTech is collaborating with Pfizer to develop four S protein vaccine candidates. They are using a nucleoside modified mRNA. Phases I/II clinical trials are running in Germany (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04380701">NCT04380701</ext-link>) and the United States (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04368728">NCT04368728</ext-link>), with a multi&#8208;site Phase III study planned. The vaccine induced both cellular and humoral responses in mice [<xref rid="cei13517-bib-0197" ref-type="ref">197</xref>] and induced neutralizing antibody in the clinical study [<xref rid="cei13517-bib-0198" ref-type="ref">198</xref>]. They have performed a further two clinical studies, observing similar responses in a second study with their initial construct (BNT162b1) which encodes a RBD trimer [<xref rid="cei13517-bib-0199" ref-type="ref">199</xref>]. In a comparator study they observed similar levels of immunogenicity to a stabilised membrane anchored spike protein (BNT162b2), but with lower levels of reactogenicity [<xref rid="cei13517-bib-0200" ref-type="ref">200</xref>]. Both CureVac and The People&#8217;s Liberation Army have also developed mRNA vaccines that are in clinical trials, but no results have been published as yet.</p><p>Imperial College London and its spin&#8208;out social enterprise, VacEquity Global Health, are developing an saRNA vaccine encoding the S protein. Intramuscular injection with LNP formulation induced high neutralizing antibody titres in mice [<xref rid="cei13517-bib-0103" ref-type="ref">103</xref>]. Tested doses of the preclinical vaccine ranged from 0&#183;01&#160;&#181;g to 10&#160;&#181;g, with a boost of the same dose at week 4 post&#8208;vaccination. Human trials of the vaccine with 420&#160;participants started in June 2020 (ISRCTN17072692). Arcturus, based in Singapore, are also developing an saRNA vaccine encoding a prefusion spike, which is in Phase I clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04480957">NCT04480957</ext-link>).</p></sec></sec><sec id="cei13517-sec-0042"><title>Other aspects concerning vaccines</title><sec id="cei13517-sec-0043"><title>Adjuvants</title><p>Protein vaccines can have low levels of immunogenicity. This can be boosted by adjuvants [<xref rid="cei13517-bib-0201" ref-type="ref">201</xref>]. Adjuvants enhance the immune response through multiple mechanisms, causing a depot effect; up&#8208;regulating the production of chemokines and cytokines; enhancing the cellular recruitment to site of injection; increasing antigen uptake and presentation by APCs and increasing inflammasome activation [<xref rid="cei13517-bib-0202" ref-type="ref">202</xref>]. Adjuvants can also tailor the immune response, guiding it towards producing the most effective form of immunity against the specific pathogen being vaccinated against [<xref rid="cei13517-bib-0203" ref-type="ref">203</xref>, <xref rid="cei13517-bib-0204" ref-type="ref">204</xref>, <xref rid="cei13517-bib-0205" ref-type="ref">205</xref>]. A range of adjuvants have been proposed for use with SARS&#8208;CoV&#8208;2 protein vaccines. These include Advax, alum, AS03 (GSK), Matrix&#8208;M (Novavax), CpG (Dynavax) and MF59 (CSL).</p></sec><sec id="cei13517-sec-0044"><title>Formulation and delivery</title><p>Additional components are also included with nucleic acid vaccines to enhance uptake and immunogenicity. Nucleic acids are combined with a range of formulations, including lipid nanoparticles (LNPs), liposomes and polyplexes. Such formulations are essential for RNA vaccines, as &#8216;naked&#8217; RNA is susceptible to being degraded by extracellular RNAses which will prevent efficient cell uptake. LNPs have previously been used for other RNA therapeutics and Moderna, Imperial College London, Arcturus, Curevac and BioNTech vaccines all utilize this technology. The stability of these formulations can be a concern and may necessitate vaccine storage at a lower temperature which might, in turn, impact access to the vaccine. For DNA vaccines, delivery devices are often used to increase uptake. Inovio uses an electroporation device (Cellectra<sup>&#174;</sup> 2000), which delivers an electric current to the site of injection: in a study on acceptability, acute pain (six of 10 on the VAS score) was recorded for the first 5&#160;min after immunization, but this receded [<xref rid="cei13517-bib-0206" ref-type="ref">206</xref>]. A similar effect was observed in a study using a different electroporation device [<xref rid="cei13517-bib-0207" ref-type="ref">207</xref>]. Genexine are also using electroporation in their trial, but they are also comparing with a needle&#8208;free biojector. Biojector devices have been shown to increase the antibody response to DNA vaccines [<xref rid="cei13517-bib-0208" ref-type="ref">208</xref>, <xref rid="cei13517-bib-0209" ref-type="ref">209</xref>].</p></sec><sec id="cei13517-sec-0045"><title>Inducing non&#8208;specific immunity with vaccines</title><p>One of the more experimental approaches proposed to reduce the impact of COVID&#8208;19 has been the use of other live vaccines as non&#8208;specific vaccines [<xref rid="cei13517-bib-0210" ref-type="ref">210</xref>]. This has been proposed for bacille Calmette&#8211;Gu&#233;rin (BCG), oral polio vaccine [<xref rid="cei13517-bib-0211" ref-type="ref">211</xref>] and measles, mumps and rubella (MMR) [<xref rid="cei13517-bib-0212" ref-type="ref">212</xref>]. The proposed mechanism is described as trained immunity, where exposure to one agent alters the epigenetic profile of innate immune cells, potentially increasing the production of cytokines. In preclinical models, BCG pretreatment has been shown to reduce influenza viral titres [<xref rid="cei13517-bib-0213" ref-type="ref">213</xref>]. Early ecological data (in April 2020) suggested that countries with mandatory BCG vaccination had reduced mortality from COVID&#8208;19, but this analysis has a number of issues, mainly associated with demographics and the timing of when the virus reached different countries [<xref rid="cei13517-bib-0214" ref-type="ref">214</xref>]. A more recent study has supported this protective effect [<xref rid="cei13517-bib-0215" ref-type="ref">215</xref>]. Remarkably, a number of randomized clinical trials have been set up to directly test whether BCG can reduce the burden of COVID&#8208;19.</p></sec></sec><sec id="cei13517-sec-0046"><title>Pros and cons of different platforms</title><p>The COVID&#8208;19 pandemic has led to a surge of different vaccines being rapidly moved to clinical trials. A number of these vaccines have been around for several years as promising preclinical platforms, but not necessarily been attractive enough to generate funding to support human trials. Each of the approaches has advantages and disadvantages (Table <xref rid="cei13517-tbl-0004" ref-type="table">4</xref>): which aspects are the most important will only be identified following efficacy studies. Live attenuated vaccines have a long track record of safety and efficacy, but they may not be feasible in the current pandemic due to the length of time it takes to generate a candidate and test for attenuation. Inactivated vaccines also have a long track record of protective efficacy, and they have the advantage that they are fast to generate; however, they require high&#8208;containment facilities to generate the virus stock. There is also a concern about vaccine&#8208;induced immunopathology with an inactivated vaccine, which has been seen for some other respiratory viruses and in preclinical models of SARS&#8208;CoV&#8208;1; whether this is the case for inactivated SARS&#8208;CoV&#8208;2 vaccines will only be seen after larger and longer Phases II/III trials. Recombinant protein vaccines have been in use since the 1980s; they are a more targeted approach than using a whole virus, which may focus the immune response on a key antigen, but this may lose some breadth of protection. Protein candidates were somewhat slower to enter clinical trials but may have a faster route to licensure, being a more known product than newer vaccines. One challenge is to use the correct conformation of the protein, Spike is metastable and may be less protective if used in a post&#8208;fusion form. One peptide vaccine has registered a clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04527575">NCT04527575</ext-link>) from the Vector institute in Koltsovo, Russia; it is adjuvanted with alum.</p><table-wrap id="cei13517-tbl-0004" xml:lang="en" content-type="Table" orientation="portrait" position="float"><label>Table 4</label><caption><p>Advantages and disadvantages of different vaccine platforms</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Vaccine</th><th align="center" valign="top" rowspan="1" colspan="1">Advantage</th><th align="center" valign="top" rowspan="1" colspan="1">Disadvantage</th></tr></thead><tbody><tr><td align="left" rowspan="4" colspan="1">
<underline underline-style="single">Live Attenuated</underline>
</td><td align="left" rowspan="1" colspan="1">Good track record</td><td align="left" rowspan="1" colspan="1">Risk of reversion to pathogenic form</td></tr><tr><td align="left" rowspan="1" colspan="1">Manufacturing capacity</td><td align="left" rowspan="1" colspan="1">Slow to develop new versions</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Risk of infection in immunocompromised patients</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">May require BSLIII to generate and test</td></tr><tr><td align="left" rowspan="2" colspan="1">
<underline underline-style="single">Inactivated vaccines</underline>
</td><td align="left" rowspan="1" colspan="1">Fast to generate</td><td align="left" rowspan="1" colspan="1">Need live virus and facility to grow large amounts</td></tr><tr><td align="left" rowspan="1" colspan="1">Long track record</td><td align="left" rowspan="1" colspan="1">Risk of vaccine&#8208;enhanced disease</td></tr><tr><td align="left" rowspan="1" colspan="1">
<underline underline-style="single">Protein vaccines</underline>
</td><td align="left" rowspan="1" colspan="1">Safe</td><td align="left" rowspan="1" colspan="1">Potentially poorly immunogenic without adjuvant</td></tr><tr><td align="left" rowspan="2" colspan="1">
<underline underline-style="single">Including VLP</underline>
</td><td align="left" rowspan="1" colspan="1">Very common platform</td><td align="left" rowspan="1" colspan="1">Risk of wrong conformation</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Slow and more expensive manufacture</td></tr><tr><td align="left" rowspan="2" colspan="1">
<underline underline-style="single">Peptide</underline>
</td><td align="left" rowspan="1" colspan="1">T cell response</td><td align="left" rowspan="1" colspan="1">Risk of T cell enhanced disease</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Poorly immunogenic</td></tr><tr><td align="left" rowspan="2" colspan="1">
<underline underline-style="single">aAPC</underline>
</td><td align="left" rowspan="1" colspan="1">T cell response</td><td align="left" rowspan="1" colspan="1">Requires cell manufacture, issues of scale up</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Impractical</td></tr><tr><td align="left" rowspan="4" colspan="1">
<underline underline-style="single">Viral vectored vaccines</underline>
</td><td align="left" rowspan="1" colspan="1">No need to grow live virus</td><td align="left" rowspan="1" colspan="1">Pre&#8208;existing anti&#8208;vector immunity</td></tr><tr><td align="left" rowspan="1" colspan="1">Fast to generate</td><td align="left" rowspan="1" colspan="1">T cell focused response, lower antibody induction</td></tr><tr><td align="left" rowspan="1" colspan="1">Safe track record</td><td align="left" rowspan="1" colspan="1">Requires low temperature (&#8208;80&#176;C) storage</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Replicating vectors not suitable for immunocompromised patients</td></tr><tr><td align="left" rowspan="3" colspan="1">
<underline underline-style="single">DNA vaccines</underline>
</td><td align="left" rowspan="1" colspan="1">Fast to generate</td><td align="left" rowspan="1" colspan="1">Poor track record of immunogenicity in human trials</td></tr><tr><td align="left" rowspan="1" colspan="1">Safe</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Thermostable</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="3" colspan="1">
<underline underline-style="single">mRNA vaccines</underline>
</td><td align="left" rowspan="1" colspan="1">Fast to generate</td><td align="left" rowspan="1" colspan="1">New platform: Not yet used in human efficacy study</td></tr><tr><td align="left" rowspan="1" colspan="1">Translation in cytosol</td><td align="left" rowspan="1" colspan="1">Unstable</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Needs formulation</td></tr><tr><td align="left" rowspan="3" colspan="1">
<underline underline-style="single">saRNA vaccines</underline>
</td><td align="left" rowspan="1" colspan="1">Fast to generate</td><td align="left" rowspan="1" colspan="1">New platform: Previously not been in human clinical trial</td></tr><tr><td align="left" rowspan="1" colspan="1">Requires lower dose than mRNA</td><td align="left" rowspan="1" colspan="1">Unstable</td></tr><tr><td align="left" rowspan="1" colspan="1">Potential for mass production</td><td align="left" rowspan="1" colspan="1">Needs formulation</td></tr></tbody></table><permissions><copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder></permissions></table-wrap><p>The cellular&#8208;based approaches, using aAPC, do not seem to be practical for wide&#8208;scale rollout. Nucleic acid vaccines, both DNA and RNA, have much potential in terms of speed of response and scale&#8208;up: this outbreak will be an important test for whether they can deliver on their promise. DNA vaccines have historically been less immunogenic than other platforms, although with alternate delivery devices that may be overcome. RNA vaccines have not been widely tested for infectious diseases; this is the first time an saRNA vaccine has been trialled. RNA may have a slight issue concerning heat&#8208;stability, necessitating &#8211;80&#730;C storage. Viral vectored vaccines are the furthest ahead in clinical trials, with three candidates in later Phase clinical trials. They are known to be safe, but may be reactogenic at higher doses. Historically, these approaches have had mixed results for efficacy and one concern is pre&#8208;existing immunity against the vector, especially when a human viral&#8208;derived vector such as Ad5 is used. It will be of great interest to see which platforms and candidates are protective in efficacy trials.</p><p>As of September 2020, the furthest advanced candidates have completed Phase I trials (Table <xref rid="cei13517-tbl-0003" ref-type="table">3</xref>), although so far not all the organizations involved have published data from completed trials. All the data published so far indicate that the vaccines are safe, but there are more adverse events at higher doses: both the Moderna [<xref rid="cei13517-bib-0196" ref-type="ref">196</xref>] and BioNTech [<xref rid="cei13517-bib-0198" ref-type="ref">198</xref>] vaccines had severe adverse effects at the highest doses, leading to a lower dose in later studies; some severe adverse effects were also recorded in the Cansino [<xref rid="cei13517-bib-0166" ref-type="ref">166</xref>, <xref rid="cei13517-bib-0167" ref-type="ref">167</xref>] and University of Oxford [<xref rid="cei13517-bib-0165" ref-type="ref">165</xref>] vectored vaccine trials. The vaccines all appear to be immunogenic, although it is hard to compare directly, as different groups will have used subtly different ELISA and neutralization assays. A further complication for comparison is when data have been published as press releases rather than peer&#8208;reviewed papers. Ultimately, vaccine efficacy in a randomized trial is the most important issue, but here again, different primary end&#8208;points are being explored. Some studies are looking at reduction of disease, while others are looking at reduction of confirmed infections.</p></sec><sec id="cei13517-sec-0047"><title>Translation into a real&#8208;world vaccine</title><p>The COVID&#8208;19 crisis represents an opportunity for several experimental vaccine platforms to progress to clinical trials. However, there are considerations between a promising preclinical candidate and a global vaccination campaign, including trials, regulation and manufacture.</p><sec id="cei13517-sec-0048"><title>Clinical trials during a pandemic</title><p>Clinical vaccine trials conventionally undergo four broad Phases, from early safety in small numbers of volunteers (Phase I) to wide&#8208;scale post&#8208;licensure monitoring (Phase IV). Usually, each of the Phases take months or even years to complete before moving on. In a pandemic setting, there is need to speed up the transition between Phases; this has been achieved with co&#8208;operation of regulatory agencies and research ethics committees. Additionally, Phases can be merged, with planning of Phases II/III trials initiated before the Phase I trial has even begun. There is the potential that data obtained from Phase I will mean that planned later&#8208;Phase trials are cancelled due to safety concerns or futility. Ultimately, pushing a vaccine through the different stages of a clinical trial does not negate the need for complete safety data sets to be collected, but close co&#8208;operation with the researchers and regulators can accelerate a progress that could reduce 10 years to 18 months. One consideration is that due to the accelerated time&#8208;scale, post&#8208;licensure monitoring will be extremely important. Another issue concerns the sample size required for efficacy studies; as cases fall, larger studies will be necessary or an alternate trial design. A ring trial was used in Ebola [<xref rid="cei13517-bib-0216" ref-type="ref">216</xref>], which allowed efficacy to be assessed in a few individuals.</p></sec><sec id="cei13517-sec-0049"><title>Manufacturing</title><p>One of the major hurdles to a vaccine relieving the COVID&#8208;19 pandemic is manufacturing enough doses to achieve global herd immunity. The number of doses needed to achieve global coverage depends upon the regime used, but is potentially as many as 16&#160;billion (assuming a prime boost regime with some contingency). To ensure licensure and prequalification status, good manufacturing process (GMP) standards must be upheld during up&#8208;scaled manufacturing and clinical studies. Manufacturing a vaccine at a global scale in the time&#8208;frame required is a unique challenge. Vaccines that are not only safe and effective but also highly scalable, to produce millions or even billions of doses, would be the most desirable tool for curbing the pandemic. Logistics are a key consideration, including access to components to manufacture the vaccines&#160;&#8211;&#160;for example, nucleic acid vaccines require nucleotide triphosphates (NTPs), which are also in high demand for the diagnostic tests. The vaccines also require plant and materials to fill and finish the final product; one bottleneck is exactly that: glass bottles. In parallel with the accelerated clinical trials, accelerated manufacturing scale&#8208;up is required. This telescoped manufacturing process means that investment in the next step is being made before the results of the previous step are known. This has considerable financial risk, especially in terms of setting up the necessary manufacturing plant if it cannot be repurposed, either for other pandemic vaccines or other biologicals.</p><p>Funding is a critical part of the vaccine development process. It remains to be seen whether the total costs of research, development and licensure of any novel vaccine platforms for SARS&#8208;CoV&#8208;2 is comparable to traditional vaccines, such as Dengvaxia, which costed approximately $1.5&#160;billion until licensure [<xref rid="cei13517-bib-0217" ref-type="ref">217</xref>]. A range of funding mechanisms have supported vaccine development. One of the major bodies co&#8208;ordinating the funding is CEPI, which has received funding from multi&#8208;national sources, including governments and charities. Other vaccine candidate teams are being supported by their governments &#8216;fast&#8208;tracking&#8217; their candidates through clinical trials and streamlining their manufacturing. For example, Operation Warp Speed in the United States, is supporting six candidates from AstraZeneca (AZD1222), Moderna (RNA), Pfizer (RNA with BioNTech), Merck (vectored vaccine with Themis), Johnson and Johnson (vectored vaccine) and Novavax (recombinant protein). A UK Vaccine Task Force was announced on 20 April 2020 [<xref rid="cei13517-bib-0218" ref-type="ref">218</xref>] to support UK&#8208;based candidates and reviewing government regulations to facilitate rapid and safe vaccine trials.</p><p>Several vaccine candidates have never progressed past Phase I before, therefore manufacturing GMP material at scale poses new challenges. Many of the vaccines are being developed by either academic groups or small&#8208; to medium&#8208;sized biotech companies, neither of which necessarily have capacity to manufacture at a large scale. One approach is outsourcing to contract manufacturing organizations (CMOs), which can have licensing complications. Some companies have invested in manufacturing capacity; for example in July 2018, Moderna opened a manufacturing facility in Norwood (USA) [<xref rid="cei13517-bib-0219" ref-type="ref">219</xref>], which produce RNA up to the gram scale. However, they still need to work with external companies to complete formulation protocols. New manufacturing facilities are also being constructed elsewhere, including the Vaccines Manufacture and Innovation Centre (VMIC) in the United Kingdom, which has been accelerated and is planned to open in mid&#8208;2021, and Valneva opened an expanded BSLIII facility in Scotland in August 2020.</p><p>Larger companies may have more experience and capacity of manufacturing; for example, Janssen and AstraZeneca are making adenovirus vectors and Sanofi is making a protein vaccine. In the initial stages of the outbreak there was relatively little publicized activity from the larger pharmaceutical companies, with most of the attention on smaller biotechs and academic groups. It is not clear why this was the case. One possible reason could have been exemption from liability, although vaccine manufacturers are exempt in the United States under the 2005 Public Readiness and Emergency Preparedness, or PREP Act.</p><p>Integrating national funding programmes with equitable global access to vaccines is vital. There is a concern that wealthy countries will monopolize initial production runs of vaccines, with preorders outstripping manufacturing capacity. Alternative models of licensure, social enterprise and spoke and hub manufacture may be necessary. For example, the AstraZeneca/Oxford vaccine has been licensed to the Serum Institute of India, the largest global manufacturer of vaccines by doses produced, and Imperial College London have established a social enterprise company to enable equitable access.</p></sec><sec id="cei13517-sec-0050"><title>Regulation of SARS&#8208;CoV&#8208;2 vaccines</title><p>Vaccines require regulation to be introduced as a licensed product. There are a range of national and international bodies which cover this process; for example, any product trialled in the United Kingdom will be considered for approval by the Medicines and Healthcare products Regulatory Agency (MHRA). The product is then considered for prequalification by the WHO for multi&#8208;national distribution, which has supported the regulation and distribution of vaccines for 33 years [<xref rid="cei13517-bib-0220" ref-type="ref">220</xref>]. This process can normally take a substantial amount of time; however, during the COVID&#8208;19 pandemic manufacturers and regulators are striving towards the delivery of a vaccine that is safe and effective within 18&#160;months from February 2020. There is a precedent for accelerated licensure in the context of a pandemic, as seen with the approval of rVSV&#8208;ZEBOV [<xref rid="cei13517-bib-0221" ref-type="ref">221</xref>] as a vaccine for Ebola. The WHO supported the accelerated regulatory approval for rVSV&#8208;ZEBOV&#8208;GP using an expedited prequalification review following its receiving conditional marketing authorization from the European Medicines Agency (EMA) [<xref rid="cei13517-bib-0222" ref-type="ref">222</xref>, <xref rid="cei13517-bib-0223" ref-type="ref">223</xref>]. The WHO has issued guidance and recommendations for the regulation of SARS&#8208;CoV&#8208;2 vaccines [<xref rid="cei13517-bib-0220" ref-type="ref">220</xref>].</p></sec></sec><sec id="cei13517-sec-0051"><title>Lessons learned</title><p>The issues faced during this pandemic and the vaccine platforms being developed to address it will be invaluable for future outbreak control. While, at this stage, it is not possible to say which platform is best, and what works best for one infection may not be best for all infections or for all populations. One of the biggest considerations of all the platforms is speed into trials <italic toggle="yes">versus</italic> ability to deploy the vaccine. While some of the high&#8208;speed platforms, for example RNA, have entered into Phase I trials faster than other approaches, their lack of track record means that approaches for global scale&#8208;up are potentially slower. Older approaches may leapfrog the newer platforms in the scale&#8208;up and manufacturing stage. One observation of interest is the speed with which one of the oldest technologies for viral vaccines, inactivation, has been able to move forwards. Prior to COVID&#8208;19, much of the attention for pandemic vaccine preparedness was on newer technologies; however, of the candidates in Phase III in August 2020, two of four are inactivated vaccines. Safety and efficacy data from these large studies will be critical. Another consideration is that while distributed global manufacture is effective and appropriate for routine scheduled vaccination, local surge manufacturing capacity for new vaccines is important. This capacity may have to be maintained at a loss for large amounts of time, unless alternative commercial contracts can be found for the same facility that can then be replaced at short notice. This reflects a broader consideration that investment in public health, which may appear expensive to begin with, can save a considerable amount in the long term; one study estimated that every &#163;1 spent on public health saves &#163;14 in return [<xref rid="cei13517-bib-0224" ref-type="ref">224</xref>]. Another consideration is for greater standardization of assays and end&#8208;points. Comparisons of the different trials has been made significantly harder by the use of different methodologies. This is part of the broader global context of a true pandemic. Collaborative worldwide action is required to control the virus, which necessitates leadership and a willingness to share by countries with more developed scientific research programmes. Ultimately, while lessons will be learned from this pandemic, the next one will be different and sticking rigidly to a plan that controlled this coronavirus will not necessarily work for a different virus, as the German strategist Helmuth von Moltke &#8216;sort of&#8217; said: &#8216;No plan survives contact with the enemy&#8217;.</p></sec><sec sec-type="conclusions" id="cei13517-sec-0052"><title>Conclusion</title><p>It is still far too early to know what the best approach will be to control COVID&#8208;19 with vaccines. Speculating as to which vaccine platform is &#8216;best&#8217;, while academically enjoyable, is not of value here. That so many platforms, both new and old, are moving into efficacy study makes this an extremely exciting time for vaccinology. The outbreak will certainly be a test case for the novel vaccine platforms, particularly nucleic acid vaccines, which have promised much to date but not been licensed for human use. One issue is whether vaccines will play a role in reducing the burden of the pandemic. Even at maximum speed, the first efficacy trials will start 9 months after the start of the pandemic and the first licensed doses are unlikely to be ready for 18 months, by which time the virus will have caused a large wave of mortality and a larger wave of global disruption. Important questions remain (Box <xref rid="cei13517-fea-0001" ref-type="boxed-text">1</xref>) regarding what is a successful vaccine, how should it be deployed and who should be prioritized. These will depend in part upon the results of the efficacy studies, although the WHO has produced some draft guidance [<xref rid="cei13517-bib-0225" ref-type="ref">225</xref>]. Overall, it has been a remarkable chapter in vaccine development, with widespread collaboration and partnership in a race against the virus.</p><boxed-text position="float" content-type="Box" id="cei13517-fea-0001" orientation="portrait"><label>Box 1</label><caption><title>Questions remaining</title></caption><sec id="cei13517-sec-0053"><p>
<table-wrap id="nlm-table-wrap-1" xml:lang="en" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">What is the best type of protection?</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Is sterilizing immunity the only approach or would disease reduction, without altering disease transmission work?</td></tr><tr><td align="left" rowspan="1" colspan="1">How to achieve equitable global distribution?</td></tr><tr><td align="left" rowspan="1" colspan="1">Is human challenge part of the pathway to a licensed product?</td></tr><tr><td align="left" rowspan="1" colspan="1">What is the risk of immunopathology?</td></tr><tr><td align="left" rowspan="1" colspan="1">How long will protection last after natural infection or vaccination?</td></tr><tr><td align="left" rowspan="1" colspan="1">Can better immunogenicity be achieved with vaccination than after natural infection?</td></tr></tbody></table></table-wrap>
</p></sec></boxed-text></sec><sec sec-type="COI-statement" id="cei13517-sec-0055"><title>Disclosures</title><p>H. M. C. and K. M. P. are investigators on the Imperial College London vaccine program. B. F. P. works in part for VacEquity Global Health. K.M.P. is an invited member of the Sanofi influenza vaccine advisory panel 2020.</p></sec></body><back><ack id="cei13517-sec-0054"><title>Acknowledgements</title><p>The authors thank Dr Ed Parker, Professor Beate Kampmann and the team at the Vaccine Centre at the London School of Hygiene and Tropical Medicine for developing and maintaining the COVID&#8208;19 vaccine tracker tool, which was invaluable for this review. B.F.P. is funded by the Department of Health and Social Care using UK Aid funding and is managed by the Engineering and Physical Sciences Research Council (EPSRC, grant number: EP/R013764/1, note: the views expressed in this publication are those of the author(s) and not necessarily those of the Department of Health and Social Care). J.S.T. and K.M.P. are supported by the Imperial College NIHR BRC.</p></ack><ref-list content-type="cited-references" id="cei13517-bibl-0001"><title>References</title><ref id="cei13517-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="cei13517-cit-0001"><string-name name-style="western"><surname>Zhu</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>W</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>A novel coronavirus from patients with pneumonia in China, 2019</article-title>. <source xml:lang="en">N Engl J Med</source><year>2020</year>; <volume>382</volume>:<fpage>727</fpage>&#8211;<lpage>33</lpage>.<pub-id pub-id-type="pmid">31978945</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2001017</pub-id><pub-id pub-id-type="pmcid">PMC7092803</pub-id></mixed-citation></ref><ref id="cei13517-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="cei13517-cit-0002"><string-name name-style="western"><surname>Schoeman</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Fielding</surname><given-names>BC</given-names></string-name>. <article-title>Coronavirus envelope protein: current knowledge</article-title>. <source xml:lang="en">Virol J</source><year>2019</year>; <volume>16</volume>:<fpage>69</fpage>.<pub-id pub-id-type="pmid">31133031</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12985-019-1182-0</pub-id><pub-id pub-id-type="pmcid">PMC6537279</pub-id></mixed-citation></ref><ref id="cei13517-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="cei13517-cit-0003"><string-name name-style="western"><surname>Wrapp</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Corbett</surname><given-names>KS</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Cryo&#8208;EM structure of the 2019&#8208;nCoV spike in the prefusion conformation</article-title>. <source xml:lang="en">Science</source><year>2020</year>; <volume>367</volume>:<fpage>1260</fpage>&#8211;<lpage>3</lpage>.<pub-id pub-id-type="pmid">32075877</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abb2507</pub-id><pub-id pub-id-type="pmcid">PMC7164637</pub-id></mixed-citation></ref><ref id="cei13517-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="cei13517-cit-0004"><string-name name-style="western"><surname>Conceicao</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Thakur</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Human</surname><given-names>S</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>The SARS&#8208;CoV&#8208;2 spike protein has a broad tropism for mammalian ACE2 proteins</article-title>. <source xml:lang="en">bioRxiv</source><year>2020</year>:2020.06.17.156471.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pbio.3001016</pub-id><pub-id pub-id-type="pmcid">PMC7751883</pub-id><pub-id pub-id-type="pmid">33347434</pub-id></mixed-citation></ref><ref id="cei13517-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="cei13517-cit-0005"><string-name name-style="western"><surname>Bai</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Yao</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Wei</surname><given-names>T</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Presumed Asymptomatic Carrier Transmission of COVID&#8208;19</article-title>. <source xml:lang="en">JAMA</source><year>2020</year>; <volume>323</volume>:<fpage>1406</fpage>&#8211;<lpage>1407</lpage>.<pub-id pub-id-type="pmid">32083643</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2020.2565</pub-id><pub-id pub-id-type="pmcid">PMC7042844</pub-id></mixed-citation></ref><ref id="cei13517-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="cei13517-cit-0006"><string-name name-style="western"><surname>Menni</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Valdes</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Freidin</surname><given-names>MB</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Real&#8208;time tracking of self&#8208;reported symptoms to predict potential COVID&#8208;19</article-title>. <source xml:lang="en">Nat Med</source><year>2020</year>; <volume>26</volume>:<fpage>1037</fpage>&#8211;<lpage>40</lpage>.<pub-id pub-id-type="pmid">32393804</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-020-0916-2</pub-id><pub-id pub-id-type="pmcid">PMC7751267</pub-id></mixed-citation></ref><ref id="cei13517-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="cei13517-cit-0007"><string-name name-style="western"><surname>Spinato</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Fabbris</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Polesel</surname><given-names>J</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Alterations in smell or taste in mildly symptomatic outpatients with SARS&#8208;CoV&#8208;2 infection</article-title>. <source xml:lang="en">JAMA, J Am Med Assocs</source><year>2020</year>; <volume>323</volume>:<fpage>2089</fpage>&#8211;<lpage>90</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2020.6771</pub-id><pub-id pub-id-type="pmcid">PMC7177631</pub-id><pub-id pub-id-type="pmid">32320008</pub-id></mixed-citation></ref><ref id="cei13517-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="cei13517-cit-0008"><string-name name-style="western"><surname>Wu</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>B</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>A new coronavirus associated with human respiratory disease in China</article-title>. <source xml:lang="en">Nature</source><year>2020</year>; <volume>579</volume>:<fpage>265</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">32015508</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-020-2008-3</pub-id><pub-id pub-id-type="pmcid">PMC7094943</pub-id></mixed-citation></ref><ref id="cei13517-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="cei13517-cit-0009"><string-name name-style="western"><surname>Williamson</surname><given-names>EJ</given-names></string-name>, <string-name name-style="western"><surname>Walker</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Bhaskaran</surname><given-names>K</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>OpenSAFELY: factors associated with COVID&#8208;19 death in 17 million patients</article-title>. <source xml:lang="en">Nature</source><year>2020</year>; <volume>584</volume>:<fpage>430</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="pmid">32640463</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-020-2521-4</pub-id><pub-id pub-id-type="pmcid">PMC7611074</pub-id></mixed-citation></ref><ref id="cei13517-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="cei13517-cit-0010"><string-name name-style="western"><surname>Sariol</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Perlman</surname><given-names>S</given-names></string-name>. <article-title>Lessons for COVID&#8208;19 Immunity from Other Coronavirus Infections</article-title>. <source xml:lang="en">Immunity</source><year>2020</year>; <volume>53</volume>:<fpage>248</fpage>&#8211;<lpage>63</lpage>.<pub-id pub-id-type="pmid">32717182</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.immuni.2020.07.005</pub-id><pub-id pub-id-type="pmcid">PMC7359787</pub-id></mixed-citation></ref><ref id="cei13517-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="cei13517-cit-0011"><string-name name-style="western"><surname>Chen</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>John Wherry</surname><given-names>E</given-names></string-name>. <article-title>T cell responses in patients with COVID&#8208;19</article-title>. <source xml:lang="en">Nat Rev Immunol</source><year>2020</year>; <volume>20</volume>:<fpage>529</fpage>&#8211;<lpage>36</lpage>.<pub-id pub-id-type="pmid">32728222</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41577-020-0402-6</pub-id><pub-id pub-id-type="pmcid">PMC7389156</pub-id></mixed-citation></ref><ref id="cei13517-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="cei13517-cit-0012"><string-name name-style="western"><surname>Chen</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Lau</surname><given-names>YF</given-names></string-name>, <string-name name-style="western"><surname>Lamirande</surname><given-names>EW</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Cellular immune responses to severe acute respiratory syndrome coronavirus (SARS&#8208;CoV) infection in senescent BALB/c mice: CD4+ T cells are important in control of SARS&#8208;CoV infection</article-title>. <source xml:lang="en">J Virol</source><year>2010</year>; <volume>84</volume>:<fpage>1289</fpage>&#8211;<lpage>301</lpage>.<pub-id pub-id-type="pmid">19906920</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.01281-09</pub-id><pub-id pub-id-type="pmcid">PMC2812346</pub-id></mixed-citation></ref><ref id="cei13517-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="cei13517-cit-0013"><string-name name-style="western"><surname>Kamepalli</surname><given-names>M</given-names></string-name>, <collab collab-type="authors">FIDSA C</collab>
. <article-title>How immune T&#8208;cell augmentation can help prevent COVID&#8208;19: a possible nutritional solution using ketogenic lifestyle</article-title>. <source xml:lang="en">Univ Louisville J Respir Infect</source><year>2020</year>; <volume>4</volume>. <pub-id pub-id-type="doi">10.18297/jri/vol4/iss1/7</pub-id>.</mixed-citation></ref><ref id="cei13517-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="cei13517-cit-0014"><string-name name-style="western"><surname>Zhao</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Perlman</surname><given-names>S</given-names></string-name>. <article-title>T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus&#8208;infected mice</article-title>. <source xml:lang="en">J Virol</source><year>2010</year>; <volume>84</volume>:<fpage>9318</fpage>&#8211;<lpage>25</lpage>.<pub-id pub-id-type="pmid">20610717</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.01049-10</pub-id><pub-id pub-id-type="pmcid">PMC2937604</pub-id></mixed-citation></ref><ref id="cei13517-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="cei13517-cit-0015"><string-name name-style="western"><surname>Channappanavar</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Fett</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Meyerholz</surname><given-names>DK</given-names></string-name>, <string-name name-style="western"><surname>Perlman</surname><given-names>S</given-names></string-name>. <article-title>Virus&#8208;specific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection</article-title>. <source xml:lang="en">J Virol</source><year>2014</year>; <volume>88</volume>:<fpage>11034</fpage>&#8211;<lpage>44</lpage>.<pub-id pub-id-type="pmid">25056892</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.01505-14</pub-id><pub-id pub-id-type="pmcid">PMC4178831</pub-id></mixed-citation></ref><ref id="cei13517-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="cei13517-cit-0016"><string-name name-style="western"><surname>Fan</surname><given-names>Y&#8208;Y</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>Z&#8208;T</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>L</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Characterization of SARS&#8208;CoV&#8208;specific memory T cells from recovered individuals 4 years after infection</article-title>. <source xml:lang="en">Adv Virol</source><year>2009</year>; <volume>154</volume>:<fpage>1093</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00705-009-0409-6</pub-id><pub-id pub-id-type="pmcid">PMC2796960</pub-id><pub-id pub-id-type="pmid">19526193</pub-id></mixed-citation></ref><ref id="cei13517-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="cei13517-cit-0017"><string-name name-style="western"><surname>Grifoni</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Weiskopf</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Ramirez</surname><given-names>SI</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Targets of T cell responses to SARS&#8208;CoV&#8208;2 coronavirus in humans with COVID&#8208;19 disease and unexposed individuals</article-title>. <source xml:lang="en">Cell</source><year>2020</year>; <volume>181</volume>:<fpage>1489</fpage>&#8211;<lpage>501.e15</lpage>.<pub-id pub-id-type="pmid">32473127</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2020.05.015</pub-id><pub-id pub-id-type="pmcid">PMC7237901</pub-id></mixed-citation></ref><ref id="cei13517-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="cei13517-cit-0018"><string-name name-style="western"><surname>Sekine</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Perez&#8208;Potti</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Rivera&#8208;Ballesteros</surname><given-names>O</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID&#8208;19</article-title>. <source xml:lang="en">Cell</source><year>2020</year>. <pub-id pub-id-type="doi">10.1016/j.cell.2020.08.017</pub-id><pub-id pub-id-type="pmcid">PMC7427556</pub-id><pub-id pub-id-type="pmid">32979941</pub-id></mixed-citation></ref><ref id="cei13517-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="cei13517-cit-0019"><string-name name-style="western"><surname>Gallais</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Velay</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Wendling</surname><given-names>M&#8208;J</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Intrafamilial exposure to SARS&#8208;CoV&#8208;2 induces cellular immune response without seroconversion</article-title>. <source xml:lang="en">medRxiv</source><year>2020</year>:2020.06.21.20132449.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3201/eid2701.203611</pub-id><pub-id pub-id-type="pmcid">PMC7774579</pub-id><pub-id pub-id-type="pmid">33261718</pub-id></mixed-citation></ref><ref id="cei13517-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="cei13517-cit-0020"><string-name name-style="western"><surname>Tan</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>R</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Immunopathological characteristics of coronavirus disease 2019 cases in Guangzhou, China</article-title>. <source xml:lang="en">Immunology</source><year>2020</year>; <volume>160</volume>:<fpage>261</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">32460357</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/imm.13223</pub-id><pub-id pub-id-type="pmcid">PMC7283723</pub-id></mixed-citation></ref><ref id="cei13517-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="cei13517-cit-0021"><string-name name-style="western"><surname>Braun</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Loyal</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Frentsch</surname><given-names>M</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Presence of SARS&#8208;CoV&#8208;2 reactive T cells in COVID&#8208;19 patients and healthy donors</article-title>. <source xml:lang="en">Nature</source><year>2020</year>. <pub-id pub-id-type="doi">10.1038/s41586-020-2598-9</pub-id><pub-id pub-id-type="pmid">32726801</pub-id></mixed-citation></ref><ref id="cei13517-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="cei13517-cit-0022"><string-name name-style="western"><surname>Hotez</surname><given-names>PJ</given-names></string-name>, <string-name name-style="western"><surname>Bottazzi</surname><given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Corry</surname><given-names>DB</given-names></string-name>. <article-title>The potential role of TH17 immune responses in coronavirus immunopathology and vaccine&#8208;induced immune enhancement: Elsevier</article-title>. <source xml:lang="en">Microbes Infect</source><year>2020</year>; <volume>22</volume>:<fpage>165</fpage>&#8211;<lpage>167</lpage>.<pub-id pub-id-type="pmid">32305501</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.micinf.2020.04.005</pub-id><pub-id pub-id-type="pmcid">PMC7162764</pub-id></mixed-citation></ref><ref id="cei13517-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="cei13517-cit-0023"><string-name name-style="western"><surname>Lucas</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Wong</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Klein</surname><given-names>J</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Longitudinal analyses reveal immunological misfiring in severe COVID&#8208;19</article-title>. <source xml:lang="en">Nature</source><year>2020</year>; <volume>584</volume>:<fpage>463</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">32717743</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-020-2588-y</pub-id><pub-id pub-id-type="pmcid">PMC7477538</pub-id></mixed-citation></ref><ref id="cei13517-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="cei13517-cit-0024"><string-name name-style="western"><surname>Yang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Dai</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>X</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Analysis of adaptive immune cell populations and phenotypes in the patients infected by SARS&#8208;CoV&#8208;2</article-title>. <source xml:lang="en">medRxiv</source><year>2020</year>. <pub-id pub-id-type="doi">10.1101/2020.03.23.20040675</pub-id></mixed-citation></ref><ref id="cei13517-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="cei13517-cit-0025"><string-name name-style="western"><surname>Liu</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Fontanet</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>P&#8208;H</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Two&#8208;year prospective study of the humoral immune response of patients with severe acute respiratory syndrome</article-title>. <source xml:lang="en">J Infect Dis</source><year>2006</year>; <volume>193</volume>:<fpage>792</fpage>&#8211;<lpage>5</lpage>.<pub-id pub-id-type="pmid">16479513</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1086/500469</pub-id><pub-id pub-id-type="pmcid">PMC7109932</pub-id></mixed-citation></ref><ref id="cei13517-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="cei13517-cit-0026"><string-name name-style="western"><surname>Barth</surname><given-names>RE</given-names></string-name>, <string-name name-style="western"><surname>De Regt</surname><given-names>MJ</given-names></string-name>. <article-title>Persistence of viral RNA in stool samples from patients recovering from COVID&#8208;19</article-title>. <source xml:lang="en">BMJ</source><year>2020</year>; <volume>369</volume>:<fpage>m1724</fpage>. <pub-id pub-id-type="doi">10.1136/bmj.m1724</pub-id><pub-id pub-id-type="pmid">32381489</pub-id></mixed-citation></ref><ref id="cei13517-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="cei13517-cit-0027"><string-name name-style="western"><surname>Sui</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Murakami</surname><given-names>A</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association</article-title>. <source xml:lang="en">Proc Natl Acad Sci USA</source><year>2004</year>; <volume>101</volume>:<fpage>2536</fpage>&#8211;<lpage>41</lpage>.<pub-id pub-id-type="pmid">14983044</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0307140101</pub-id><pub-id pub-id-type="pmcid">PMC356985</pub-id></mixed-citation></ref><ref id="cei13517-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="cei13517-cit-0028"><string-name name-style="western"><surname>Hsueh</surname><given-names>P&#8208;R</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>L&#8208;M</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>P&#8208;J</given-names></string-name>, <string-name name-style="western"><surname>Kao</surname><given-names>C&#8208;L</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>P&#8208;C</given-names></string-name>. <article-title>Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS&#8208;associated coronavirus</article-title>. <source xml:lang="en">Clin Microbiol Infect</source><year>2004</year>; <volume>10</volume>:<fpage>1062</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="pmid">15606632</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1469-0691.2004.01009.x</pub-id><pub-id pub-id-type="pmcid">PMC7129952</pub-id></mixed-citation></ref><ref id="cei13517-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="cei13517-cit-0029"><string-name name-style="western"><surname>Park</surname><given-names>WB</given-names></string-name>, <string-name name-style="western"><surname>Perera</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Choe</surname><given-names>PG</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Kinetics of serologic responses to MERS coronavirus infection in humans, South Korea</article-title>. <source xml:lang="en">Emerg Infect Dis</source><year>2015</year>; <volume>21</volume>:<fpage>2186</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">26583829</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3201/eid2112.151421</pub-id><pub-id pub-id-type="pmcid">PMC4672454</pub-id></mixed-citation></ref><ref id="cei13517-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="cei13517-cit-0030"><string-name name-style="western"><surname>Presty</surname><given-names>FP</given-names></string-name>. <article-title>Converting detachable wheelchair armrests into parallel bars</article-title>. <source xml:lang="en">Phys Ther</source><year>1969</year>; <volume>49</volume>:<fpage>763</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="pmid">5791336</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ptj/49.7.763</pub-id></mixed-citation></ref><ref id="cei13517-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="cei13517-cit-0031"><string-name name-style="western"><surname>Drosten</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Meyer</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Muller</surname><given-names>MA</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Transmission of MERS&#8208;coronavirus in household contacts</article-title>. <source xml:lang="en">NEJM</source><year>2014</year>; <volume>371</volume>:<fpage>828</fpage>&#8211;<lpage>35</lpage>.<pub-id pub-id-type="pmid">25162889</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1405858</pub-id></mixed-citation></ref><ref id="cei13517-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="cei13517-cit-0032"><string-name name-style="western"><surname>Huang</surname><given-names>AT</given-names></string-name>, <string-name name-style="western"><surname>Garcia&#8208;Carreras</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Hitchings</surname><given-names>MDT</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>A systematic review of antibody mediated immunity to coronaviruses: antibody kinetics, correlates of protection, and association of antibody responses with severity of disease</article-title>. <source xml:lang="en">medRxiv</source><year>2020</year>:2020.04.14.20065771.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-020-18450-4</pub-id><pub-id pub-id-type="pmcid">PMC7499300</pub-id><pub-id pub-id-type="pmid">32943637</pub-id></mixed-citation></ref><ref id="cei13517-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="cei13517-cit-0033"><string-name name-style="western"><surname>Seow</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Graham</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Merrick</surname><given-names>B</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Longitudinal evaluation and decline of antibody responses in SARS&#8208;CoV&#8208;2 infection</article-title>. <source xml:lang="en">medRxiv</source><year>2020</year>:2020.07.09.20148429.</mixed-citation></ref><ref id="cei13517-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="cei13517-cit-0034"><string-name name-style="western"><surname>Callow</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Parry</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Sergeant</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Tyrrell</surname><given-names>D</given-names></string-name>. <article-title>The time course of the immune response to experimental coronavirus infection of man</article-title>. <source xml:lang="en">Epidemiol Infect</source><year>1990</year>; <volume>105</volume>:<fpage>435</fpage>&#8211;<lpage>46</lpage>.<pub-id pub-id-type="pmid">2170159</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/s0950268800048019</pub-id><pub-id pub-id-type="pmcid">PMC2271881</pub-id></mixed-citation></ref><ref id="cei13517-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="cei13517-cit-0035"><string-name name-style="western"><surname>To</surname><given-names>KK&#8208;W</given-names></string-name>, <string-name name-style="western"><surname>Hung</surname><given-names>IF&#8208;N</given-names></string-name>, <string-name name-style="western"><surname>Ip</surname><given-names>JD</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>COVID&#8208;19 re&#8208;infection by a phylogenetically distinct SARS&#8208;coronavirus&#8208;2 strain confirmed by whole genome sequencing</article-title>. <source xml:lang="en">Clin Infect Dis</source><year>2020</year>:<elocation-id>ciaa1275</elocation-id><pub-id pub-id-type="pmid">32840608</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cid/ciaa1275</pub-id><pub-id pub-id-type="pmcid">PMC7499500</pub-id></mixed-citation></ref><ref id="cei13517-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="cei13517-cit-0036"><string-name name-style="western"><surname>Tillet</surname><given-names>RL</given-names></string-name>, <string-name name-style="western"><surname>Sevinsky</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Hartley</surname><given-names>PD</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Genomic evidence for a case of reinfection with SARS&#8208;CoV&#8208;2</article-title>. <source xml:lang="en">Lancet</source><year>2020</year>. <pub-id pub-id-type="doi">10.2139/ssrn.3680955</pub-id><pub-id pub-id-type="pmcid">PMC7550103</pub-id><pub-id pub-id-type="pmid">33058797</pub-id></mixed-citation></ref><ref id="cei13517-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="cei13517-cit-0037"><string-name name-style="western"><surname>Qiu</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Mao</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Identification of potential cross&#8208;protective epitope between a new type of coronavirus (2019&#8208;nCoV) and severe acute respiratory syndrome virus</article-title>. <source xml:lang="en">J Genet Genomics</source><year>2020</year>; <volume>47</volume>:<fpage>115</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">32171450</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jgg.2020.01.003</pub-id><pub-id pub-id-type="pmcid">PMC7111282</pub-id></mixed-citation></ref><ref id="cei13517-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="cei13517-cit-0038"><string-name name-style="western"><surname>Tian</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>A</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus&#8208;specific human monoclonal antibody</article-title>. <source xml:lang="en">Emerg Microbes Infect</source><year>2020</year>; <volume>9</volume>:<fpage>382</fpage>&#8211;<lpage>5</lpage>.<pub-id pub-id-type="pmid">32065055</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/22221751.2020.1729069</pub-id><pub-id pub-id-type="pmcid">PMC7048180</pub-id></mixed-citation></ref><ref id="cei13517-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="cei13517-cit-0039"><string-name name-style="western"><surname>Seydoux</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Homad</surname><given-names>LJ</given-names></string-name>, <string-name name-style="western"><surname>MacCamy</surname><given-names>AJ</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Analysis of a SARS&#8208;CoV&#8208;2&#8208;infected individual reveals development of potent neutralizing antibodies with limited somatic mutation</article-title>. <source xml:lang="en">Immunity</source><year>2020</year>; <volume>53</volume>:<fpage>98</fpage>&#8211;<lpage>105.e5</lpage>.<pub-id pub-id-type="pmid">32561270</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.immuni.2020.06.001</pub-id><pub-id pub-id-type="pmcid">PMC7276322</pub-id></mixed-citation></ref><ref id="cei13517-bib-0040"><label>40</label><mixed-citation publication-type="miscellaneous" id="cei13517-cit-0040"><string-name name-style="western"><surname>Aziz</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Iheanacho</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Hashmi</surname><given-names>MF</given-names></string-name>. <article-title>Physiology, Antibody in StatsPearls</article-title>. <year>2019</year>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK546670/">https://www.ncbi.nlm.nih.gov/books/NBK546670/</ext-link><pub-id pub-id-type="pmid">31536276</pub-id></mixed-citation></ref><ref id="cei13517-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="cei13517-cit-0041"><string-name name-style="western"><surname>Fu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Cheng</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>Y</given-names></string-name>. <article-title>Understanding SARS&#8208;CoV&#8208;2&#8208;mediated inflammatory responses: from mechanisms to potential therapeutic tools</article-title>. <source xml:lang="en">Virol Sinica</source><year>2020</year>; <volume>35</volume>:<fpage>266</fpage>&#8211;<lpage>71</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12250-020-00207-4</pub-id><pub-id pub-id-type="pmcid">PMC7090474</pub-id><pub-id pub-id-type="pmid">32125642</pub-id></mixed-citation></ref><ref id="cei13517-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="cei13517-cit-0042"><string-name name-style="western"><surname>Chao</surname><given-names>YX</given-names></string-name>, <string-name name-style="western"><surname>R&#246;tzschke</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Tan</surname><given-names>E&#8208;K</given-names></string-name>. <article-title>The role of IgA in COVID&#8208;19</article-title>. <source xml:lang="en">Brain Behav Immun</source><year>2020</year>; <volume>87</volume>:<fpage>182</fpage>&#8211;<lpage>3</lpage>.<pub-id pub-id-type="pmid">32454136</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbi.2020.05.057</pub-id><pub-id pub-id-type="pmcid">PMC7245198</pub-id></mixed-citation></ref><ref id="cei13517-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="cei13517-cit-0043"><string-name name-style="western"><surname>Schonberger</surname><given-names>LB</given-names></string-name>, <string-name name-style="western"><surname>Bregman</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Sullivan&#8208;Bolyai</surname><given-names>JZ</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Guillain&#8211;Barr&#233; syndrome following vaccination in the national influenza immunization program, United States, 1976&#8211;1977</article-title>. <source xml:lang="en">Am J Epidemiol</source><year>1979</year>; <volume>110</volume>:<fpage>105</fpage>&#8211;<lpage>23</lpage>.<pub-id pub-id-type="pmid">463869</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/oxfordjournals.aje.a112795</pub-id></mixed-citation></ref><ref id="cei13517-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="cei13517-cit-0044"><string-name name-style="western"><surname>Nellore</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Randall</surname><given-names>TD</given-names></string-name>. <article-title>Narcolepsy and influenza vaccination&#8212;the inappropriate awakening of immunity</article-title>. <source xml:lang="en">Ann Transl Med</source><year>2016</year>; <volume>4</volume>:<elocation-id>S29</elocation-id>.<pub-id pub-id-type="pmid">27867997</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.21037/atm.2016.10.60</pub-id><pub-id pub-id-type="pmcid">PMC5104623</pub-id></mixed-citation></ref><ref id="cei13517-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="cei13517-cit-0045"><string-name name-style="western"><surname>Jacob</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Leib</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Ollila</surname><given-names>HM</given-names></string-name>, <string-name name-style="western"><surname>Bonvalet</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Adams</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Mignot</surname><given-names>E</given-names></string-name>. <article-title>Comparison of Pandemrix and Arepanrix, two pH1N1 AS03&#8208;adjuvanted vaccines differentially associated with narcolepsy development</article-title>. <source xml:lang="en">Brain Behav Immun</source><year>2015</year>; <volume>47</volume>:<fpage>44</fpage>&#8211;<lpage>57</lpage>.<pub-id pub-id-type="pmid">25452148</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbi.2014.11.004</pub-id></mixed-citation></ref><ref id="cei13517-bib-0046"><label>46</label><mixed-citation publication-type="journal" id="cei13517-cit-0046"><string-name name-style="western"><surname>Vaarala</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Vuorela</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Partinen</surname><given-names>M</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Antigenic differences between AS03 adjuvanted influenza A (H1N1) pandemic vaccines: implications for pandemrix&#8208;associated narcolepsy risk</article-title>. <source xml:lang="en">PLOS ONE</source><year>2014</year>; <volume>9</volume>:<elocation-id>e114361</elocation-id><pub-id pub-id-type="pmid">25501681</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0114361</pub-id><pub-id pub-id-type="pmcid">PMC4266499</pub-id></mixed-citation></ref><ref id="cei13517-bib-0047"><label>47</label><mixed-citation publication-type="journal" id="cei13517-cit-0047"><string-name name-style="western"><surname>Ahmed</surname><given-names>SS</given-names></string-name>, <string-name name-style="western"><surname>Volkmuth</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Duca</surname><given-names>J</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Antibodies to influenza nucleoprotein cross&#8208;react with human hypocretin receptor 2</article-title>. <source xml:lang="en">Sci Transl Med</source><year>2015</year>; <volume>7</volume>:<elocation-id>294ra105</elocation-id>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scitranslmed.aab2354</pub-id><pub-id pub-id-type="pmid">26136476</pub-id></mixed-citation></ref><ref id="cei13517-bib-0048"><label>48</label><mixed-citation publication-type="book" id="cei13517-cit-0048"><collab collab-type="authors">World Health Organization</collab>
. <source xml:lang="en">Statement on narcolepsy and vaccination</source>. <year>2011</year>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/vaccine_safety/committee/topics/influenza/pandemic/h1n1_safety_assessing/narcolepsy_statement/en/">https://www.who.int/vaccine_safety/committee/topics/influenza/pandemic/h1n1_safety_assessing/narcolepsy_statement/en/</ext-link></mixed-citation></ref><ref id="cei13517-bib-0049"><label>49</label><mixed-citation publication-type="journal" id="cei13517-cit-0049"><string-name name-style="western"><surname>Rauh</surname><given-names>LW</given-names></string-name>, <string-name name-style="western"><surname>Schmidt</surname><given-names>R</given-names></string-name>. <article-title>Measles immunization with killed virus vaccine: serum antibody titers and experience with exposure to measles epidemic</article-title>. <source xml:lang="en">Am J Dis Child</source><year>1965</year>; <volume>109</volume>:<fpage>232</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">14246070</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/archpedi.1965.02090020234007</pub-id></mixed-citation></ref><ref id="cei13517-bib-0050"><label>50</label><mixed-citation publication-type="journal" id="cei13517-cit-0050"><string-name name-style="western"><surname>Kim</surname><given-names>HW</given-names></string-name>, <string-name name-style="western"><surname>Canchola</surname><given-names>JG</given-names></string-name>, <string-name name-style="western"><surname>Brandt</surname><given-names>CD</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine</article-title>. <source xml:lang="en">Am J Epidemiol</source><year>1969</year>; <volume>89</volume>:<fpage>422</fpage>&#8211;<lpage>34</lpage>.<pub-id pub-id-type="pmid">4305198</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/oxfordjournals.aje.a120955</pub-id></mixed-citation></ref><ref id="cei13517-bib-0051"><label>51</label><mixed-citation publication-type="journal" id="cei13517-cit-0051"><string-name name-style="western"><surname>Sridhar</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Luedtke</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Langevin</surname><given-names>E</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Effect of dengue serostatus on dengue vaccine safety and efficacy</article-title>. <source xml:lang="en">N Engl J Med</source><year>2018</year>; <volume>379</volume>:<fpage>327</fpage>&#8211;<lpage>40</lpage>.<pub-id pub-id-type="pmid">29897841</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1800820</pub-id></mixed-citation></ref><ref id="cei13517-bib-0052"><label>52</label><mixed-citation publication-type="journal" id="cei13517-cit-0052"><string-name name-style="western"><surname>Kim</surname><given-names>A&#8208;R</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>D&#8208;H</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>S&#8208;H</given-names></string-name>, <string-name name-style="western"><surname>Rubino</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Choi</surname><given-names>H&#8208;J</given-names></string-name>, <string-name name-style="western"><surname>Quan</surname><given-names>F&#8208;S</given-names></string-name>. <article-title>Protection induced by virus&#8208;like particle vaccine containing tandem repeat gene of respiratory syncytial virus G protein</article-title>. <source xml:lang="en">PLOS ONE</source><year>2018</year>; <volume>13</volume>:<elocation-id>e0191277</elocation-id>.<pub-id pub-id-type="pmid">29338045</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0191277</pub-id><pub-id pub-id-type="pmcid">PMC5770062</pub-id></mixed-citation></ref><ref id="cei13517-bib-0053"><label>53</label><mixed-citation publication-type="journal" id="cei13517-cit-0053"><string-name name-style="western"><surname>Kim</surname><given-names>K&#8208;H</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>Y&#8208;T</given-names></string-name>, <string-name name-style="western"><surname>Hwang</surname><given-names>HS</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Alum adjuvant enhances protection against respiratory syncytial virus but exacerbates pulmonary inflammation by modulating multiple innate and adaptive immune cells</article-title>. <source xml:lang="en">PLOS ONE</source><year>2015</year>; <volume>10</volume>:<elocation-id>e0139916</elocation-id>.<pub-id pub-id-type="pmid">26468884</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0139916</pub-id><pub-id pub-id-type="pmcid">PMC4607166</pub-id></mixed-citation></ref><ref id="cei13517-bib-0054"><label>54</label><mixed-citation publication-type="journal" id="cei13517-cit-0054"><string-name name-style="western"><surname>O&#8217;Konek</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Makidon</surname><given-names>PE</given-names></string-name>, <string-name name-style="western"><surname>Landers</surname><given-names>JJ</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Intranasal nanoemulsion&#8208;based inactivated respiratory syncytial virus vaccines protect against viral challenge in cotton rats</article-title>. <source xml:lang="en">Hum Vaccin Immunother</source><year>2015</year>; <volume>11</volume>:<fpage>2904</fpage>&#8211;<lpage>12</lpage>.<pub-id pub-id-type="pmid">26307915</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/21645515.2015.1075680</pub-id><pub-id pub-id-type="pmcid">PMC5054793</pub-id></mixed-citation></ref><ref id="cei13517-bib-0055"><label>55</label><mixed-citation publication-type="journal" id="cei13517-cit-0055"><string-name name-style="western"><surname>Van Der Merwe</surname><given-names>PA</given-names></string-name>, <string-name name-style="western"><surname>Dushek</surname><given-names>O</given-names></string-name>. <article-title>Mechanisms for T cell receptor triggering</article-title>. <source xml:lang="en">Nat Rev Immunol</source><year>2011</year>; <volume>11</volume>:<fpage>47</fpage>&#8211;<lpage>55</lpage>.<pub-id pub-id-type="pmid">21127503</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nri2887</pub-id></mixed-citation></ref><ref id="cei13517-bib-0056"><label>56</label><mixed-citation publication-type="journal" id="cei13517-cit-0056"><string-name name-style="western"><surname>Agrawal</surname><given-names>AS</given-names></string-name>, <string-name name-style="western"><surname>Tao</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Algaissi</surname><given-names>A</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Immunization with inactivated Middle East respiratory syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus</article-title>. <source xml:lang="en">Hum Vaccin Immunother</source><year>2016</year>; <volume>12</volume>:<fpage>2351</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="pmid">27269431</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/21645515.2016.1177688</pub-id><pub-id pub-id-type="pmcid">PMC5027702</pub-id></mixed-citation></ref><ref id="cei13517-bib-0057"><label>57</label><mixed-citation publication-type="journal" id="cei13517-cit-0057"><string-name name-style="western"><surname>Rothman</surname><given-names>AL</given-names></string-name>. <article-title>Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms</article-title>. <source xml:lang="en">Nat Rev Immunol</source><year>2011</year>; <volume>11</volume>:<fpage>532</fpage>&#8211;<lpage>43</lpage>.<pub-id pub-id-type="pmid">21760609</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nri3014</pub-id></mixed-citation></ref><ref id="cei13517-bib-0058"><label>58</label><mixed-citation publication-type="journal" id="cei13517-cit-0058"><string-name name-style="western"><surname>Moghaddam</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Olszewska</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>B</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>A potential molecular mechanism for hypersensitivity caused by formalin&#8208;inactivated vaccines</article-title>. <source xml:lang="en">Nat Med</source><year>2006</year>; <volume>12</volume>:<fpage>905</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">16862151</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nm1456</pub-id></mixed-citation></ref><ref id="cei13517-bib-0059"><label>59</label><mixed-citation publication-type="journal" id="cei13517-cit-0059"><string-name name-style="western"><surname>Tsunetsugu&#8208;Yokota</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Ato</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Takahashi</surname><given-names>Y</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Formalin&#8208;treated UV&#8208;inactivated SARS coronavirus vaccine retains its immunogenicity and promotes Th2&#8208;type immune responses</article-title>. <source xml:lang="en">Jpn J Infect Dis</source><year>2007</year>; <volume>60</volume>:<fpage>106</fpage>&#8208;<lpage>12</lpage>.<pub-id pub-id-type="pmid">17515642</pub-id></mixed-citation></ref><ref id="cei13517-bib-0060"><label>60</label><mixed-citation publication-type="journal" id="cei13517-cit-0060"><string-name name-style="western"><surname>Astill</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Alkie</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Yitbarek</surname><given-names>A</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Examination of the effects of virus inactivation methods on the induction of antibody&#8208;and cell&#8208;mediated immune responses against whole inactivated H9N2 avian influenza virus vaccines in chickens</article-title>. <source xml:lang="en">Vaccine</source><year>2018</year>; <volume>36</volume>:<fpage>3908</fpage>&#8211;<lpage>16</lpage>.<pub-id pub-id-type="pmid">29853199</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2018.05.093</pub-id></mixed-citation></ref><ref id="cei13517-bib-0061"><label>61</label><mixed-citation publication-type="journal" id="cei13517-cit-0061"><string-name name-style="western"><surname>Openshaw</surname><given-names>PJ</given-names></string-name>, <string-name name-style="western"><surname>Tregoning</surname><given-names>JS</given-names></string-name>. <article-title>Immune responses and disease enhancement during respiratory syncytial virus infection</article-title>. <source xml:lang="en">Clin Microbiol Rev</source><year>2005</year>; <volume>18</volume>:<fpage>541</fpage>&#8211;<lpage>55</lpage>.<pub-id pub-id-type="pmid">16020689</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/CMR.18.3.541-555.2005</pub-id><pub-id pub-id-type="pmcid">PMC1195968</pub-id></mixed-citation></ref><ref id="cei13517-bib-0062"><label>62</label><mixed-citation publication-type="journal" id="cei13517-cit-0062"><string-name name-style="western"><surname>Kollmann</surname><given-names>TR</given-names></string-name>, <string-name name-style="western"><surname>Marchant</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Way</surname><given-names>SS</given-names></string-name>. <article-title>Vaccination strategies to enhance immunity in neonates</article-title>. <source xml:lang="en">Science</source><year>2020</year>; <volume>368</volume>:<fpage>612</fpage>&#8211;<lpage>5</lpage>.<pub-id pub-id-type="pmid">32381718</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.aaz9447</pub-id><pub-id pub-id-type="pmcid">PMC7734703</pub-id></mixed-citation></ref><ref id="cei13517-bib-0063"><label>63</label><mixed-citation publication-type="journal" id="cei13517-cit-0063"><string-name name-style="western"><surname>Huisman</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Martina</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Rimmelzwaan</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Gruters</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Osterhaus</surname><given-names>A</given-names></string-name>. <article-title>Vaccine&#8208;induced enhancement of viral infections</article-title>. <source xml:lang="en">Vaccine</source><year>2009</year>; <volume>27</volume>:<fpage>505</fpage>&#8211;<lpage>12</lpage>.<pub-id pub-id-type="pmid">19022319</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2008.10.087</pub-id><pub-id pub-id-type="pmcid">PMC7131326</pub-id></mixed-citation></ref><ref id="cei13517-bib-0064"><label>64</label><mixed-citation publication-type="journal" id="cei13517-cit-0064"><string-name name-style="western"><surname>Dandekar</surname><given-names>AA</given-names></string-name>, <string-name name-style="western"><surname>Perlman</surname><given-names>S</given-names></string-name>. <article-title>Immunopathogenesis of coronavirus infections: implications for SARS</article-title>. <source xml:lang="en">Nat Rev Immunol</source><year>2005</year>; <volume>5</volume>:<fpage>917</fpage>&#8211;<lpage>27</lpage>.<pub-id pub-id-type="pmid">16322745</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nri1732</pub-id><pub-id pub-id-type="pmcid">PMC7097326</pub-id></mixed-citation></ref><ref id="cei13517-bib-0065"><label>65</label><mixed-citation publication-type="journal" id="cei13517-cit-0065"><string-name name-style="western"><surname>Polack</surname><given-names>FP</given-names></string-name>, <string-name name-style="western"><surname>Teng</surname><given-names>MN</given-names></string-name>, <string-name name-style="western"><surname>L.Collins</surname><given-names>P</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>A role for immune complexes in enhanced respiratory syncytial virus disease</article-title>. <source xml:lang="en">J Exp Med</source><year>2002</year>; <volume>196</volume>:<fpage>859</fpage>&#8211;<lpage>65</lpage>.<pub-id pub-id-type="pmid">12235218</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1084/jem.20020781</pub-id><pub-id pub-id-type="pmcid">PMC2194058</pub-id></mixed-citation></ref><ref id="cei13517-bib-0066"><label>66</label><mixed-citation publication-type="journal" id="cei13517-cit-0066"><string-name name-style="western"><surname>Halstead</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>O&#8217;Rourke</surname><given-names>EJ</given-names></string-name>, <string-name name-style="western"><surname>Allison</surname><given-names>AC</given-names></string-name>. <article-title>Dengue viruses and mononuclear phagocytes. II. Identity of blood and tissue leukocytes supporting <italic toggle="yes">in vitro</italic> infection</article-title>. <source xml:lang="en">J Exp Med</source><year>1977</year>; <volume>146</volume>:<fpage>218</fpage>&#8211;<lpage>29</lpage>.<pub-id pub-id-type="pmid">195000</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1084/jem.146.1.218</pub-id><pub-id pub-id-type="pmcid">PMC2180735</pub-id></mixed-citation></ref><ref id="cei13517-bib-0067"><label>67</label><mixed-citation publication-type="journal" id="cei13517-cit-0067"><string-name name-style="western"><surname>Screaton</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Mongkolsapaya</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Yacoub</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Roberts</surname><given-names>C</given-names></string-name>. <article-title>New insights into the immunopathology and control of dengue virus infection</article-title>. <source xml:lang="en">Nat Rev Immunol</source><year>2015</year>; <volume>15</volume>:<fpage>745</fpage>&#8211;<lpage>59</lpage>.<pub-id pub-id-type="pmid">26603900</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nri3916</pub-id></mixed-citation></ref><ref id="cei13517-bib-0068"><label>68</label><mixed-citation publication-type="journal" id="cei13517-cit-0068"><string-name name-style="western"><surname>Delgado</surname><given-names>MF</given-names></string-name>, <string-name name-style="western"><surname>Coviello</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Monsalvo</surname><given-names>AC</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Lack of antibody affinity maturation due to poor Toll&#8208;like receptor stimulation leads to enhanced respiratory syncytial virus disease</article-title>. <source xml:lang="en">Nat Med</source><year>2009</year>; <volume>15</volume>:<fpage>34</fpage>&#8211;<lpage>41</lpage>.<pub-id pub-id-type="pmid">19079256</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nm.1894</pub-id><pub-id pub-id-type="pmcid">PMC2987729</pub-id></mixed-citation></ref><ref id="cei13517-bib-0069"><label>69</label><mixed-citation publication-type="journal" id="cei13517-cit-0069"><string-name name-style="western"><surname>Tseng</surname><given-names>C&#8208;T</given-names></string-name>, <string-name name-style="western"><surname>Sbrana</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Iwata&#8208;Yoshikawa</surname><given-names>N</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus</article-title>. <source xml:lang="en">PLOS ONE</source><year>2012</year>; <volume>7</volume>:<elocation-id>e35421</elocation-id>.<pub-id pub-id-type="pmid">22536382</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0035421</pub-id><pub-id pub-id-type="pmcid">PMC3335060</pub-id></mixed-citation></ref><ref id="cei13517-bib-0070"><label>70</label><mixed-citation publication-type="journal" id="cei13517-cit-0070"><string-name name-style="western"><surname>Weingartl</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Czub</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Czub</surname><given-names>S</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Immunization with modified vaccinia virus Ankara&#8208;based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets</article-title>. <source xml:lang="en">J Virol</source><year>2004</year>; <volume>78</volume>:<fpage>12672</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="pmid">15507655</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.78.22.12672-12676.2004</pub-id><pub-id pub-id-type="pmcid">PMC525089</pub-id></mixed-citation></ref><ref id="cei13517-bib-0071"><label>71</label><mixed-citation publication-type="journal" id="cei13517-cit-0071"><string-name name-style="western"><surname>Liu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Wei</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>Q</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Anti&#8211;spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS&#8208;CoV infection</article-title>. <source xml:lang="en">JCI Insight</source><year>2019</year>; <volume>4</volume>:<elocation-id>e123158</elocation-id>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/jci.insight.123158</pub-id><pub-id pub-id-type="pmcid">PMC6478436</pub-id><pub-id pub-id-type="pmid">30830861</pub-id></mixed-citation></ref><ref id="cei13517-bib-0072"><label>72</label><mixed-citation publication-type="journal" id="cei13517-cit-0072"><string-name name-style="western"><surname>Wan</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Shang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>S</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Molecular mechanism for antibody&#8208;dependent enhancement of coronavirus entry</article-title>. <source xml:lang="en">J Virol</source><year>2020</year>; <volume>94</volume>:<elocation-id>e02015&#8208;19</elocation-id>.<pub-id pub-id-type="pmid">31826992</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.02015-19</pub-id><pub-id pub-id-type="pmcid">PMC7022351</pub-id></mixed-citation></ref><ref id="cei13517-bib-0073"><label>73</label><mixed-citation publication-type="journal" id="cei13517-cit-0073"><string-name name-style="western"><surname>Arvin</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Fink</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Schmid</surname><given-names>MA</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>A perspective on potential antibody&#8208;dependent enhancement of SARS&#8208;CoV&#8208;2</article-title>. <source xml:lang="en">Nature</source><year>2020</year>; <volume>584</volume>:<fpage>353</fpage>&#8211;<lpage>63</lpage>.<pub-id pub-id-type="pmid">32659783</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-020-2538-8</pub-id></mixed-citation></ref><ref id="cei13517-bib-0074"><label>74</label><mixed-citation publication-type="journal" id="cei13517-cit-0074"><string-name name-style="western"><surname>Subbarao</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Roberts</surname><given-names>A</given-names></string-name>. <article-title>Is there an ideal animal model for SARS?</article-title><source xml:lang="en">Trends Microbiol</source><year>2006</year>; <volume>14</volume>:<fpage>299</fpage>&#8211;<lpage>303</lpage>.<pub-id pub-id-type="pmid">16759866</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tim.2006.05.007</pub-id><pub-id pub-id-type="pmcid">PMC7119110</pub-id></mixed-citation></ref><ref id="cei13517-bib-0075"><label>75</label><mixed-citation publication-type="journal" id="cei13517-cit-0075"><string-name name-style="western"><surname>Rao</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Porter</surname><given-names>DC</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Herliczek</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Lowe</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Keyomarsi</surname><given-names>K</given-names></string-name>. <article-title>Lovastatin&#8208;mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl&#8208;CoA reductase</article-title>. <source xml:lang="en">Proc Natl Acad Sci USA</source><year>1999</year>; <volume>96</volume>:<fpage>7797</fpage>&#8211;<lpage>802</lpage>.<pub-id pub-id-type="pmid">10393901</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.96.14.7797</pub-id><pub-id pub-id-type="pmcid">PMC22141</pub-id></mixed-citation></ref><ref id="cei13517-bib-0076"><label>76</label><mixed-citation publication-type="miscellaneous" id="cei13517-cit-0076"><string-name name-style="western"><surname>Marshall</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Enserink</surname><given-names>M</given-names></string-name>. <article-title>Caution urged on SARS vaccines: American Association for the Advancement of Science</article-title>, <year>2004</year>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.303.5660.944</pub-id><pub-id pub-id-type="pmid">14963300</pub-id></mixed-citation></ref><ref id="cei13517-bib-0077"><label>77</label><mixed-citation publication-type="journal" id="cei13517-cit-0077"><string-name name-style="western"><surname>Roberts</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Paddock</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Vogel</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Butler</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Zaki</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Subbarao</surname><given-names>K</given-names></string-name>. <article-title>Aged BALB/c mice as a model for increased severity of severe acute respiratory syndrome in elderly humans</article-title>. <source xml:lang="en">J Virol</source><year>2005</year>; <volume>79</volume>:<fpage>5833</fpage>&#8211;<lpage>38</lpage>.<pub-id pub-id-type="pmid">15827197</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.79.9.5833-5838.2005</pub-id><pub-id pub-id-type="pmcid">PMC1082763</pub-id></mixed-citation></ref><ref id="cei13517-bib-0078"><label>78</label><mixed-citation publication-type="journal" id="cei13517-cit-0078"><string-name name-style="western"><surname>McCray</surname><given-names>PB</given-names><suffix>Jr</suffix></string-name>, <string-name name-style="western"><surname>Pewe</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Wohlford&#8208;Lenane</surname><given-names>C</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Lethal infection of K18&#8208;hACE2 mice infected with severe acute respiratory syndrome coronavirus</article-title>. <source xml:lang="en">J Virol</source><year>2007</year>; <volume>81</volume>:<fpage>813</fpage>&#8211;<lpage>21</lpage>.<pub-id pub-id-type="pmid">17079315</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.02012-06</pub-id><pub-id pub-id-type="pmcid">PMC1797474</pub-id></mixed-citation></ref><ref id="cei13517-bib-0079"><label>79</label><mixed-citation publication-type="journal" id="cei13517-cit-0079"><string-name name-style="western"><surname>Sutton</surname><given-names>TC</given-names></string-name>, <string-name name-style="western"><surname>Subbarao</surname><given-names>K</given-names></string-name>. <article-title>Development of animal models against emerging coronaviruses: from SARS to MERS coronavirus</article-title>. <source xml:lang="en">Virology</source><year>2015</year>; <volume>479</volume>:<fpage>247</fpage>&#8211;<lpage>58</lpage>.<pub-id pub-id-type="pmid">25791336</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.virol.2015.02.030</pub-id><pub-id pub-id-type="pmcid">PMC4793273</pub-id></mixed-citation></ref><ref id="cei13517-bib-0080"><label>80</label><mixed-citation publication-type="journal" id="cei13517-cit-0080"><string-name name-style="western"><surname>Rodon</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Okba</surname><given-names>NM</given-names></string-name>, <string-name name-style="western"><surname>Te</surname><given-names>N</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Blocking transmission of Middle East respiratory syndrome coronavirus (MERS&#8208;CoV) in llamas by vaccination with a recombinant spike protein</article-title>. <source xml:lang="en">Emerg Microb Infect</source><year>2019</year>; <volume>8</volume>:<fpage>1593</fpage>&#8211;<lpage>603</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/22221751.2019.1685912</pub-id><pub-id pub-id-type="pmcid">PMC6853226</pub-id><pub-id pub-id-type="pmid">31711379</pub-id></mixed-citation></ref><ref id="cei13517-bib-0081"><label>81</label><mixed-citation publication-type="journal" id="cei13517-cit-0081"><string-name name-style="western"><surname>Alharbi</surname><given-names>NK</given-names></string-name>, <string-name name-style="western"><surname>Qasim</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Almasoud</surname><given-names>A</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Humoral immunogenicity and efficacy of a single dose of ChAdOx1 MERS vaccine candidate in dromedary camels</article-title>. <source xml:lang="en">Sci Rep</source><year>2019</year>; <volume>9</volume>:<fpage>1</fpage>&#8211;<lpage>11</lpage>.<pub-id pub-id-type="pmid">31705137</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-019-52730-4</pub-id><pub-id pub-id-type="pmcid">PMC6841732</pub-id></mixed-citation></ref><ref id="cei13517-bib-0082"><label>82</label><mixed-citation publication-type="journal" id="cei13517-cit-0082"><string-name name-style="western"><surname>Bao</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Deng</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>B</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>The pathogenicity of SARS&#8208;CoV&#8208;2 in hACE2 transgenic mice</article-title>. <source xml:lang="en">Nature</source><year>2020</year>; <volume>583</volume>:<fpage>830</fpage>&#8211;<lpage>3</lpage>.<pub-id pub-id-type="pmid">32380511</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-020-2312-y</pub-id></mixed-citation></ref><ref id="cei13517-bib-0083"><label>83</label><mixed-citation publication-type="journal" id="cei13517-cit-0083"><string-name name-style="western"><surname>Oreshkova</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Molenaar</surname><given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Vreman</surname><given-names>S</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>SARS&#8208;CoV&#8208;2 infection in farmed minks, the Netherlands, April and May 2020</article-title>. <source xml:lang="en">Eurosurveillance</source><year>2020</year>; <volume>25</volume>:<fpage>2001005</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.2807/1560-7917.ES.2020.25.23.2001005</pub-id><pub-id pub-id-type="pmcid">PMC7403642</pub-id><pub-id pub-id-type="pmid">32553059</pub-id></mixed-citation></ref><ref id="cei13517-bib-0084"><label>84</label><mixed-citation publication-type="journal" id="cei13517-cit-0084"><string-name name-style="western"><surname>Shi</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wen</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Zhong</surname><given-names>G</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS&#8211;coronavirus 2</article-title>. <source xml:lang="en">Science</source><year>2020</year>; <volume>368</volume>:<fpage>1016</fpage>&#8211;<lpage>20</lpage>.<pub-id pub-id-type="pmid">32269068</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abb7015</pub-id><pub-id pub-id-type="pmcid">PMC7164390</pub-id></mixed-citation></ref><ref id="cei13517-bib-0085"><label>85</label><mixed-citation publication-type="journal" id="cei13517-cit-0085"><string-name name-style="western"><surname>Bao</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Deng</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>H</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Reinfection could not occur in SARS&#8208;CoV&#8208;2 infected rhesus macaques</article-title>. <source xml:lang="en">BioRxiv</source><year>2020</year>. <pub-id pub-id-type="doi">10.1101/2020.03.13.990226</pub-id></mixed-citation></ref><ref id="cei13517-bib-0086"><label>86</label><mixed-citation publication-type="journal" id="cei13517-cit-0086"><string-name name-style="western"><surname>Richards</surname><given-names>AD</given-names></string-name>. <article-title>Ethical guidelines for deliberately infecting volunteers with COVID&#8208;19</article-title>. <source xml:lang="en">J Med Ethics</source><year>2020</year>; <volume>46</volume>:<fpage>502</fpage>&#8211;<lpage>4</lpage>.<pub-id pub-id-type="pmid">32461245</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/medethics-2020-106322</pub-id><pub-id pub-id-type="pmcid">PMC7316118</pub-id></mixed-citation></ref><ref id="cei13517-bib-0087"><label>87</label><mixed-citation publication-type="journal" id="cei13517-cit-0087"><string-name name-style="western"><surname>Eyal</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Lipsitch</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname><given-names>PG</given-names></string-name>. <article-title>Human challenge studies to accelerate coronavirus vaccine licensure</article-title>. <source xml:lang="en">J Infect Dis</source><year>2020</year>; <volume>221</volume>:<fpage>1752</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="pmid">32232474</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/infdis/jiaa152</pub-id><pub-id pub-id-type="pmcid">PMC7184325</pub-id></mixed-citation></ref><ref id="cei13517-bib-0088"><label>88</label><mixed-citation publication-type="journal" id="cei13517-cit-0088"><string-name name-style="western"><surname>Baay</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Neels</surname><given-names>P</given-names></string-name>. <article-title>SARS&#8208;CoV&#8208;2 controlled human infection models: ethics, challenge agent production and regulatory issues</article-title>. <source xml:lang="en">Biologicals</source><year>2020</year>. <pub-id pub-id-type="doi">10.1016/j.biologicals.2020.08.006</pub-id><pub-id pub-id-type="pmcid">PMC7428779</pub-id><pub-id pub-id-type="pmid">32829985</pub-id></mixed-citation></ref><ref id="cei13517-bib-0089"><label>89</label><mixed-citation publication-type="journal" id="cei13517-cit-0089"><string-name name-style="western"><surname>Horby</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Lim</surname><given-names>WS</given-names></string-name>, <string-name name-style="western"><surname>Emberson</surname><given-names>J</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Effect of dexamethasone in hospitalized patients with COVID&#8208;19. Preliminary report</article-title>. <source xml:lang="en">medRxiv</source><year>2020</year>:2020.06.22.20137273.</mixed-citation></ref><ref id="cei13517-bib-0090"><label>90</label><mixed-citation publication-type="journal" id="cei13517-cit-0090"><string-name name-style="western"><surname>Spinner</surname><given-names>CD</given-names></string-name>, <string-name name-style="western"><surname>Gottlieb</surname><given-names>RL</given-names></string-name>, <string-name name-style="western"><surname>Criner</surname><given-names>GJ</given-names></string-name><italic toggle="yes">et al</italic>, <collab collab-type="authors">for the GSUSI</collab>
. <article-title>Effect of Remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID&#8208;19: a randomized clinical trial</article-title>. <source xml:lang="en">JAMA</source><year>2020</year>; <volume>324</volume>:<fpage>1048</fpage>&#8211;<lpage>57</lpage>.<pub-id pub-id-type="pmid">32821939</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2020.16349</pub-id><pub-id pub-id-type="pmcid">PMC7442954</pub-id></mixed-citation></ref><ref id="cei13517-bib-0091"><label>91</label><mixed-citation publication-type="miscellaneous" id="cei13517-cit-0091"><collab collab-type="authors">World Health Organization</collab>
. <article-title>Key criteria for the ethical acceptability of COVID&#8208;19 human challenge studies</article-title>. <year>2020</year>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/ethics/publications/key-criteria-ethical-acceptability-of-covid-19-human-challenge/en/">https://www.who.int/ethics/publications/key&#8208;criteria&#8208;ethical&#8208;acceptability&#8208;of&#8208;covid&#8208;19&#8208;human&#8208;challenge/en/</ext-link> (accessed September 2020).</mixed-citation></ref><ref id="cei13517-bib-0092"><label>92</label><mixed-citation publication-type="journal" id="cei13517-cit-0092"><string-name name-style="western"><surname>Deming</surname><given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Michael</surname><given-names>NL</given-names></string-name>, <string-name name-style="western"><surname>Robb</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Cohen</surname><given-names>MS</given-names></string-name>, <string-name name-style="western"><surname>Neuzil</surname><given-names>KM</given-names></string-name>. <article-title>Accelerating development of SARS&#8208;CoV&#8208;2 vaccines&#160;&#8211;&#160;the role for controlled human infection models</article-title>. <source xml:lang="en">N Engl J Med</source><year>2020</year>; <volume>383</volume>:<fpage>e63</fpage>. <pub-id pub-id-type="doi">10.1056/NEJMp2020076</pub-id><pub-id pub-id-type="pmid">32610006</pub-id><pub-id pub-id-type="pmcid">PMC7968616</pub-id></mixed-citation></ref><ref id="cei13517-bib-0093"><label>93</label><mixed-citation publication-type="journal" id="cei13517-cit-0093"><string-name name-style="western"><surname>Mallory</surname><given-names>ML</given-names></string-name>, <string-name name-style="western"><surname>Lindesmith</surname><given-names>LC</given-names></string-name>, <string-name name-style="western"><surname>Baric</surname><given-names>RS</given-names></string-name>. <article-title>Vaccination&#8208;induced herd immunity: successes and challenges</article-title>. <source xml:lang="en">J Allergy Clin Immunol</source><year>2018</year>; <volume>142</volume>:<fpage>64</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="pmid">29803799</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaci.2018.05.007</pub-id><pub-id pub-id-type="pmcid">PMC6433118</pub-id></mixed-citation></ref><ref id="cei13517-bib-0094"><label>94</label><mixed-citation publication-type="journal" id="cei13517-cit-0094"><string-name name-style="western"><surname>Scarbrough Lefebvre</surname><given-names>CD</given-names></string-name>, <string-name name-style="western"><surname>Terlinden</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Standaert</surname><given-names>B</given-names></string-name>. <article-title>Dissecting the indirect effects caused by vaccines into the basic elements</article-title>. <source xml:lang="en">Hum Vaccin Immunother</source><year>2015</year>; <volume>11</volume>:<fpage>2142</fpage>&#8211;<lpage>57</lpage>.<pub-id pub-id-type="pmid">26186100</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/21645515.2015.1052196</pub-id><pub-id pub-id-type="pmcid">PMC4635729</pub-id></mixed-citation></ref><ref id="cei13517-bib-0095"><label>95</label><mixed-citation publication-type="journal" id="cei13517-cit-0095"><string-name name-style="western"><surname>Zheng</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Song</surname><given-names>L</given-names></string-name>. <article-title>Novel antibody epitopes dominate the antigenicity of spike glycoprotein in SARS&#8208;CoV&#8208;2 compared to SARS&#8208;CoV</article-title>. <source xml:lang="en">Cell Mol Immunol</source><year>2020</year>; <volume>17</volume>:<fpage>536</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">32132669</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41423-020-0385-z</pub-id><pub-id pub-id-type="pmcid">PMC7091851</pub-id></mixed-citation></ref><ref id="cei13517-bib-0096"><label>96</label><mixed-citation publication-type="journal" id="cei13517-cit-0096"><string-name name-style="western"><surname>Tortorici</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Walls</surname><given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>Lang</surname><given-names>Y</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Structural basis for human coronavirus attachment to sialic acid receptors</article-title>. <source xml:lang="en">Nat Struct Mol Biol</source><year>2019</year>; <volume>26</volume>:<fpage>481</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">31160783</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41594-019-0233-y</pub-id><pub-id pub-id-type="pmcid">PMC6554059</pub-id></mixed-citation></ref><ref id="cei13517-bib-0097"><label>97</label><mixed-citation publication-type="journal" id="cei13517-cit-0097"><string-name name-style="western"><surname>Li</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Giorgi</surname><given-names>EE</given-names></string-name>, <string-name name-style="western"><surname>Marichannegowda</surname><given-names>MH</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Emergence of SARS&#8208;CoV&#8208;2 through recombination and strong purifying selection</article-title>. <source xml:lang="en">Sci Adv</source><year>2020</year>:<elocation-id>eabb9153</elocation-id>.<pub-id pub-id-type="pmid">32937441</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/sciadv.abb9153</pub-id><pub-id pub-id-type="pmcid">PMC7458444</pub-id></mixed-citation></ref><ref id="cei13517-bib-0098"><label>98</label><mixed-citation publication-type="journal" id="cei13517-cit-0098"><string-name name-style="western"><surname>McLellan</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Leung</surname><given-names>S</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Structure of RSV fusion glycoprotein trimer bound to a prefusion&#8208;specific neutralizing antibody</article-title>. <source xml:lang="en">Science</source><year>2013</year>; <volume>340</volume>:<fpage>1113</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">23618766</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.1234914</pub-id><pub-id pub-id-type="pmcid">PMC4459498</pub-id></mixed-citation></ref><ref id="cei13517-bib-0099"><label>99</label><mixed-citation publication-type="journal" id="cei13517-cit-0099"><string-name name-style="western"><surname>Ngwuta</surname><given-names>JO</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Modjarrad</surname><given-names>K</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Prefusion F&#8208;specific antibodies determine the magnitude of RSV neutralizing activity in human sera</article-title>. <source xml:lang="en">Sci Transl Med</source><year>2015</year>; <volume>7</volume>:<elocation-id>309ra162</elocation-id>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scitranslmed.aac4241</pub-id><pub-id pub-id-type="pmcid">PMC4672383</pub-id><pub-id pub-id-type="pmid">26468324</pub-id></mixed-citation></ref><ref id="cei13517-bib-0100"><label>100</label><mixed-citation publication-type="journal" id="cei13517-cit-0100"><string-name name-style="western"><surname>Liu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Liang</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>X</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Human parainfluenza virus type 3 expressing the respiratory syncytial virus pre&#8208;fusion F protein modified for virion packaging yields protective intranasal vaccine candidates</article-title>. <source xml:lang="en">PLOS ONE</source><year>2020</year>; <volume>15</volume>:<elocation-id>e0228572</elocation-id>.<pub-id pub-id-type="pmid">32045432</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0228572</pub-id><pub-id pub-id-type="pmcid">PMC7012412</pub-id></mixed-citation></ref><ref id="cei13517-bib-0101"><label>101</label><mixed-citation publication-type="journal" id="cei13517-cit-0101"><string-name name-style="western"><surname>Stewart&#8208;Jones</surname><given-names>GB</given-names></string-name>, <string-name name-style="western"><surname>Thomas</surname><given-names>PV</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>M</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>A cysteine zipper stabilizes a pre&#8208;fusion F glycoprotein vaccine for respiratory syncytial virus</article-title>. <source xml:lang="en">PLOS ONE</source><year>2015</year>; <volume>10</volume>:<elocation-id>e0128779</elocation-id>.<pub-id pub-id-type="pmid">26098893</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0128779</pub-id><pub-id pub-id-type="pmcid">PMC4476739</pub-id></mixed-citation></ref><ref id="cei13517-bib-0102"><label>102</label><mixed-citation publication-type="journal" id="cei13517-cit-0102"><string-name name-style="western"><surname>Berry</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Jones</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Drebot</surname><given-names>MA</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Development and characterisation of neutralising monoclonal antibody to the SARS&#8208;coronavirus</article-title>. <source xml:lang="en">J Virol Methods</source><year>2004</year>; <volume>120</volume>:<fpage>87</fpage>&#8211;<lpage>96</lpage>.<pub-id pub-id-type="pmid">15234813</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jviromet.2004.04.009</pub-id><pub-id pub-id-type="pmcid">PMC7119589</pub-id></mixed-citation></ref><ref id="cei13517-bib-0103"><label>103</label><mixed-citation publication-type="journal" id="cei13517-cit-0103"><string-name name-style="western"><surname>McKay</surname><given-names>PF</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Blakney</surname><given-names>AK</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Self&#8208;amplifying RNA SARS&#8208;CoV&#8208;2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice</article-title>. <source xml:lang="en">Nat Commun</source><year>2020</year>; <volume>11</volume>:<fpage>3523</fpage>.<pub-id pub-id-type="pmid">32647131</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-020-17409-9</pub-id><pub-id pub-id-type="pmcid">PMC7347890</pub-id></mixed-citation></ref><ref id="cei13517-bib-0104"><label>104</label><mixed-citation publication-type="journal" id="cei13517-cit-0104"><string-name name-style="western"><surname>Wang</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Q</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Interactions of SARS coronavirus nucleocapsid protein with the host cell proteasome subunit p42</article-title>. <source xml:lang="en">Virol J</source><year>2010</year>; <volume>7</volume>:<fpage>99</fpage>.<pub-id pub-id-type="pmid">20478047</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1743-422X-7-99</pub-id><pub-id pub-id-type="pmcid">PMC2894783</pub-id></mixed-citation></ref><ref id="cei13517-bib-0105"><label>105</label><mixed-citation publication-type="journal" id="cei13517-cit-0105"><string-name name-style="western"><surname>Channappanavar</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Perlman</surname><given-names>S</given-names></string-name>. <article-title>T cell&#8208;mediated immune response to respiratory coronaviruses</article-title>. <source xml:lang="en">Immunol Res</source><year>2014</year>; <volume>59</volume>:<fpage>118</fpage>&#8211;<lpage>28</lpage>.<pub-id pub-id-type="pmid">24845462</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12026-014-8534-z</pub-id><pub-id pub-id-type="pmcid">PMC4125530</pub-id></mixed-citation></ref><ref id="cei13517-bib-0106"><label>106</label><mixed-citation publication-type="journal" id="cei13517-cit-0106"><string-name name-style="western"><surname>Yasui</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Kai</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Kitabatake</surname><given-names>M</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Prior immunization with severe acute respiratory syndrome (SARS)&#8208;associated coronavirus (SARS&#8208;CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS&#8208;CoV</article-title>. <source xml:lang="en">J Immunol</source><year>2008</year>; <volume>181</volume>:<fpage>6337</fpage>&#8211;<lpage>48</lpage>.<pub-id pub-id-type="pmid">18941225</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.181.9.6337</pub-id></mixed-citation></ref><ref id="cei13517-bib-0107"><label>107</label><mixed-citation publication-type="journal" id="cei13517-cit-0107"><string-name name-style="western"><surname>Gilbert</surname><given-names>SC</given-names></string-name>. <article-title>Influenza vaccines and immunopathology</article-title>. <source xml:lang="en">Expert Rev Vaccin</source><year>2012</year>; <volume>11</volume>:<fpage>873</fpage>&#8211;<lpage>5</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1586/erv.12.65</pub-id><pub-id pub-id-type="pmid">23002965</pub-id></mixed-citation></ref><ref id="cei13517-bib-0108"><label>108</label><mixed-citation publication-type="journal" id="cei13517-cit-0108"><string-name name-style="western"><surname>Kiyotani</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Toyoshima</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Nemoto</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Nakamura</surname><given-names>Y</given-names></string-name>. <article-title>Bioinformatic prediction of potential T cell epitopes for SARS&#8208;Cov&#8208;2</article-title>. <source xml:lang="en">J Hum Genet</source><year>2020</year>; <volume>65</volume>:<fpage>569</fpage>&#8211;<lpage>75</lpage>.<pub-id pub-id-type="pmid">32372051</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s10038-020-0771-5</pub-id><pub-id pub-id-type="pmcid">PMC7200206</pub-id></mixed-citation></ref><ref id="cei13517-bib-0109"><label>109</label><mixed-citation publication-type="miscellaneous" id="cei13517-cit-0109"><collab collab-type="authors">World Health Organization</collab>
. <article-title>DRAFT landscape of COVID&#8208;19 candidate vaccines</article-title>. <year>2020</year>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines">https://www.who.int/publications/m/item/draft&#8208;landscape&#8208;of&#8208;covid&#8208;19&#8208;candidate&#8208;vaccines</ext-link></mixed-citation></ref><ref id="cei13517-bib-0110"><label>110</label><mixed-citation publication-type="journal" id="cei13517-cit-0110"><string-name name-style="western"><surname>Wang</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>. <article-title>Recent advances in the production of recombinant subunit vaccines in Pichia pastoris</article-title>. <source xml:lang="en">Bioengineered</source><year>2016</year>; <volume>7</volume>:<fpage>155</fpage>&#8211;<lpage>65</lpage>.<pub-id pub-id-type="pmid">27246656</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/21655979.2016.1191707</pub-id><pub-id pub-id-type="pmcid">PMC4927204</pub-id></mixed-citation></ref><ref id="cei13517-bib-0111"><label>111</label><mixed-citation publication-type="journal" id="cei13517-cit-0111"><string-name name-style="western"><surname>Nascimento</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Leite</surname><given-names>L</given-names></string-name>. <article-title>Recombinant vaccines and the development of new vaccine strategies</article-title>. <source xml:lang="en">Braz J Med Biol Res</source><year>2012</year>; <volume>45</volume>:<fpage>1102</fpage>&#8211;<lpage>11</lpage>.<pub-id pub-id-type="pmid">22948379</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1590/S0100-879X2012007500142</pub-id><pub-id pub-id-type="pmcid">PMC3854212</pub-id></mixed-citation></ref><ref id="cei13517-bib-0112"><label>112</label><mixed-citation publication-type="journal" id="cei13517-cit-0112"><string-name name-style="western"><surname>Magistrelli</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Poitevin</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Schlosser</surname><given-names>F</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Optimizing assembly and production of native bispecific antibodies by codon de&#8208;optimization</article-title>. <source xml:lang="en">MAbs</source><year>2017</year>; <volume>9</volume>:<fpage>231</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">28001485</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/19420862.2016.1267088</pub-id><pub-id pub-id-type="pmcid">PMC5297534</pub-id></mixed-citation></ref><ref id="cei13517-bib-0113"><label>113</label><mixed-citation publication-type="journal" id="cei13517-cit-0113"><string-name name-style="western"><surname>Tang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Tao</surname><given-names>X</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Optimization of antigen dose for a receptor&#8208;binding domain&#8208;based subunit vaccine against MERS coronavirus</article-title>. <source xml:lang="en">Hum Vaccin Immunother</source><year>2015</year>; <volume>11</volume>:<fpage>1244</fpage>&#8211;<lpage>50</lpage>.<pub-id pub-id-type="pmid">25874632</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/21645515.2015.1021527</pub-id><pub-id pub-id-type="pmcid">PMC4514392</pub-id></mixed-citation></ref><ref id="cei13517-bib-0114"><label>114</label><mixed-citation publication-type="journal" id="cei13517-cit-0114"><string-name name-style="western"><surname>Mou</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Raj</surname><given-names>VS</given-names></string-name>, <string-name name-style="western"><surname>van Kuppeveld</surname><given-names>FJ</given-names></string-name>, <string-name name-style="western"><surname>Rottier</surname><given-names>PJ</given-names></string-name>, <string-name name-style="western"><surname>Haagmans</surname><given-names>BL</given-names></string-name>, <string-name name-style="western"><surname>Bosch</surname><given-names>BJ</given-names></string-name>. <article-title>The receptor binding domain of the new Middle East respiratory syndrome coronavirus maps to a 231&#8208;residue region in the spike protein that efficiently elicits neutralizing antibodies</article-title>. <source xml:lang="en">J Virol</source><year>2013</year>; <volume>87</volume>:<fpage>9379</fpage>&#8211;<lpage>83</lpage>.<pub-id pub-id-type="pmid">23785207</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.01277-13</pub-id><pub-id pub-id-type="pmcid">PMC3754068</pub-id></mixed-citation></ref><ref id="cei13517-bib-0115"><label>115</label><mixed-citation publication-type="journal" id="cei13517-cit-0115"><string-name name-style="western"><surname>Ma</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Tao</surname><given-names>X</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Searching for an ideal vaccine candidate among different MERS coronavirus receptor&#8208;binding fragments&#8212;the importance of immunofocusing in subunit vaccine design</article-title>. <source xml:lang="en">Vaccine</source><year>2014</year>; <volume>32</volume>:<fpage>6170</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="pmid">25240756</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2014.08.086</pub-id><pub-id pub-id-type="pmcid">PMC4194190</pub-id></mixed-citation></ref><ref id="cei13517-bib-0116"><label>116</label><mixed-citation publication-type="journal" id="cei13517-cit-0116"><string-name name-style="western"><surname>Keng</surname><given-names>C&#8208;T</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Shen</surname><given-names>S</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Amino acids 1055 to 1192 in the S2 region of severe acute respiratory syndrome coronavirus S protein induce neutralizing antibodies: implications for the development of vaccines and antiviral agents</article-title>. <source xml:lang="en">J Virol</source><year>2005</year>; <volume>79</volume>:<fpage>3289</fpage>&#8211;<lpage>96</lpage>.<pub-id pub-id-type="pmid">15731223</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.79.6.3289-3296.2005</pub-id><pub-id pub-id-type="pmcid">PMC1075733</pub-id></mixed-citation></ref><ref id="cei13517-bib-0117"><label>117</label><mixed-citation publication-type="journal" id="cei13517-cit-0117"><string-name name-style="western"><surname>Pogrebnyak</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Golovkin</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Andrianov</surname><given-names>V</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Severe acute respiratory syndrome (SARS) S protein production in plants: development of recombinant vaccine</article-title>. <source xml:lang="en">Proc Natl Acad Sci USA</source><year>2005</year>; <volume>102</volume>:<fpage>9062</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">15956182</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0503760102</pub-id><pub-id pub-id-type="pmcid">PMC1157057</pub-id></mixed-citation></ref><ref id="cei13517-bib-0118"><label>118</label><mixed-citation publication-type="journal" id="cei13517-cit-0118"><string-name name-style="western"><surname>He</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Siddiqui</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>S</given-names></string-name>. <article-title>Receptor&#8208;binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation&#8208;dependent epitopes that induce highly potent neutralizing antibodies</article-title>. <source xml:lang="en">J Immunol</source><year>2005</year>; <volume>174</volume>:<fpage>4908</fpage>&#8211;<lpage>15</lpage>.<pub-id pub-id-type="pmid">15814718</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.174.8.4908</pub-id></mixed-citation></ref><ref id="cei13517-bib-0119"><label>119</label><mixed-citation publication-type="journal" id="cei13517-cit-0119"><string-name name-style="western"><surname>Ma</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>L</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Intranasal vaccination with recombinant receptor&#8208;binding domain of MERS&#8208;CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines</article-title>. <source xml:lang="en">Vaccine</source><year>2014</year>; <volume>32</volume>:<fpage>2100</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">24560617</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2014.02.004</pub-id><pub-id pub-id-type="pmcid">PMC4194189</pub-id></mixed-citation></ref><ref id="cei13517-bib-0120"><label>120</label><mixed-citation publication-type="miscellaneous" id="cei13517-cit-0120"><collab collab-type="authors">PipelineReview</collab>
. <article-title>Clover Initiates Development of Recombinant Subunit&#8208;Trimer Vaccine for Wuhan Coronavirus (2019&#8208;nCoV)</article-title>. <year>2020</year>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pipelinereview.com/index.php/2020012873644/Vaccines/Clover-Initiates-Development-of-Recombinant-Subunit-Trimer-Vaccine-for-Wuhan-Coronavirus-2019-nCoV.html">https://pipelinereview.com/index.php/2020012873644/Vaccines/Clover&#8208;Initiates&#8208;Development&#8208;of&#8208;Recombinant&#8208;Subunit&#8208;Trimer&#8208;Vaccine&#8208;for&#8208;Wuhan&#8208;Coronavirus&#8208;2019&#8208;nCoV.html</ext-link> (accessed September 2020).</mixed-citation></ref><ref id="cei13517-bib-0121"><label>121</label><mixed-citation publication-type="book" id="cei13517-cit-0121"><collab collab-type="authors">PipelineReview</collab>
. <source xml:lang="en">Clover successfully produced 2019&#8208;nCoV subunit vaccine candidate and detected cross&#8208;reacting antibodies from sera of multiple infected patients</source>. <year>2020</year>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pipelinereview.com/index.php/2020021073754/Vaccines/Clover-Successfully-Produced-2019-nCoV-Subunit-Vaccine-Candidate-and-Detected-Cross-Reacting-Antibodies-from-Sera-of-Multiple-Infected-Patients.html">https://pipelinereview.com/index.php/2020021073754/Vaccines/Clover&#8208;Successfully&#8208;Produced&#8208;2019&#8208;nCoV&#8208;Subunit&#8208;Vaccine&#8208;Candidate&#8208;and&#8208;Detected&#8208;Cross&#8208;Reacting&#8208;Antibodies&#8208;from&#8208;Sera&#8208;of&#8208;Multiple&#8208;Infected&#8208;Patients.html</ext-link> (accessed September 2020)</mixed-citation></ref><ref id="cei13517-bib-0122"><label>122</label><mixed-citation publication-type="miscellaneous" id="cei13517-cit-0122"><string-name name-style="western"><surname>Hodgson</surname><given-names>J</given-names></string-name>. <article-title>The pandemic pipeline</article-title>. Nat Biotechnol News <year>2020</year>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.nature.com/articles/d41587-020-00005-z">https://www.nature.com/articles/d41587&#8208;020&#8208;00005&#8208;z</ext-link> (accessed September 2020).</mixed-citation></ref><ref id="cei13517-bib-0123"><label>123</label><mixed-citation publication-type="miscellaneous" id="cei13517-cit-0123"><collab collab-type="authors">GSK</collab>
. <article-title>Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID&#8208;19</article-title>. <year>2020</year>. Press release <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.gsk.com/en-gb/media/press-releases/sanofi-and-gsk-to-join-forces-in-unprecedented-vaccine-collaboration-to-fight-covid-19/">https://www.gsk.com/en&#8208;gb/media/press&#8208;releases/sanofi&#8208;and&#8208;gsk&#8208;to&#8208;join&#8208;forces&#8208;in&#8208;unprecedented&#8208;vaccine&#8208;collaboration&#8208;to&#8208;fight&#8208;covid&#8208;19/</ext-link> (accessed September 2020).</mixed-citation></ref><ref id="cei13517-bib-0124"><label>124</label><mixed-citation publication-type="journal" id="cei13517-cit-0124"><string-name name-style="western"><surname>Syomin</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Ilyin</surname><given-names>Y</given-names></string-name>. <article-title>Virus&#8208;like particles as an instrument of vaccine production</article-title>. <source xml:lang="en">Mol Biol</source><year>2019</year>; <volume>53</volume>:<fpage>323</fpage>&#8211;<lpage>34</lpage>.<pub-id pub-id-type="pmid">32214478</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1134/S0026893319030154</pub-id><pub-id pub-id-type="pmcid">PMC7088979</pub-id></mixed-citation></ref><ref id="cei13517-bib-0125"><label>125</label><mixed-citation publication-type="journal" id="cei13517-cit-0125"><string-name name-style="western"><surname>Ho</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>P&#8208;H</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>CY</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>S&#8208;P</given-names></string-name>, <string-name name-style="western"><surname>Chao</surname><given-names>Y&#8208;C</given-names></string-name>. <article-title>Assembly of human severe acute respiratory syndrome coronavirus&#8208;like particles</article-title>. <source xml:lang="en">Biochem Biophys Res Comm</source><year>2004</year>; <volume>318</volume>:<fpage>833</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">15147946</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbrc.2004.04.111</pub-id><pub-id pub-id-type="pmcid">PMC7111196</pub-id></mixed-citation></ref><ref id="cei13517-bib-0126"><label>126</label><mixed-citation publication-type="book" id="cei13517-cit-0126"><collab collab-type="authors">Novavax</collab>
. <source xml:lang="en">Novavax Awarded Funding from CEPI for COVID&#8208;19 Vaccine Development</source>. <year>2020</year>. Press release <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://ir.novavax.com/news-releases/news-release-details/novavax-awarded-funding-cepi-covid-19-vaccine-development">https://ir.novavax.com/news&#8208;releases/news&#8208;release&#8208;details/novavax&#8208;awarded&#8208;funding&#8208;cepi&#8208;covid&#8208;19&#8208;vaccine&#8208;development</ext-link> (accessed September 2020).</mixed-citation></ref><ref id="cei13517-bib-0127"><label>127</label><mixed-citation publication-type="book" id="cei13517-cit-0127"><collab collab-type="authors">Novavax</collab>
. <source xml:lang="en">Novavax Recombinant Protein Nanoparticle Vaccine Technology</source>. <year>2020</year>. Press release <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://novavax.com/our-unique-technology">https://novavax.com/our&#8208;unique&#8208;technology</ext-link> (accessed September 2020).</mixed-citation></ref><ref id="cei13517-bib-0128"><label>128</label><mixed-citation publication-type="journal" id="cei13517-cit-0128"><string-name name-style="western"><surname>Keech</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Albert</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Cho</surname><given-names>I</given-names></string-name>, <italic toggle="yes">et al</italic>. <article-title>Phase 1&#8211;2 trial of a SARS&#8208;CoV&#8208;2 recombinant spike protein nanoparticle vaccine</article-title>. <source xml:lang="en">NEJM</source>. <year>2020</year>. <pub-id pub-id-type="doi">10.1056/NEJMoa2026920</pub-id><pub-id pub-id-type="pmcid">PMC7494251</pub-id><pub-id pub-id-type="pmid">32877576</pub-id></mixed-citation></ref><ref id="cei13517-bib-0129"><label>129</label><mixed-citation publication-type="journal" id="cei13517-cit-0129"><string-name name-style="western"><surname>Tian</surname><given-names>J&#8208;H</given-names></string-name>, <string-name name-style="western"><surname>Patel</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Haupt</surname><given-names>R</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>SARS&#8208;CoV&#8208;2 spike glycoprotein vaccine candidate NVX&#8208;CoV2373 elicits immunogenicity in baboons and protection in mice</article-title>. <source xml:lang="en">bioRxiv</source><year>2020</year>:2020.06.29.178509.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-020-20653-8</pub-id><pub-id pub-id-type="pmcid">PMC7809486</pub-id><pub-id pub-id-type="pmid">33446655</pub-id></mixed-citation></ref><ref id="cei13517-bib-0130"><label>130</label><mixed-citation publication-type="book" id="cei13517-cit-0130"><collab collab-type="authors">Medicago</collab>
. <source xml:lang="en">COVID&#8208;19: Medicago&#8217;s Development Programs. 2020 Medicago</source>. <year>2020</year>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.medicago.com/en/newsroom/medicago-begins-phase-i-clinical-trials-for-its-covid-19-vaccine-candidate/">https://www.medicago.com/en/newsroom/medicago&#8208;begins&#8208;phase&#8208;i&#8208;clinical&#8208;trials&#8208;for&#8208;its&#8208;covid&#8208;19&#8208;vaccine&#8208;candidate/</ext-link> (accessed September 2020).</mixed-citation></ref><ref id="cei13517-bib-0131"><label>131</label><mixed-citation publication-type="journal" id="cei13517-cit-0131"><string-name name-style="western"><surname>Zha</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Mohsen</surname><given-names>MO</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Development of a COVID&#8208;19 vaccine based on the receptor binding domain displayed on virus&#8208;like particles</article-title>. <source xml:lang="en">bioRxiv</source><year>2020</year>. <pub-id pub-id-type="doi">10.1101/2020.05.06.079830</pub-id><pub-id pub-id-type="pmcid">PMC8073353</pub-id><pub-id pub-id-type="pmid">33923573</pub-id></mixed-citation></ref><ref id="cei13517-bib-0132"><label>132</label><mixed-citation publication-type="journal" id="cei13517-cit-0132"><string-name name-style="western"><surname>Sesardic</surname><given-names>D</given-names></string-name>. <article-title>Synthetic peptide vaccines</article-title>. <source xml:lang="en">J Med Microbiol</source><year>1993</year>; <volume>39</volume>:<fpage>241</fpage>&#8211;<lpage>2</lpage>.<pub-id pub-id-type="pmid">7692052</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1099/00222615-39-4-241</pub-id></mixed-citation></ref><ref id="cei13517-bib-0133"><label>133</label><mixed-citation publication-type="journal" id="cei13517-cit-0133"><string-name name-style="western"><surname>Bijker</surname><given-names>MS</given-names></string-name>, <string-name name-style="western"><surname>Melief</surname><given-names>CJ</given-names></string-name>, <string-name name-style="western"><surname>Offringa</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Van Der Burg</surname><given-names>SH</given-names></string-name>. <article-title>Design and development of synthetic peptide vaccines: past, present and future</article-title>. <source xml:lang="en">Expert Rev Vaccin</source><year>2007</year>; <volume>6</volume>:<fpage>591</fpage>&#8211;<lpage>603</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1586/14760584.6.4.591</pub-id><pub-id pub-id-type="pmid">17669012</pub-id></mixed-citation></ref><ref id="cei13517-bib-0134"><label>134</label><mixed-citation publication-type="journal" id="cei13517-cit-0134"><string-name name-style="western"><surname>Zhang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Hong</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>D</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Comparing pooled peptides with intact protein for accessing cross&#8208;presentation pathways for protective CD8+ and CD4+ T cells</article-title>. <source xml:lang="en">J Biol Chem</source><year>2009</year>; <volume>284</volume>:<fpage>9184</fpage>&#8211;<lpage>91</lpage>.<pub-id pub-id-type="pmid">19193636</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M809456200</pub-id><pub-id pub-id-type="pmcid">PMC2666570</pub-id></mixed-citation></ref><ref id="cei13517-bib-0135"><label>135</label><mixed-citation publication-type="journal" id="cei13517-cit-0135"><string-name name-style="western"><surname>Rosalia</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Quakkelaar</surname><given-names>ED</given-names></string-name>, <string-name name-style="western"><surname>Redeker</surname><given-names>A</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T&#8208;cell activation</article-title>. <source xml:lang="en">Eur J Immunol</source><year>2013</year>; <volume>43</volume>:<fpage>2554</fpage>&#8211;<lpage>65</lpage>.<pub-id pub-id-type="pmid">23836147</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/eji.201343324</pub-id></mixed-citation></ref><ref id="cei13517-bib-0136"><label>136</label><mixed-citation publication-type="journal" id="cei13517-cit-0136"><string-name name-style="western"><surname>Purcell</surname><given-names>AW</given-names></string-name>, <string-name name-style="western"><surname>McCluskey</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Rossjohn</surname><given-names>J</given-names></string-name>. <article-title>More than one reason to rethink the use of peptides in vaccine design</article-title>. <source xml:lang="en">Nat Rev Drug Discov</source><year>2007</year>; <volume>6</volume>:<fpage>404</fpage>&#8211;<lpage>14</lpage>.<pub-id pub-id-type="pmid">17473845</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrd2224</pub-id></mixed-citation></ref><ref id="cei13517-bib-0137"><label>137</label><mixed-citation publication-type="journal" id="cei13517-cit-0137"><string-name name-style="western"><surname>Li</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Joshi</surname><given-names>MD</given-names></string-name>, <string-name name-style="western"><surname>Singhania</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ramsey</surname><given-names>KH</given-names></string-name>, <string-name name-style="western"><surname>Murthy</surname><given-names>AK</given-names></string-name>. <article-title>Peptide vaccine: progress and challenges</article-title>. <source xml:lang="en">Vaccines</source><year>2014</year>; <volume>2</volume>:<fpage>515</fpage>&#8211;<lpage>36</lpage>.<pub-id pub-id-type="pmid">26344743</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines2030515</pub-id><pub-id pub-id-type="pmcid">PMC4494216</pub-id></mixed-citation></ref><ref id="cei13517-bib-0138"><label>138</label><mixed-citation publication-type="journal" id="cei13517-cit-0138"><string-name name-style="western"><surname>Ahmed</surname><given-names>SF</given-names></string-name>, <string-name name-style="western"><surname>Quadeer</surname><given-names>AA</given-names></string-name>, <string-name name-style="western"><surname>McKay</surname><given-names>MR</given-names></string-name>. <article-title>Preliminary identification of potential vaccine targets for the COVID&#8208;19 coronavirus (SARS&#8208;CoV&#8208;2) based on SARS&#8208;CoV immunological studies</article-title>. <source xml:lang="en">Viruses</source><year>2020</year>; <volume>12</volume>:<fpage>254</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/v12030254</pub-id><pub-id pub-id-type="pmcid">PMC7150947</pub-id><pub-id pub-id-type="pmid">32106567</pub-id></mixed-citation></ref><ref id="cei13517-bib-0139"><label>139</label><mixed-citation publication-type="journal" id="cei13517-cit-0139"><string-name name-style="western"><surname>Bhattacharya</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Sharma</surname><given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>Patra</surname><given-names>P</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Development of epitope&#8208;based peptide vaccine against novel coronavirus 2019 (SARS&#8208;COV&#8208;2): immunoinformatics approach</article-title>. <source xml:lang="en">J Med Virol</source><year>2020</year>; <volume>92</volume>:<fpage>618</fpage>&#8211;<lpage>31</lpage>.<pub-id pub-id-type="pmid">32108359</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jmv.25736</pub-id><pub-id pub-id-type="pmcid">PMC7228377</pub-id></mixed-citation></ref><ref id="cei13517-bib-0140"><label>140</label><mixed-citation publication-type="miscellaneous" id="cei13517-cit-0140"><string-name name-style="western"><surname>Kadam</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Sukhramani</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Bishnoi</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Pable</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Barvkar</surname><given-names>V</given-names></string-name>. <article-title>Molecular and Structural Insights into COVID&#8208;19 Pandemic</article-title>. <year>2020</year>. <fpage>2020050519</fpage>. <pub-id pub-id-type="doi">10.20944/preprints202005.0519.v1</pub-id><pub-id pub-id-type="pmcid">PMC8013332</pub-id><pub-id pub-id-type="pmid">33460172</pub-id></mixed-citation></ref><ref id="cei13517-bib-0141"><label>141</label><mixed-citation publication-type="journal" id="cei13517-cit-0141"><string-name name-style="western"><surname>Kalita</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Padhi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>KY</given-names></string-name>, <string-name name-style="western"><surname>Tripathi</surname><given-names>T</given-names></string-name>. <article-title>Design of a peptide&#8208;based subunit vaccine against novel coronavirus SARS&#8208;CoV&#8208;2</article-title>. <source xml:lang="en">Microb Pathog</source><year>2020</year>; <volume>145</volume>:<elocation-id>104236</elocation-id>.<pub-id pub-id-type="pmid">32376359</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.micpath.2020.104236</pub-id><pub-id pub-id-type="pmcid">PMC7196559</pub-id></mixed-citation></ref><ref id="cei13517-bib-0142"><label>142</label><mixed-citation publication-type="journal" id="cei13517-cit-0142"><string-name name-style="western"><surname>Gauttier</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Morello</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Girault</surname><given-names>I</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Tissue&#8208;resident memory CD8 T&#8208;cell responses elicited by a single injection of a multi&#8208;target COVID&#8208;19 vaccine</article-title>. <source xml:lang="en">bioRxiv</source><year>2020</year>:2020.08.14.240093.</mixed-citation></ref><ref id="cei13517-bib-0143"><label>143</label><mixed-citation publication-type="journal" id="cei13517-cit-0143"><string-name name-style="western"><surname>Couture</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Garnier</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Docagne</surname><given-names>F</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>HLA&#8208;class II artificial antigen presenting cells in CD4+ T cell&#8208;based immunotherapy</article-title>. <source xml:lang="en">Front Immunol</source><year>2019</year>; <volume>10</volume>:<elocation-id>1081</elocation-id>.<pub-id pub-id-type="pmid">31156634</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2019.01081</pub-id><pub-id pub-id-type="pmcid">PMC6533590</pub-id></mixed-citation></ref><ref id="cei13517-bib-0144"><label>144</label><mixed-citation publication-type="journal" id="cei13517-cit-0144"><string-name name-style="western"><surname>Kim</surname><given-names>YC</given-names></string-name>, <string-name name-style="western"><surname>Dema</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Reyes&#8208;Sandoval</surname><given-names>A</given-names></string-name>. <article-title>COVID&#8208;19 vaccines: breaking record times to first&#8208;in&#8208;human trials</article-title>. <source xml:lang="en">NPJ Vaccin</source><year>2020</year>; <volume>5</volume>:<fpage>1</fpage>&#8211;<lpage>3</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41541-020-0188-3</pub-id><pub-id pub-id-type="pmcid">PMC7193619</pub-id><pub-id pub-id-type="pmid">32377399</pub-id></mixed-citation></ref><ref id="cei13517-bib-0145"><label>145</label><mixed-citation publication-type="journal" id="cei13517-cit-0145"><string-name name-style="western"><surname>Bolles</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Deming</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Long</surname><given-names>K</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>A double&#8208;inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge</article-title>. <source xml:lang="en">J Virol</source><year>2011</year>; <volume>85</volume>:<fpage>12201</fpage>&#8211;<lpage>15</lpage>.<pub-id pub-id-type="pmid">21937658</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.06048-11</pub-id><pub-id pub-id-type="pmcid">PMC3209347</pub-id></mixed-citation></ref><ref id="cei13517-bib-0146"><label>146</label><mixed-citation publication-type="journal" id="cei13517-cit-0146"><string-name name-style="western"><surname>Deng</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Lan</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Bao</surname><given-names>L</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Enhanced protection in mice induced by immunization with inactivated whole viruses compare to spike protein of middle east respiratory syndrome coronavirus</article-title>. <source xml:lang="en">Emerg Microbes Infect</source><year>2018</year>; <volume>7</volume>:<fpage>1</fpage>&#8211;<lpage>10</lpage>.<pub-id pub-id-type="pmid">29618723</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41426-018-0056-7</pub-id><pub-id pub-id-type="pmcid">PMC5884803</pub-id></mixed-citation></ref><ref id="cei13517-bib-0147"><label>147</label><mixed-citation publication-type="journal" id="cei13517-cit-0147"><string-name name-style="western"><surname>Qin</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Shi</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Tang</surname><given-names>L</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Immunogenicity and protective efficacy in monkeys of purified inactivated Vero&#8208;cell SARS vaccine</article-title>. <source xml:lang="en">Vaccine</source><year>2006</year>; <volume>24</volume>:<fpage>1028</fpage>&#8211;<lpage>34</lpage>.<pub-id pub-id-type="pmid">16388880</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2005.06.038</pub-id><pub-id pub-id-type="pmcid">PMC7115602</pub-id></mixed-citation></ref><ref id="cei13517-bib-0148"><label>148</label><mixed-citation publication-type="journal" id="cei13517-cit-0148"><string-name name-style="western"><surname>Gao</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Bao</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Mao</surname><given-names>H</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Development of an inactivated vaccine candidate for SARS&#8208;CoV&#8208;2</article-title>. <source xml:lang="en">Science</source><year>2020</year>; <volume>6499</volume>:<fpage>77</fpage>&#8211;<lpage>81</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abc1932</pub-id><pub-id pub-id-type="pmcid">PMC7202686</pub-id><pub-id pub-id-type="pmid">32376603</pub-id></mixed-citation></ref><ref id="cei13517-bib-0149"><label>149</label><mixed-citation publication-type="journal" id="cei13517-cit-0149"><string-name name-style="western"><surname>Zhang</surname><given-names>Y&#8208;J</given-names></string-name>, <string-name name-style="western"><surname>Zeng</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Pan</surname><given-names>H&#8208;X</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Immunogenicity and safety of a SARS&#8208;CoV&#8208;2 inactivated vaccine in healthy adults aged 18&#8211;59 years: report of the randomized, double&#8208;blind, and placebo&#8208;controlled Phase 2 clinical trial</article-title>. <source xml:lang="en">medRxiv</source><year>2020</year>:2020.07.31.20161216.</mixed-citation></ref><ref id="cei13517-bib-0150"><label>150</label><mixed-citation publication-type="journal" id="cei13517-cit-0150"><string-name name-style="western"><surname>Xia</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Duan</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Effect of an inactivated vaccine against SARS&#8208;CoV&#8208;2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials</article-title>. <source xml:lang="en">JAMA</source><year>2020</year>; <volume>324</volume>:<fpage>951</fpage>&#8211;<lpage>60</lpage>.<pub-id pub-id-type="pmid">32789505</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2020.15543</pub-id><pub-id pub-id-type="pmcid">PMC7426884</pub-id></mixed-citation></ref><ref id="cei13517-bib-0151"><label>151</label><mixed-citation publication-type="journal" id="cei13517-cit-0151"><string-name name-style="western"><surname>Schlegl</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Weber</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Wruss</surname><given-names>J</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Influence of elemental impurities in aluminum hydroxide adjuvant on the stability of inactivated Japanese Encephalitis vaccine, IXIARO&#174;</article-title>. <source xml:lang="en">Vaccine</source><year>2015</year>; <volume>33</volume>:<fpage>5989</fpage>&#8211;<lpage>96</lpage>.<pub-id pub-id-type="pmid">26095510</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2015.05.103</pub-id></mixed-citation></ref><ref id="cei13517-bib-0152"><label>152</label><mixed-citation publication-type="journal" id="cei13517-cit-0152"><string-name name-style="western"><surname>Yong</surname><given-names>CY</given-names></string-name>, <string-name name-style="western"><surname>Ong</surname><given-names>HK</given-names></string-name>, <string-name name-style="western"><surname>Yeap</surname><given-names>SK</given-names></string-name>, <string-name name-style="western"><surname>Ho</surname><given-names>KL</given-names></string-name>, <string-name name-style="western"><surname>Tan</surname><given-names>WS</given-names></string-name>. <article-title>Recent advances in the vaccine development against middle east respiratory syndrome&#160;&#8211;&#160;coronavirus</article-title>. <source xml:lang="en">Front Microbiol</source><year>2019</year>; <volume>10</volume>:<fpage>1781</fpage>.<pub-id pub-id-type="pmid">31428074</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmicb.2019.01781</pub-id><pub-id pub-id-type="pmcid">PMC6688523</pub-id></mixed-citation></ref><ref id="cei13517-bib-0153"><label>153</label><mixed-citation publication-type="journal" id="cei13517-cit-0153"><string-name name-style="western"><surname>Wareing</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Tannock</surname><given-names>G</given-names></string-name>. <article-title>Live attenuated vaccines against influenza; an historical review</article-title>. <source xml:lang="en">Vaccine</source><year>2001</year>; <volume>19</volume>:<fpage>3320</fpage>&#8211;<lpage>30</lpage>.<pub-id pub-id-type="pmid">11348696</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0264-410x(01)00045-7</pub-id></mixed-citation></ref><ref id="cei13517-bib-0154"><label>154</label><mixed-citation publication-type="journal" id="cei13517-cit-0154"><string-name name-style="western"><surname>Regla&#8208;Nava</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Nieto&#8208;Torres</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Jimenez&#8208;Guarde&#241;o</surname><given-names>JM</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Severe acute respiratory syndrome coronaviruses with mutations in the E protein are attenuated and promising vaccine candidates</article-title>. <source xml:lang="en">J Virol</source><year>2015</year>; <volume>89</volume>:<fpage>3870</fpage>&#8211;<lpage>87</lpage>.<pub-id pub-id-type="pmid">25609816</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.03566-14</pub-id><pub-id pub-id-type="pmcid">PMC4403406</pub-id></mixed-citation></ref><ref id="cei13517-bib-0155"><label>155</label><mixed-citation publication-type="journal" id="cei13517-cit-0155"><string-name name-style="western"><surname>Almaz&#225;n</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>DeDiego</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Sola</surname><given-names>I</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Engineering a replication&#8208;competent, propagation&#8208;defective Middle East respiratory syndrome coronavirus as a vaccine candidate</article-title>. <source xml:lang="en">mBio</source><year>2013</year>; <volume>4</volume>:<elocation-id>e00650&#8208;13</elocation-id>.<pub-id pub-id-type="pmid">24023385</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/mBio.00650-13</pub-id><pub-id pub-id-type="pmcid">PMC3774192</pub-id></mixed-citation></ref><ref id="cei13517-bib-0156"><label>156</label><mixed-citation publication-type="journal" id="cei13517-cit-0156"><string-name name-style="western"><surname>Mueller</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Stauft</surname><given-names>CB</given-names></string-name>, <string-name name-style="western"><surname>Kalkeri</surname><given-names>R</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>A codon&#8208;pair deoptimized live&#8208;attenuated vaccine against respiratory syncytial virus is immunogenic and efficacious in non&#8208;human primates</article-title>. <source xml:lang="en">Vaccine</source><year>2020</year>; <volume>38</volume>:<fpage>2943</fpage>&#8211;<lpage>2948</lpage>.<pub-id pub-id-type="pmid">32107060</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2020.02.056</pub-id><pub-id pub-id-type="pmcid">PMC7092643</pub-id></mixed-citation></ref><ref id="cei13517-bib-0157"><label>157</label><mixed-citation publication-type="book" id="cei13517-cit-0157"><collab collab-type="authors">BioSpace</collab>
. <source xml:lang="en">Codagenix and Serum Institute of India Initiate Co&#8208;Development of a Scalable, Live&#8208;Attenuated Vaccine Against the 2019 Novel Coronavirus, COVID&#8208;19</source>. <publisher-name>BioSpace</publisher-name>, <year>2020</year>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.biospace.com/article/releases/codagenix-and-serum-institute-of-india-initiate-co-development-of-a-scalable-live-attenuated-vaccine-against-the-2019-novel-coronavirus-covid-19/">https://www.biospace.com/article/releases/codagenix&#8208;and&#8208;serum&#8208;institute&#8208;of&#8208;india&#8208;initiate&#8208;co&#8208;development&#8208;of&#8208;a&#8208;scalable&#8208;live&#8208;attenuated&#8208;vaccine&#8208;against&#8208;the&#8208;2019&#8208;novel&#8208;coronavirus&#8208;covid&#8208;19/</ext-link> (accessed September 2020).</mixed-citation></ref><ref id="cei13517-bib-0158"><label>158</label><mixed-citation publication-type="journal" id="cei13517-cit-0158"><string-name name-style="western"><surname>Choi</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Chang</surname><given-names>J</given-names></string-name>. <article-title>Viral vectors for vaccine applications</article-title>. <source xml:lang="en">Clin Exp Vaccin Res</source><year>2013</year>; <volume>2</volume>:<fpage>97</fpage>&#8211;<lpage>105</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.7774/cevr.2013.2.2.97</pub-id><pub-id pub-id-type="pmcid">PMC3710930</pub-id><pub-id pub-id-type="pmid">23858400</pub-id></mixed-citation></ref><ref id="cei13517-bib-0159"><label>159</label><mixed-citation publication-type="journal" id="cei13517-cit-0159"><string-name name-style="western"><surname>Bisht</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Roberts</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Vogel</surname><given-names>L</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice</article-title>. <source xml:lang="en">Proc Natl Acad Sci USA</source><year>2004</year>; <volume>101</volume>:<fpage>6641</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="pmid">15096611</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0401939101</pub-id><pub-id pub-id-type="pmcid">PMC404098</pub-id></mixed-citation></ref><ref id="cei13517-bib-0160"><label>160</label><mixed-citation publication-type="journal" id="cei13517-cit-0160"><string-name name-style="western"><surname>Folegatti</surname><given-names>PM</given-names></string-name>, <string-name name-style="western"><surname>Bittaye</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Flaxman</surname><given-names>A</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral&#8208;vectored vaccine: a dose&#8208;escalation, open&#8208;label, non&#8208;randomised, uncontrolled, phase 1 trial</article-title>. <source xml:lang="en">Lancet Infect Dis</source><year>2020</year>; <volume>20</volume>:<fpage>816</fpage>&#8211;<lpage>26</lpage>.<pub-id pub-id-type="pmid">32325038</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1473-3099(20)30160-2</pub-id><pub-id pub-id-type="pmcid">PMC7172901</pub-id></mixed-citation></ref><ref id="cei13517-bib-0161"><label>161</label><mixed-citation publication-type="journal" id="cei13517-cit-0161"><string-name name-style="western"><surname>Wold</surname><given-names>WSM</given-names></string-name>, <string-name name-style="western"><surname>Toth</surname><given-names>K</given-names></string-name>. <article-title>Adenovirus vectors for gene therapy, vaccination and cancer gene therapy</article-title>. <source xml:lang="en">Curr Gene Ther</source><year>2013</year>; <volume>13</volume>:<fpage>421</fpage>&#8211;<lpage>33</lpage>.<pub-id pub-id-type="pmid">24279313</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1566523213666131125095046</pub-id><pub-id pub-id-type="pmcid">PMC4507798</pub-id></mixed-citation></ref><ref id="cei13517-bib-0162"><label>162</label><mixed-citation publication-type="journal" id="cei13517-cit-0162"><string-name name-style="western"><surname>Graham</surname><given-names>SP</given-names></string-name>, <string-name name-style="western"><surname>McLean</surname><given-names>RK</given-names></string-name>, <string-name name-style="western"><surname>Spencer</surname><given-names>AJ</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Evaluation of the immunogenicity of prime&#8208;boost vaccination with the replication&#8208;deficient viral vectored COVID&#8208;19 vaccine candidate ChAdOx1 nCoV&#8208;19</article-title>. <source xml:lang="en">bioRxiv</source><year>2020</year>:2020.06.20.159715.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41541-020-00221-3</pub-id><pub-id pub-id-type="pmcid">PMC7385486</pub-id><pub-id pub-id-type="pmid">32793398</pub-id></mixed-citation></ref><ref id="cei13517-bib-0163"><label>163</label><mixed-citation publication-type="journal" id="cei13517-cit-0163"><string-name name-style="western"><surname>van Doremalen</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Lambe</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Spencer</surname><given-names>A</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>ChAdOx1 nCoV&#8208;19 vaccine prevents SARS&#8208;CoV&#8208;2 pneumonia in rhesus macaques</article-title>. <source xml:lang="en">Nature</source><year>2020</year>. <pub-id pub-id-type="doi">10.1038/s41586-020-2608-y</pub-id><pub-id pub-id-type="pmcid">PMC8436420</pub-id><pub-id pub-id-type="pmid">32731258</pub-id></mixed-citation></ref><ref id="cei13517-bib-0164"><label>164</label><mixed-citation publication-type="journal" id="cei13517-cit-0164"><string-name name-style="western"><surname>van Doremalen</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Lambe</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Spencer</surname><given-names>A</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>ChAdOx1 nCoV&#8208;19 vaccination prevents SARS&#8208;CoV&#8208;2 pneumonia in rhesus macaques</article-title>. <source xml:lang="en">bioRxiv</source><year>2020</year>. <pub-id pub-id-type="doi">10.1101/2020.05.13.093195</pub-id></mixed-citation></ref><ref id="cei13517-bib-0165"><label>165</label><mixed-citation publication-type="journal" id="cei13517-cit-0165"><string-name name-style="western"><surname>Folegatti</surname><given-names>PM</given-names></string-name>, <string-name name-style="western"><surname>Ewer</surname><given-names>KJ</given-names></string-name>, <string-name name-style="western"><surname>Aley</surname><given-names>PK</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Safety and immunogenicity of the ChAdOx1 nCoV&#8208;19 vaccine against SARS&#8208;CoV&#8208;2: a preliminary report of a phase 1/2, single&#8208;blind, randomised controlled trial</article-title>. <source xml:lang="en">Lancet</source><year>2020</year>; <volume>396</volume>:<fpage>467</fpage>&#8211;<lpage>78</lpage>.<pub-id pub-id-type="pmid">32702298</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)31604-4</pub-id><pub-id pub-id-type="pmcid">PMC7445431</pub-id></mixed-citation></ref><ref id="cei13517-bib-0166"><label>166</label><mixed-citation publication-type="journal" id="cei13517-cit-0166"><string-name name-style="western"><surname>Zhu</surname><given-names>F&#8208;C</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Y&#8208;H</given-names></string-name>, <string-name name-style="western"><surname>Guan</surname><given-names>X&#8208;H</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Safety, tolerability, and immunogenicity of a recombinant adenovirus type&#8208;5 vectored COVID&#8208;19 vaccine: a dose&#8208;escalation, open&#8208;label, non&#8208;randomised, first&#8208;in&#8208;human trial</article-title>. <source xml:lang="en">Lancet</source><year>2020</year>; <volume>395</volume>:<fpage>1845</fpage>&#8211;<lpage>54</lpage>.<pub-id pub-id-type="pmid">32450106</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)31208-3</pub-id><pub-id pub-id-type="pmcid">PMC7255193</pub-id></mixed-citation></ref><ref id="cei13517-bib-0167"><label>167</label><mixed-citation publication-type="journal" id="cei13517-cit-0167"><string-name name-style="western"><surname>Zhu</surname><given-names>F&#8208;C</given-names></string-name>, <string-name name-style="western"><surname>Guan</surname><given-names>X&#8208;H</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Y&#8208;H</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Immunogenicity and safety of a recombinant adenovirus type&#8208;5&#8208;vectored COVID&#8208;19 vaccine in healthy adults aged 18 years or older: a randomised, double&#8208;blind, placebo&#8208;controlled, phase 2 trial</article-title>. <source xml:lang="en">Lancet</source><year>2020</year>; <volume>396</volume>:<fpage>479</fpage>&#8211;<lpage>88</lpage>.<pub-id pub-id-type="pmid">32702299</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)31605-6</pub-id><pub-id pub-id-type="pmcid">PMC7836858</pub-id></mixed-citation></ref><ref id="cei13517-bib-0168"><label>168</label><mixed-citation publication-type="miscellaneous" id="cei13517-cit-0168"><collab collab-type="authors">Janssen</collab>
. <article-title>Patented Technologies to Advance Disease Research</article-title>. <year>2020</year>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.janssen.com/emea/emea/janssen-vaccine-technologies">https://www.janssen.com/emea/emea/janssen&#8208;vaccine&#8208;technologies</ext-link> (accessed September 2020).</mixed-citation></ref><ref id="cei13517-bib-0169"><label>169</label><mixed-citation publication-type="book" id="cei13517-cit-0169"><collab collab-type="authors">Businesswire</collab>
. <source xml:lang="en">Johnson &amp; Johnson Receives Positive CHMP Opinion for Janssen&#8217;s Investigational Preventive Ebola Vaccine Regimen</source>. <publisher-name>Businesswire</publisher-name>, <year>2020</year>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.businesswire.com/news/home/20200529005263/en/%C2%A0Johnson-Johnson-Receives-Positive-CHMP-Opinion-for-Janssen%E2%80%99s-Investigational-Preventive-Ebola-Vaccine-Regimen">https://www.businesswire.com/news/home/20200529005263/en/%C2%A0Johnson&#8208;Johnson&#8208;Receives&#8208;Positive&#8208;CHMP&#8208;Opinion&#8208;for&#8208;Janssen%E2%80%99s&#8208;Investigational&#8208;Preventive&#8208;Ebola&#8208;Vaccine&#8208;Regimen</ext-link> (accessed September 2020).</mixed-citation></ref><ref id="cei13517-bib-0170"><label>170</label><mixed-citation publication-type="journal" id="cei13517-cit-0170"><string-name name-style="western"><surname>Mercado</surname><given-names>NB</given-names></string-name>, <string-name name-style="western"><surname>Zahn</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Wegmann</surname><given-names>F</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Single&#8208;shot Ad26 vaccine protects against SARS&#8208;CoV&#8208;2 in rhesus macaques</article-title>. <source xml:lang="en">Nature</source><year>2020</year>. <pub-id pub-id-type="doi">10.1038/s41586-020-2607-z</pub-id><pub-id pub-id-type="pmcid">PMC7581548</pub-id><pub-id pub-id-type="pmid">32731257</pub-id></mixed-citation></ref><ref id="cei13517-bib-0171"><label>171</label><mixed-citation publication-type="journal" id="cei13517-cit-0171"><string-name name-style="western"><surname>Logunov</surname><given-names>DY</given-names></string-name>, <string-name name-style="western"><surname>Dolzhikova</surname><given-names>IV</given-names></string-name>, <string-name name-style="western"><surname>Zubkova</surname><given-names>OV</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Safety and immunogenicity of an rAd26 and rAd5 vector&#8208;based heterologous prime&#8208;boost COVID&#8208;19 vaccine in two formulations: two open, non&#8208;randomised phase 1/2 studies from Russia</article-title>. <source xml:lang="en">Lancet</source><year>2020</year>. <pub-id pub-id-type="doi">10.1016/S0140-6736(20)31866-3</pub-id><pub-id pub-id-type="pmcid">PMC7471804</pub-id><pub-id pub-id-type="pmid">32896291</pub-id></mixed-citation></ref><ref id="cei13517-bib-0172"><label>172</label><mixed-citation publication-type="journal" id="cei13517-cit-0172"><string-name name-style="western"><surname>Ramsauer</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Schwameis</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Firbas</surname><given-names>C</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Immunogenicity, safety, and tolerability of a recombinant measles&#8208;virus&#8208;based chikungunya vaccine: a randomised, double&#8208;blind, placebo&#8208;controlled, active&#8208;comparator, first&#8208;in&#8208;man trial</article-title>. <source xml:lang="en">Lancet Infect Dis</source><year>2015</year>; <volume>15</volume>:<fpage>519</fpage>&#8211;<lpage>27</lpage>.<pub-id pub-id-type="pmid">25739878</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1473-3099(15)70043-5</pub-id></mixed-citation></ref><ref id="cei13517-bib-0173"><label>173</label><mixed-citation publication-type="miscellaneous" id="cei13517-cit-0173"><collab collab-type="authors">Migal</collab>
. <article-title>MIGAL&#8217;s Coronavirus Vaccine Project</article-title>. <year>2020</year>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.migal.org.il/en/node/7010">https://www.migal.org.il/en/node/7010</ext-link> (accessed September 2020).</mixed-citation></ref><ref id="cei13517-bib-0174"><label>174</label><mixed-citation publication-type="journal" id="cei13517-cit-0174"><string-name name-style="western"><surname>Tregoning</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Kinnear</surname><given-names>E</given-names></string-name>. <article-title>Using plasmids as DNA vaccines for infectious diseases</article-title>. <source xml:lang="en">Microbiol Spectr</source><year>2014</year>; <volume>2</volume>. <pub-id pub-id-type="doi">10.1128/microbiolspec.PLAS-0028-2014</pub-id><pub-id pub-id-type="pmid">26104452</pub-id></mixed-citation></ref><ref id="cei13517-bib-0175"><label>175</label><mixed-citation publication-type="journal" id="cei13517-cit-0175"><string-name name-style="western"><surname>Porgador</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Irvine</surname><given-names>KR</given-names></string-name>, <string-name name-style="western"><surname>Iwasaki</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Barber</surname><given-names>BH</given-names></string-name>, <string-name name-style="western"><surname>Restifo</surname><given-names>NP</given-names></string-name>, <string-name name-style="western"><surname>Germain</surname><given-names>RN</given-names></string-name>. <article-title>Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization</article-title>. <source xml:lang="en">J Exp Med</source><year>1998</year>; <volume>188</volume>:<fpage>1075</fpage>&#8211;<lpage>82</lpage>.<pub-id pub-id-type="pmid">9743526</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1084/jem.188.6.1075</pub-id><pub-id pub-id-type="pmcid">PMC2212529</pub-id></mixed-citation></ref><ref id="cei13517-bib-0176"><label>176</label><mixed-citation publication-type="journal" id="cei13517-cit-0176"><string-name name-style="western"><surname>Ishikawa</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Barber</surname><given-names>GN</given-names></string-name>. <article-title>STING regulates intracellular DNA&#8208;mediated, type I interferon&#8208;dependent innate immunity</article-title>. <source xml:lang="en">Nature</source><year>2009</year>; <volume>461</volume>:<fpage>788</fpage>&#8211;<lpage>92</lpage>.<pub-id pub-id-type="pmid">19776740</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature08476</pub-id><pub-id pub-id-type="pmcid">PMC4664154</pub-id></mixed-citation></ref><ref id="cei13517-bib-0177"><label>177</label><mixed-citation publication-type="journal" id="cei13517-cit-0177"><string-name name-style="western"><surname>Joffre</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Nolte</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Sporri</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Reis e Sousa</surname><given-names>C</given-names></string-name>. <article-title>Inflammatory signals in dendritic cell activation and the induction of adaptive immunity</article-title>. <source xml:lang="en">Immunol Rev</source><year>2009</year>; <volume>227</volume>:<fpage>234</fpage>&#8211;<lpage>47</lpage>.<pub-id pub-id-type="pmid">19120488</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1600-065X.2008.00718.x</pub-id></mixed-citation></ref><ref id="cei13517-bib-0178"><label>178</label><mixed-citation publication-type="journal" id="cei13517-cit-0178"><string-name name-style="western"><surname>Kim</surname><given-names>BM</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>DS</given-names></string-name>, <string-name name-style="western"><surname>Choi</surname><given-names>JH</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>In vivo kinetics and biodistribution of a HIV&#8208;1 DNA vaccine after administration in mice</article-title>. <source xml:lang="en">Arch Pharm Res</source><year>2003</year>; <volume>26</volume>:<fpage>493</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">12877561</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF02976869</pub-id></mixed-citation></ref><ref id="cei13517-bib-0179"><label>179</label><mixed-citation publication-type="journal" id="cei13517-cit-0179"><string-name name-style="western"><surname>Capecchi</surname><given-names>MR</given-names></string-name>. <article-title>High efficiency transformation by direct microinjection of DNA into cultured mammalian cells</article-title>. <source xml:lang="en">Cell</source><year>1980</year>; <volume>22</volume>:<fpage>479</fpage>&#8211;<lpage>88</lpage>.<pub-id pub-id-type="pmid">6256082</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0092-8674(80)90358-x</pub-id></mixed-citation></ref><ref id="cei13517-bib-0180"><label>180</label><mixed-citation publication-type="journal" id="cei13517-cit-0180"><string-name name-style="western"><surname>Okada</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Takemoto</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Okuno</surname><given-names>Y</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>The development of vaccines against SARS corona virus in mice and SCID&#8208;PBL/hu mice</article-title>. <source xml:lang="en">Vaccine</source><year>2005</year>; <volume>23</volume>:<fpage>2269</fpage>&#8211;<lpage>72</lpage>.<pub-id pub-id-type="pmid">15755609</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2005.01.036</pub-id><pub-id pub-id-type="pmcid">PMC7115605</pub-id></mixed-citation></ref><ref id="cei13517-bib-0181"><label>181</label><mixed-citation publication-type="journal" id="cei13517-cit-0181"><string-name name-style="western"><surname>Lu</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Tao</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>T</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Humoral and cellular immune responses induced by 3a DNA vaccines against severe acute respiratory syndrome (SARS) or SARS&#8208;like coronavirus in mice</article-title>. <source xml:lang="en">Clin Vaccine Immunol</source><year>2009</year>; <volume>16</volume>:<fpage>73</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">18987164</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/CVI.00261-08</pub-id><pub-id pub-id-type="pmcid">PMC2620671</pub-id></mixed-citation></ref><ref id="cei13517-bib-0182"><label>182</label><mixed-citation publication-type="journal" id="cei13517-cit-0182"><string-name name-style="western"><surname>Hu</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Tao</surname><given-names>L</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Induction of specific immune responses by severe acute respiratory syndrome coronavirus spike DNA vaccine with or without interleukin&#8208;2 immunization using different vaccination routes in mice</article-title>. <source xml:lang="en">Clin Vaccine Immunol</source><year>2007</year>; <volume>14</volume>:<fpage>894</fpage>&#8211;<lpage>901</lpage>.<pub-id pub-id-type="pmid">17494640</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/CVI.00019-07</pub-id><pub-id pub-id-type="pmcid">PMC1951058</pub-id></mixed-citation></ref><ref id="cei13517-bib-0183"><label>183</label><mixed-citation publication-type="journal" id="cei13517-cit-0183"><string-name name-style="western"><surname>Martin</surname><given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>Louder</surname><given-names>MK</given-names></string-name>, <string-name name-style="western"><surname>Holman</surname><given-names>LA</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial</article-title>. <source xml:lang="en">Vaccine</source><year>2008</year>; <volume>26</volume>:<fpage>6338</fpage>&#8211;<lpage>43</lpage>.<pub-id pub-id-type="pmid">18824060</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2008.09.026</pub-id><pub-id pub-id-type="pmcid">PMC2612543</pub-id></mixed-citation></ref><ref id="cei13517-bib-0184"><label>184</label><mixed-citation publication-type="journal" id="cei13517-cit-0184"><string-name name-style="western"><surname>Modjarrad</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Roberts</surname><given-names>CC</given-names></string-name>, <string-name name-style="western"><surname>Mills</surname><given-names>KT</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Safety and immunogenicity of an anti&#8208;Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open&#8208;label, single&#8208;arm, dose&#8208;escalation trial</article-title>. <source xml:lang="en">Lancet Infect Dis</source><year>2019</year>; <volume>19</volume>:<fpage>1013</fpage>&#8211;<lpage>22</lpage>.<pub-id pub-id-type="pmid">31351922</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1473-3099(19)30266-X</pub-id><pub-id pub-id-type="pmcid">PMC7185789</pub-id></mixed-citation></ref><ref id="cei13517-bib-0185"><label>185</label><mixed-citation publication-type="journal" id="cei13517-cit-0185"><string-name name-style="western"><surname>Smith</surname><given-names>TRF</given-names></string-name>, <string-name name-style="western"><surname>Patel</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Ramos</surname><given-names>S</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Immunogenicity of a DNA vaccine candidate for COVID&#8208;19</article-title>. <source xml:lang="en">Nat Commun</source><year>2020</year>; <volume>11</volume>:<fpage>2601</fpage>.<pub-id pub-id-type="pmid">32433465</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-020-16505-0</pub-id><pub-id pub-id-type="pmcid">PMC7239918</pub-id></mixed-citation></ref><ref id="cei13517-bib-0186"><label>186</label><mixed-citation publication-type="journal" id="cei13517-cit-0186"><string-name name-style="western"><surname>Patel</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Walters</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Reuschel</surname><given-names>EL</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Intradermal&#8208;delivered DNA vaccine provides anamnestic protection in a rhesus macaque SARS&#8208;CoV&#8208;2 challenge model</article-title>. <source xml:lang="en">bioRxiv</source><year>2020</year>:2020.07.28.225649.</mixed-citation></ref><ref id="cei13517-bib-0187"><label>187</label><mixed-citation publication-type="journal" id="cei13517-cit-0187"><string-name name-style="western"><surname>Chen</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Xia</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>TT</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>J</given-names></string-name>. <article-title>RNA sensors of the innate immune system and their detection of pathogens</article-title>. <source xml:lang="en">IUBMB Life</source><year>2017</year>; <volume>69</volume>:<fpage>297</fpage>&#8211;<lpage>304</lpage>.<pub-id pub-id-type="pmid">28374903</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/iub.1625</pub-id><pub-id pub-id-type="pmcid">PMC7165898</pub-id></mixed-citation></ref><ref id="cei13517-bib-0188"><label>188</label><mixed-citation publication-type="journal" id="cei13517-cit-0188"><string-name name-style="western"><surname>Edwards</surname><given-names>DK</given-names></string-name>, <string-name name-style="western"><surname>Jasny</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Yoon</surname><given-names>H</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Adjuvant effects of a sequence&#8208;engineered mRNA vaccine: translational profiling demonstrates similar human and murine innate response</article-title>. <source xml:lang="en">J Transl Med</source><year>2017</year>; <volume>15</volume>:<fpage>1</fpage>.<pub-id pub-id-type="pmid">28049494</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12967-016-1111-6</pub-id><pub-id pub-id-type="pmcid">PMC5210268</pub-id></mixed-citation></ref><ref id="cei13517-bib-0189"><label>189</label><mixed-citation publication-type="journal" id="cei13517-cit-0189"><string-name name-style="western"><surname>Pepini</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Pulichino</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Carsillo</surname><given-names>T</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Induction of an IFN&#8208;mediated antiviral response by a self&#8208;amplifying RNA vaccine: implications for vaccine design</article-title>. <source xml:lang="en">J Immunol</source><year>2017</year>; <volume>198</volume>:<fpage>4012</fpage>&#8211;<lpage>24</lpage>.<pub-id pub-id-type="pmid">28416600</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.1601877</pub-id><pub-id pub-id-type="pmcid">PMC5421303</pub-id></mixed-citation></ref><ref id="cei13517-bib-0190"><label>190</label><mixed-citation publication-type="journal" id="cei13517-cit-0190"><string-name name-style="western"><surname>Kariko</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Buckstein</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ni</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Weissman</surname><given-names>D</given-names></string-name>. <article-title>Suppression of RNA recognition by Toll&#8208;like receptors: the impact of nucleoside modification and the evolutionary origin of RNA</article-title>. <source xml:lang="en">Immunity</source><year>2005</year>; <volume>23</volume>:<fpage>165</fpage>&#8211;<lpage>75</lpage>.<pub-id pub-id-type="pmid">16111635</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.immuni.2005.06.008</pub-id></mixed-citation></ref><ref id="cei13517-bib-0191"><label>191</label><mixed-citation publication-type="journal" id="cei13517-cit-0191"><string-name name-style="western"><surname>Kariko</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Muramatsu</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Welsh</surname><given-names>FA</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability</article-title>. <source xml:lang="en">Mol Ther</source><year>2008</year>; <volume>16</volume>:<fpage>1833</fpage>&#8211;<lpage>40</lpage>.<pub-id pub-id-type="pmid">18797453</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/mt.2008.200</pub-id><pub-id pub-id-type="pmcid">PMC2775451</pub-id></mixed-citation></ref><ref id="cei13517-bib-0192"><label>192</label><mixed-citation publication-type="journal" id="cei13517-cit-0192"><string-name name-style="western"><surname>Guo</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Ingolia</surname><given-names>NT</given-names></string-name>, <string-name name-style="western"><surname>Weissman</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Bartel</surname><given-names>DP</given-names></string-name>. <article-title>Mammalian microRNAs predominantly act to decrease target mRNA levels</article-title>. <source xml:lang="en">Nature</source><year>2010</year>; <volume>466</volume>:<fpage>835</fpage>&#8211;<lpage>40</lpage>.<pub-id pub-id-type="pmid">20703300</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature09267</pub-id><pub-id pub-id-type="pmcid">PMC2990499</pub-id></mixed-citation></ref><ref id="cei13517-bib-0193"><label>193</label><mixed-citation publication-type="journal" id="cei13517-cit-0193"><string-name name-style="western"><surname>Barreau</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Paillard</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Osborne</surname><given-names>HB</given-names></string-name>. <article-title>AU&#8208;rich elements and associated factors: are there unifying principles?</article-title><source xml:lang="en">Nucleic Acids Res</source><year>2005</year>; <volume>33</volume>:<fpage>7138</fpage>&#8211;<lpage>50</lpage>.<pub-id pub-id-type="pmid">16391004</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gki1012</pub-id><pub-id pub-id-type="pmcid">PMC1325018</pub-id></mixed-citation></ref><ref id="cei13517-bib-0194"><label>194</label><mixed-citation publication-type="journal" id="cei13517-cit-0194"><string-name name-style="western"><surname>Vogel</surname><given-names>AB</given-names></string-name>, <string-name name-style="western"><surname>Lambert</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Kinnear</surname><given-names>E</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Self&#8208;amplifying RNA vaccines give equivalent protection against influenza to mRNA vaccines but at much lower doses</article-title>. <source xml:lang="en">Mol Ther</source><year>2018</year>; <volume>26</volume>:<fpage>446</fpage>&#8211;<lpage>55</lpage>.<pub-id pub-id-type="pmid">29275847</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ymthe.2017.11.017</pub-id><pub-id pub-id-type="pmcid">PMC5835025</pub-id></mixed-citation></ref><ref id="cei13517-bib-0195"><label>195</label><mixed-citation publication-type="journal" id="cei13517-cit-0195"><string-name name-style="western"><surname>Corbett</surname><given-names>KS</given-names></string-name>, <string-name name-style="western"><surname>Edwards</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Leist</surname><given-names>SR</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>SARS&#8208;CoV&#8208;2 mRNA vaccine development enabled by prototype pathogen preparedness</article-title>. <source xml:lang="en">bioRxiv</source><year>2020</year>:2020.06.11.145920.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-020-2622-0</pub-id><pub-id pub-id-type="pmcid">PMC7581537</pub-id><pub-id pub-id-type="pmid">32756549</pub-id></mixed-citation></ref><ref id="cei13517-bib-0196"><label>196</label><mixed-citation publication-type="journal" id="cei13517-cit-0196"><string-name name-style="western"><surname>Jackson</surname><given-names>LA</given-names></string-name>, <string-name name-style="western"><surname>Anderson</surname><given-names>EJ</given-names></string-name>, <string-name name-style="western"><surname>Rouphael</surname><given-names>NG</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>An mRNA Vaccine against SARS&#8208;CoV&#8208;2 &#8212; Preliminary Report</article-title>. <source xml:lang="en">N Engl J Med</source><year>2020</year>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2022483</pub-id><pub-id pub-id-type="pmcid">PMC7377258</pub-id><pub-id pub-id-type="pmid">32663912</pub-id></mixed-citation></ref><ref id="cei13517-bib-0197"><label>197</label><mixed-citation publication-type="journal" id="cei13517-cit-0197"><string-name name-style="western"><surname>Laczk&#243;</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Hogan</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Toulmin</surname><given-names>SA</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>A single immunization with nucleoside&#8208;modified mRNA vaccines elicits strong cellular and humoral immune responses against SARS&#8208;CoV&#8208;2 in mice</article-title>. <source xml:lang="en">Immunity</source><year>2020</year>. <pub-id pub-id-type="doi">10.1016/j.immuni.2020.07.019</pub-id><pub-id pub-id-type="pmcid">PMC7392193</pub-id><pub-id pub-id-type="pmid">32783919</pub-id></mixed-citation></ref><ref id="cei13517-bib-0198"><label>198</label><mixed-citation publication-type="journal" id="cei13517-cit-0198"><string-name name-style="western"><surname>Mulligan</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Lyke</surname><given-names>KE</given-names></string-name>, <string-name name-style="western"><surname>Kitchin</surname><given-names>N</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Phase 1/2 study to describe the safety and immunogenicity of a COVID&#8208;19 RNA vaccine candidate (BNT162b1) in adults 18 to 55 years of age. Interim report</article-title>. <source xml:lang="en">medRxiv</source><year>2020</year>:2020.06.30.20142570.</mixed-citation></ref><ref id="cei13517-bib-0199"><label>199</label><mixed-citation publication-type="journal" id="cei13517-cit-0199"><string-name name-style="western"><surname>Sahin</surname><given-names>U</given-names></string-name>, <string-name name-style="western"><surname>Muik</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Derhovanessian</surname><given-names>E</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Concurrent human antibody and TH1 type T&#8208;cell responses elicited by a COVID&#8208;19 RNA vaccine</article-title>. <source xml:lang="en">Medrxiv</source>. <year>2020</year>. <pub-id pub-id-type="doi">10.1101/2020.07.17.20140533</pub-id></mixed-citation></ref><ref id="cei13517-bib-0200"><label>200</label><mixed-citation publication-type="journal" id="cei13517-cit-0200"><string-name name-style="western"><surname>Walsh</surname><given-names>EE</given-names></string-name>, <string-name name-style="western"><surname>Frenck</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Falsey</surname><given-names>AR</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>RNA&#8208;Based COVID&#8208;19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study</article-title>. <source xml:lang="en">Medrxiv</source>. <year>2020</year>. <pub-id pub-id-type="doi">10.1101/2020.08.17.20176651</pub-id></mixed-citation></ref><ref id="cei13517-bib-0201"><label>201</label><mixed-citation publication-type="journal" id="cei13517-cit-0201"><string-name name-style="western"><surname>Tregoning</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Russell</surname><given-names>RF</given-names></string-name>, <string-name name-style="western"><surname>Kinnear</surname><given-names>E</given-names></string-name>. <article-title>Adjuvanted influenza vaccines</article-title>. <source xml:lang="en">Hum Vaccin Immunother</source><year>2018</year>; <volume>14</volume>:<fpage>550</fpage>&#8211;<lpage>64</lpage>.<pub-id pub-id-type="pmid">29232151</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/21645515.2017.1415684</pub-id><pub-id pub-id-type="pmcid">PMC5861793</pub-id></mixed-citation></ref><ref id="cei13517-bib-0202"><label>202</label><mixed-citation publication-type="journal" id="cei13517-cit-0202"><string-name name-style="western"><surname>Awate</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Babiuk</surname><given-names>LAB</given-names></string-name>, <string-name name-style="western"><surname>Mutwiri</surname><given-names>G</given-names></string-name>. <article-title>Mechanisms of action of adjuvants</article-title>. <source xml:lang="en">Front Immunol</source><year>2013</year>; <volume>4</volume>:<fpage>114</fpage>.<pub-id pub-id-type="pmid">23720661</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2013.00114</pub-id><pub-id pub-id-type="pmcid">PMC3655441</pub-id></mixed-citation></ref><ref id="cei13517-bib-0203"><label>203</label><mixed-citation publication-type="journal" id="cei13517-cit-0203"><string-name name-style="western"><surname>Perrie</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Mohammed</surname><given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>Kirby</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>McNeil</surname><given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>Bramwell</surname><given-names>VW</given-names></string-name>. <article-title>Vaccine adjuvant systems: enhancing the efficacy of sub&#8208;unit protein antigens</article-title>. <source xml:lang="en">Int J Pharm</source><year>2008</year>; <volume>364</volume>:<fpage>272</fpage>&#8211;<lpage>80</lpage>.<pub-id pub-id-type="pmid">18555624</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijpharm.2008.04.036</pub-id></mixed-citation></ref><ref id="cei13517-bib-0204"><label>204</label><mixed-citation publication-type="journal" id="cei13517-cit-0204"><string-name name-style="western"><surname>Coffman</surname><given-names>RL</given-names></string-name>, <string-name name-style="western"><surname>Sher</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Seder</surname><given-names>RA</given-names></string-name>. <article-title>Vaccine adjuvants: putting innate immunity to work</article-title>. <source xml:lang="en">Immunity</source><year>2010</year>; <volume>33</volume>:<fpage>492</fpage>&#8211;<lpage>503</lpage>.<pub-id pub-id-type="pmid">21029960</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.immuni.2010.10.002</pub-id><pub-id pub-id-type="pmcid">PMC3420356</pub-id></mixed-citation></ref><ref id="cei13517-bib-0205"><label>205</label><mixed-citation publication-type="journal" id="cei13517-cit-0205"><string-name name-style="western"><surname>Hogarth</surname><given-names>PJ</given-names></string-name>, <string-name name-style="western"><surname>Jahans</surname><given-names>KJ</given-names></string-name>, <string-name name-style="western"><surname>Hecker</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Hewinson</surname><given-names>RG</given-names></string-name>, <string-name name-style="western"><surname>Chambers</surname><given-names>MA</given-names></string-name>. <article-title>Evaluation of adjuvants for protein vaccines against tuberculosis in guinea pigs</article-title>. <source xml:lang="en">Vaccine</source><year>2003</year>; <volume>21</volume>:<fpage>977</fpage>&#8211;<lpage>82</lpage>.<pub-id pub-id-type="pmid">12547611</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0264-410x(02)00548-0</pub-id></mixed-citation></ref><ref id="cei13517-bib-0206"><label>206</label><mixed-citation publication-type="journal" id="cei13517-cit-0206"><string-name name-style="western"><surname>Diehl</surname><given-names>MC</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Daniels</surname><given-names>SE</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Tolerability of intramuscular and intradermal delivery by CELLECTRA(&#174;) adaptive constant current electroporation device in healthy volunteers</article-title>. <source xml:lang="en">Hum Vaccin Immunother</source><year>2013</year>; <volume>9</volume>:<fpage>2246</fpage>&#8211;<lpage>52</lpage>.<pub-id pub-id-type="pmid">24051434</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4161/hv.24702</pub-id><pub-id pub-id-type="pmcid">PMC3906411</pub-id></mixed-citation></ref><ref id="cei13517-bib-0207"><label>207</label><mixed-citation publication-type="journal" id="cei13517-cit-0207"><string-name name-style="western"><surname>Haidari</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Day</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Wood</surname><given-names>M</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>The safety and immunogenicity of GTU&#174;MultiHIV DNA vaccine delivered by transcutaneous and intramuscular injection with or without electroporation in HIV&#8208;1 positive subjects on suppressive ART</article-title>. <source xml:lang="en">Front Immunol</source><year>2019</year>; <volume>10</volume>:<fpage>2911</fpage>.<pub-id pub-id-type="pmid">31921170</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2019.02911</pub-id><pub-id pub-id-type="pmcid">PMC6923267</pub-id></mixed-citation></ref><ref id="cei13517-bib-0208"><label>208</label><mixed-citation publication-type="journal" id="cei13517-cit-0208"><string-name name-style="western"><surname>Gaudinski</surname><given-names>MR</given-names></string-name>, <string-name name-style="western"><surname>Houser</surname><given-names>KV</given-names></string-name>, <string-name name-style="western"><surname>Morabito</surname><given-names>KM</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open&#8208;label, phase 1 clinical trials</article-title>. <source xml:lang="en">Lancet</source><year>2018</year>; <volume>391</volume>:<fpage>552</fpage>&#8211;<lpage>62</lpage>.<pub-id pub-id-type="pmid">29217376</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(17)33105-7</pub-id><pub-id pub-id-type="pmcid">PMC6379903</pub-id></mixed-citation></ref><ref id="cei13517-bib-0209"><label>209</label><mixed-citation publication-type="journal" id="cei13517-cit-0209"><string-name name-style="western"><surname>Graham</surname><given-names>BS</given-names></string-name>, <string-name name-style="western"><surname>Enama</surname><given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Nason</surname><given-names>MC</given-names></string-name><italic toggle="yes">et al</italic>, <collab collab-type="authors">the VRCST</collab>
. <article-title>DNA vaccine delivered by a needle&#8208;free injection device improves potency of priming for antibody and CD8+ T&#8208;cell responses after rAd5 boost in a randomized clinical trial</article-title>. <source xml:lang="en">PLOS ONE</source><year>2013</year>; <volume>8</volume>:<elocation-id>e59340</elocation-id>.<pub-id pub-id-type="pmid">23577062</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0059340</pub-id><pub-id pub-id-type="pmcid">PMC3620125</pub-id></mixed-citation></ref><ref id="cei13517-bib-0210"><label>210</label><mixed-citation publication-type="journal" id="cei13517-cit-0210"><string-name name-style="western"><surname>O&#8217;Neill</surname><given-names>LA</given-names></string-name>, <string-name name-style="western"><surname>Netea</surname><given-names>MG</given-names></string-name>. <article-title>BCG&#8208;induced trained immunity: can it offer protection against COVID&#8208;19?</article-title><source xml:lang="en">Nat Rev Immunol</source><year>2020</year>; <volume>20</volume>:<fpage>335</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">32393823</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41577-020-0337-y</pub-id><pub-id pub-id-type="pmcid">PMC7212510</pub-id></mixed-citation></ref><ref id="cei13517-bib-0211"><label>211</label><mixed-citation publication-type="journal" id="cei13517-cit-0211"><string-name name-style="western"><surname>Chumakov</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Benn</surname><given-names>CS</given-names></string-name>, <string-name name-style="western"><surname>Aaby</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Kottilil</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Gallo</surname><given-names>R</given-names></string-name>. <article-title>Can existing live vaccines prevent COVID&#8208;19?</article-title><source xml:lang="en">Science</source><year>2020</year>; <volume>368</volume>:<fpage>1187</fpage>.<pub-id pub-id-type="pmid">32527819</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abc4262</pub-id></mixed-citation></ref><ref id="cei13517-bib-0212"><label>212</label><mixed-citation publication-type="journal" id="cei13517-cit-0212"><string-name name-style="western"><surname>Fidel</surname><given-names>PL</given-names></string-name>, <string-name name-style="western"><surname>Noverr</surname><given-names>MC</given-names></string-name>. <article-title>Could an unrelated live attenuated vaccine serve as a preventive measure to dampen septic inflammation associated with COVID&#8208;19 infection?</article-title><source xml:lang="en">mBio</source><year>2020</year>; <volume>11</volume>:<elocation-id>e00907&#8211;20</elocation-id>.<pub-id pub-id-type="pmid">32561657</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/mBio.00907-20</pub-id><pub-id pub-id-type="pmcid">PMC7304316</pub-id></mixed-citation></ref><ref id="cei13517-bib-0213"><label>213</label><mixed-citation publication-type="journal" id="cei13517-cit-0213"><string-name name-style="western"><surname>Spencer</surname><given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Ganguly</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Waldman</surname><given-names>RH</given-names></string-name>. <article-title>Nonspecific protection of mice against influenza virus infection by local or systemic immunization with bacille Calmette&#8211;Guerin</article-title>. <source xml:lang="en">J Infect Dis</source><year>1977</year>; <volume>136</volume>:<fpage>171</fpage>&#8211;<lpage>5</lpage>.<pub-id pub-id-type="pmid">894076</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/infdis/136.2.171</pub-id></mixed-citation></ref><ref id="cei13517-bib-0214"><label>214</label><mixed-citation publication-type="journal" id="cei13517-cit-0214"><string-name name-style="western"><surname>Gursel</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Gursel</surname><given-names>I</given-names></string-name>. <article-title>Is global BCG vaccination coverage relevant to the progression of SARS&#8208;CoV&#8208;2 pandemic?</article-title><source xml:lang="en">Med Hypoth</source><year>2020</year>:<fpage>109707</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/all.14345</pub-id><pub-id pub-id-type="pmcid">PMC7267226</pub-id><pub-id pub-id-type="pmid">32339299</pub-id></mixed-citation></ref><ref id="cei13517-bib-0215"><label>215</label><mixed-citation publication-type="journal" id="cei13517-cit-0215"><string-name name-style="western"><surname>Escobar</surname><given-names>LE</given-names></string-name>, <string-name name-style="western"><surname>Molina&#8208;Cruz</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Barillas&#8208;Mury</surname><given-names>C</given-names></string-name>. <article-title>BCG vaccine protection from severe coronavirus disease 2019 (COVID&#8208;19)</article-title>. <source xml:lang="en">Proc Natl Acad Sci USA</source><year>2020</year>; <volume>30</volume>:<fpage>17720</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.2008410117</pub-id><pub-id pub-id-type="pmcid">PMC7395502</pub-id><pub-id pub-id-type="pmid">32647056</pub-id></mixed-citation></ref><ref id="cei13517-bib-0216"><label>216</label><mixed-citation publication-type="journal" id="cei13517-cit-0216"><string-name name-style="western"><surname>Henao&#8208;Restrepo</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Camacho</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Longini</surname><given-names>IM</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Efficacy and effectiveness of an rVSV&#8208;vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open&#8208;label, cluster&#8208;randomised trial (Ebola &#199;a Suffit!)</article-title>. <source xml:lang="en">Lancet</source><year>2017</year>; <volume>389</volume>:<fpage>505</fpage>&#8211;<lpage>18</lpage>.<pub-id pub-id-type="pmid">28017403</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(16)32621-6</pub-id><pub-id pub-id-type="pmcid">PMC5364328</pub-id></mixed-citation></ref><ref id="cei13517-bib-0217"><label>217</label><mixed-citation publication-type="journal" id="cei13517-cit-0217"><string-name name-style="western"><surname>Thomas</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Yoon</surname><given-names>I&#8208;K</given-names></string-name>. <article-title>A review of Dengvaxia&#174;: development to deployment</article-title>. <source xml:lang="en">Hum Vaccin Immunother</source><year>2019</year>; <volume>15</volume>:<fpage>2295</fpage>&#8211;<lpage>314</lpage>.<pub-id pub-id-type="pmid">31589551</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/21645515.2019.1658503</pub-id><pub-id pub-id-type="pmcid">PMC6816420</pub-id></mixed-citation></ref><ref id="cei13517-bib-0218"><label>218</label><mixed-citation publication-type="miscellaneous" id="cei13517-cit-0218"><collab collab-type="authors">UKGov</collab>
. <article-title>Government launches vaccine taskforce to combat coronavirus 2020</article-title>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.gov.uk/government/news/government-launches-vaccine-taskforce-to-combat-coronavirus">https://www.gov.uk/government/news/government&#8208;launches&#8208;vaccine&#8208;taskforce&#8208;to&#8208;combat&#8208;coronavirus</ext-link> (accessed September 2020).</mixed-citation></ref><ref id="cei13517-bib-0219"><label>219</label><mixed-citation publication-type="book" id="cei13517-cit-0219"><collab collab-type="authors">Moderna</collab>
. <source xml:lang="en">Moderna Manufacturing: Why Norwood?</source><year>2020</year>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.modernatx.com/moderna-blog/moderna-manufacturing-why-norwood">https://www.modernatx.com/moderna&#8208;blog/moderna&#8208;manufacturing&#8208;why&#8208;norwood</ext-link> (accessed September 2020).</mixed-citation></ref><ref id="cei13517-bib-0220"><label>220</label><mixed-citation publication-type="miscellaneous" id="cei13517-cit-0220"><collab collab-type="authors">World Health Organization</collab>
. <article-title>Standardization of vaccines for coronavirus disease (COVID&#8208;19)</article-title>. <year>2020</year>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/biologicals/Standardization_Covid-19/en/">https://www.who.int/biologicals/Standardization_Covid-19/en/</ext-link> (accessed September 2020).</mixed-citation></ref><ref id="cei13517-bib-0221"><label>221</label><mixed-citation publication-type="miscellaneous" id="cei13517-cit-0221"><collab collab-type="authors">NatureNews</collab>
. <article-title>Successful Ebola vaccine provides 100% protection in trial</article-title>. <year>2015</year>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.nature.com/news/successful-ebola-vaccine-provides-100-protection-in-trial-1.18107">https://www.nature.com/news/successful&#8208;ebola&#8208;vaccine&#8208;provides&#8208;100&#8208;protection&#8208;in&#8208;trial&#8208;1.18107</ext-link> (accessed September 2020).</mixed-citation></ref><ref id="cei13517-bib-0222"><label>222</label><mixed-citation publication-type="miscellaneous" id="cei13517-cit-0222"><collab collab-type="authors">WHO</collab>
. <article-title>Roadmap for introduction and roll&#8208;out of Merck rVSV&#8208;ZEBOV</article-title>. <year>2019</year>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/medicines/news/2019/roadmap_for_intro_roll_out_licensed_ebola_vaccine/en/">https://www.who.int/medicines/news/2019/roadmap_for_intro_roll_out_licensed_ebola_vaccine/en/</ext-link> (accessed September 2020).</mixed-citation></ref><ref id="cei13517-bib-0223"><label>223</label><mixed-citation publication-type="miscellaneous" id="cei13517-cit-0223"><collab collab-type="authors">World Health Organization</collab>
. <article-title>Major milestone for WHO&#8208;supported Ebola vaccine</article-title>. <year>2019</year>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/news-room/detail/18-10-2019-major-milestone-for-who-supported-ebola-vaccine">https://www.who.int/news&#8208;room/detail/18&#8208;10&#8208;2019&#8208;major&#8208;milestone&#8208;for&#8208;who&#8208;supported&#8208;ebola&#8208;vaccine</ext-link> (accessed September 2020).</mixed-citation></ref><ref id="cei13517-bib-0224"><label>224</label><mixed-citation publication-type="journal" id="cei13517-cit-0224"><string-name name-style="western"><surname>Masters</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Anwar</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Collins</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Cookson</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Capewell</surname><given-names>S</given-names></string-name>. <article-title>Return on investment of public health interventions: a systematic review</article-title>. <source xml:lang="en">J Epidemiol Community Health</source><year>2017</year>; <volume>71</volume>:<fpage>827</fpage>.<pub-id pub-id-type="pmid">28356325</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jech-2016-208141</pub-id><pub-id pub-id-type="pmcid">PMC5537512</pub-id></mixed-citation></ref><ref id="cei13517-bib-0225"><label>225</label><mixed-citation publication-type="journal" id="cei13517-cit-0225"><string-name name-style="western"><surname>Phelan</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Eccleston&#8208;Turner</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Rourke</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Maleche</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>C</given-names></string-name>. <article-title>Legal agreements: barriers and enablers to global equitable COVID&#8208;19 vaccine access</article-title>. <source xml:lang="en">Lancet</source><year>2020</year>; <volume>396</volume>:<fpage>800</fpage>&#8211;<lpage>2</lpage>.<pub-id pub-id-type="pmid">32910908</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)31873-0</pub-id><pub-id pub-id-type="pmcid">PMC7832682</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>